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Fibroblast growth factor 23 (FGF23) plays an important role in maintaining phosphate 
homeostasis in adults largely though actions on the kidneys to excrete phosphate and reduce 
calcitriol. However, whether FGF23 is essential in maintaining phosphate homeostasis in fetuses 
had been largely unknown prior to my Ph.D. project, which hypothesized that FGF23 was 
important in regulating not only fetal serum phosphate and skeletal development, but also 
placental phosphate transport. However, studies in Phex null fetuses showed that excess FGF23 
did not disturb any phosphate parameter or placental phosphate transport. Although the 
expression of Cyp24a1 was increased in the null placenta and kidneys and the expression of 
Klotho was decreased in the null kidneys, these changes did not disturb any physiological 
parameter related to phosphate, which suggests that FGF23 is not important in fetal phosphate 
regulation. Previous studies in Fgf23 null fetuses showed FGF23 absence did not alter fetal 
phosphate parameters, placental phosphate transport or skeletal development. These results led to 
my hypothesis that other FGF members might compensate for FGF23 loss by acting on the 
FGFR/Klotho receptor complex. However, studies in Klotho null fetuses showed that serum 
FGF23 was normal and that they had a similar phenotype as Fgf23 nulls – which rejected my 
hypothesis. Previous studies showed that Pth null fetuses developed hyperphosphatemia. I then 
studied Pth/Fgf23 double knockout (DKO) fetuses to determine if absence of FGF23 would 
potentiate hyperphosphatemia in Pth nulls. The results showed that DKO had the same elevation 
in serum phosphate as Pth nulls and there were no skeletal mineral content changes between the 
two genotypes either. I finally examined the postnatal time course of phosphate metabolism in 
neonatal Fgf23 nulls, Klotho nulls, and Phex nulls, respectively. The results showed Fgf23 nulls 
and Klotho nulls were normal at birth, but developed hyperphosphatemia, increased renal gene 
 
 II 
expression of NaPi2a and NaPi2c, and increased renal phosphate reabsorption between 5 and 7 
days later. In contrast, excess FGF23 exerted effects in Phex nulls within 12 hours after birth, 
with the development of hypophosphatemia, reduced renal expression of NaPi2a and NaPi2c, 
and decreased renal phosphate reabsorption. In conclusion, my Ph.D. project suggests FGF23 is 
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Phosphorus plays an important role in normal physiological activities. Disturbance in phosphorus 
homeostasis can trigger severe disorders. In adults, it is well known that fibroblast growth factor 
23 (FGF23), parathyroid hormone (PTH) and calcitriol regulate phosphorus homeostasis. 
However, little had been known about the regulation of phosphorus homeostasis in fetuses and 
neonates by the time when I initiated my Ph.D. study. In my Ph.D. project, the main focus was 
on studying potential roles of FGF23 in fetal and neonatal phosphorus regulation. To achieve this 
goal, three mouse models were used: the Phex null model (also known as the Hyp model that 
develops spontaneous hypophosphatemia due to naturally occurring mutations in the Phex gene), 
the Fgf23 knockout (KO) model, and the Klotho KO model. By studying the three models, I was 
hoping to answer the question as to whether FGF23 is physiologically important in maintaining 
fetal and neonatal phosphorus homeostasis. 
 
1.2 Phosphorus Homeostasis in Adults 
1.2.1 Function and Distribution of Phosphorus 
Phosphorus is an essential element in all organisms [1, 2]. Compounds containing phosphorus 
have critical roles in maintaining cell structure integrity (cell membranes and nucleic acids have 
high content of phosphorus), cell metabolism (synthesis of adenosine triphosphate or ATP), cell 
signaling pathway (phosphorylation of enzymes), homeostasis of body fluids (urinary buffering), 
and bone health [3, 4]. Therefore, maintaining normal physiological phosphorus homeostasis is 
critical for well-being. A phosphorus imbalance can trigger severe disorders. Excess phosphorus 
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causes calcification of cardiovascular vessels and other soft tissues, while deficient phosphorus 
leads to undermineralized,weakened bone [i.e., osteomalacia (adults) or rickets (children)] and 
neuromuscular disturbances [5-9]. 
 
In vivo, phosphorus primarily is present in the form of phosphate. It is common to use the two 
terms interchangeably. The term phosphate is used in the following content. The majority of 
body phosphate (~85%) is deposited in the bones as hydroxyapatite [Ca10(PO4)6(OH)2] with 
calcium  [10]. The remainder exists as inorganic and organic compounds that are distributed in 
other tissues (~14%) and extracellular fluids (~1%).  
 
1.2.2 Phosphate Regulation in Adults: Intestine-Bone-Kidney Axis 
Phosphate homeostasis in adults can be explained largely by an intestine-bone-kidney axis. 
Phosphate intake is through intestinal absorption, the majority of phosphate is stored in the 
bones, and the kidneys are the primary route through which a phosphorus balance is fine-tuned.  
 
1.2.2.1 Intestinal Phosphate Absorption 
1.2.2.1.1 Phosphate Transport across the Intestines 
Phosphate is present in the majority of food sources. Milk and dairy products are the richest 
dietary sources, but others include bread, cereals, rice, meat, fish, and some non-alcoholic 
beverages. Phosphate is predominately absorbed in the duodenum and usually interacts with 
other minerals. For example, calcium and magnesium can bind to phosphate in the duodenum, 
reducing intestinal phosphate absorption. A proper amount of sodium under acidic pH promotes 
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the process [11].   
 
The intestines absorb phosphate via two distinct mechanisms: paracellular diffusion and active 
transport. The former is a process of passive transport largely driven by an electrochemical 
gradient, whereas the latter involves energy-dependent sodium-phosphate co-transporters [12]. 
How phosphate passively diffuses across the intestines remains to be elucidated. In general, 
passive diffusion of a compound occurs at a tight junction complex where membranes of two 
cells join together to form barriers (Figure 1). Adhesive anchor proteins between neighbouring 
cells maintain the complex. Common adhesive proteins in a tight junction include occludin, 
claudin 1, E-cadherin, zonula occludens-1 (ZO-1), junctional adhesion molecule-1 (JAM-1), 
catenins, cingulin, and actin [13]. Recent studies suggested that cytoskeletal pathways regulate 
passive diffusion across a tight junction, and that occludins and claudins appear to play important 
roles. For example, mutations of claudin in the small intestine caused hypomagnesemia and 
hypercalciuria [14-17]. Although more and more studies are being carried out, the process of 
phosphate-specific diffusion through an intestinal tight junction is still unclear.   
 
Unlike passive diffusion, the active transport of phosphate in the intestines has been intensively 
studied. In simple words, phosphate in the lumen is transferred into intestinal epithelial cells in a 
sodium-dependent manner. The process requires phosphate-specific transporters located on the 
surface of the epithelial cells. However, how phosphate is pumped out of intestinal epithelial 
cells at the basolaternal side remains unknown. Those transporters required for the active process 
include two families of solute carriers, the SLC34 family (also known as type II sodium-






Figure 1: A Tight Junction in the Small Intestines. Intestinal absorption occurs via passive 
paracellular diffusion and/or active transcellular transport. A tight junction is formed where the 










The type II sodium-phosphate co-transporters are the major players in the phosphate transport 
across cell membranes. They are represented by the 2a subtype (NaPi2a), the 2b subtype 
(NaPi2b), and the 2c subtype (NaPi2c). It is well known that intestinal phosphate absorption is 
facilitated through NaPi2b whereas the renal reabsorption through NaPi2a and NaPi2c [12]. It is 
noteworthy that the genes encoding NaPi2a, NaPi2b, and NaPi2c are officially named solute 
carrier family 34 member 1 (Slc34a1), solute carrier family 34 member 2 (Slc34a2), and solute 
carrier family 34 member 3 (Slc34a3), respectively. Several studies in KO mice implied that 
NaPi2b may play essential roles in sensing phosphate in the intestines and regulating the 
absorption. For example, 30 and 60 minutes after being gavaged with 0.5 M sodium phosphate 
bolus, adult mice with postnatal KO of NaPi2b had significantly lower concentrations of serum 
phosphate concentrations than normal wildtype (WT) mice receiving the same treatment [21]. 
Interestingly, despite decreased intestinal phosphate absorption, serum phosphate concentrations 
were normal in adult mice with intestine-specific NaPi2b KO. This might be achieved by a 
compensatory mechanism of increased renal phosphate reabsorption because quantitative 
immunoblot analysis showed that NaPi2a protein levels were significantly increased in the KO 
kidneys. In human patients with a NaPi2b mutation, the net changes of serum and urinary 
phosphate were found to be normal [22, 23].     
 
The type III co-transporters, now often called Pit1 and Pit2, have been shown to be broadly 
expressed on membranes of polarized epithelial cells [24]. They play roles in mediating sodium 
and phosphate movements across cell membranes. Some prior studies showed the expression of 
both Pit1 and Pit2 in Xenopus oocytes could stimulate phosphate to move inward into the cells 
in the presence of sodium, i.e. the movement was sodium-dependent [25].  
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1.2.2.1.2 Regulation of Intestinal Phosphate Transport 
When diet can provide more than sufficient phosphate, it is predominately absorbed via passive 
diffusion in the intestines. Active phosphate absorption occurs when there is a dietary phosphate 
deficiency or renal phosphate wasting. The three key players of the active process are dietary 
phosphate, 1,25-dihydroxyvitamin D (1,25(OH)2D3, also known as calcitriol), and parathyroid 
hormone (PTH). Calcitriol is the biologically active form of vitamin D. Other factors, such as 
calcium, glucocorticoids, estrogens, FGF23, epidermal growth factor (EGF), metabolic acidosis, 
and parathyroid hormone related peptide (PTHrP) are also indicated to regulate active intestinal 
phosphate absorption [2, 26-30].  
 
1.2.2.1.2.1 Dietary Phosphate 
Low dietary phosphate stimulates intestinal phosphate absorption [31-33]. The original thought 
was that dietary phosphate exerted effects on intestinal phosphate absorption through changing 
the calcitriol signalling pathway – calcitriol increases intestinal phosphate absorption (This is 
discussed in Section 1.2.2.1.2.2 titled “Calcitriol”). Indeed, this hypothesis was straightforward 
because low dietary phosphate decreases serum phosphate, which in turn stimulates 1α 
hydroxylase (the enzyme required to produce calcitriol in vivo) [34-36]. However, it was not 
until recently that the phosphate content in diet was found to change active phosphate absorption 
independent of calcitriol. Katai’s group showed that a low phosphate diet stimulated NaPi2b in 
the rats’ intestines without changing the mRNA levels of the vitamin D receptor gene  (Vdr) 
[32]. A previous study conducted by Segawa’s team illustrated that low dietary phosphate 
increased NaPi2b protein synthesis in both WT and Vdr KO mice [33]. These results suggest that 
dietary phosphate could change the process of intestinal phosphate absorption independent of 
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calcitriol. Studies by Hattenhauer’s group showed that although dietary phosphate restriction 
increased NaPi2b protein levels in normal mice, NaPi2b mRNA expression was not changed, 
suggesting that dietary phosphate could adjust intestinal absorption through post-transcriptional 
modifications [31]. 
 
1.2.2.1.2.2 Calcitriol  
Calcitriol is produced by the key enzyme, 1α-hydroxylase (encoded by the gene called 
Cyp27b1), at the proximal tubules in the kidneys. 1α-hydroxylase uses 25-hydroxyvitamin D as a 
substrate and adds a hydroxyl group on the 1’ site of the substrate molecule. Calcitriol is 
metabolised by the enzyme 1,25-dihydroxyvitamin D3 24-hydroxylase (encoded by the gene 
called Cyp24a1) – 1,25-dihydroxyvitamin D3 24-hydroxylase adds one hydroxyl on the 24’ site 
of the calcitriol molecule to suppress its functions. Calcitriol’s only known receptor, VDR, 
belongs to a nuclear receptor subfamily and is located in cytoplasm. Before being activated by 
calcitriol, VDR exists in a form of heterodimers with retinoid X receptor (RXR) [37]. After 
calcitriol binds to the heterodimer, the complex is translocated into the nucleus where it binds to 
the so-called vitamin D response element (VDRE) sequence on DNA, triggering expression of 
downstream genes. 
 
Many animal studies have shown that calcitriol can increase intestinal phosphate absorption [38, 
39]. However, the mechanism still needs further studies for several reasons. First, expression of 
NaPi2b as a response to calcitriol varies among different species. This prevents a generalizable 
statement about the mechanism of calcitriol-dependent intestinal phosphate absorption [40, 41]. 
Second, as explained above, low dietary phosphate has been shown to be able to stimulate the 
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NaPi2b protein independent of calcitriol. Third, the effect of calcitriol on NaPi2b mRNA 
expression seems to be age-dependent. This interesting phenomenon was shown in a rat study 
conducted by Xu [39]. In this study, calcitriol treatment increased intestinal phosphate absorption 
in 14-day-old suckling young rats and adult rats by 2.5-fold and 2.1-fold, respectively; however, 
NaPi2b mRNA expression in adult rats (90 – 100 days old) was not changed by calcitriol. 
NaPi2b mRNA levels were increased by 2-fold in the suckling rats under the same treatment.    
 
How many effects on intestinal phosphate absorption are from calcitriol directly remains an 
unresolved question because calcitriol can interact with other phosphate-regulating hormones.  
[40]. For example, calcitriol can inhibit PTH secretion and stimulate FGF23 production. Both 
PTH and FGF23 decrease serum phosphate in adults mainly via suppressing renal phosphate 
reabsorption. Calcitriol’s inhibitory effect on PTH has been suggested by studies showing that 
calcitriol suppressed Pth gene transcription and by the fact that calcitriol is clinically used to 
treat parathyroid hyperplasia [42-45]. In terms of calcitriol’s stimulatory role in FGF23 
production, Shimada showed that when Vdr was knocked out in mice, serum FGF23 levels were 
undetectable, even after dietary phosphate loading[46]. Ohnishi’s group reported that serum 
FGF23 in Cyp27b1 mutant mice was significantly lower than that in WT [47]. Similar results 
were also observed in Dr. Kovacs’ laboratory, which showed that adult Cyp27b1 null mice had 
very low FGF23 levels that slightly increased during pregnancy but were much lower than those 
achieved in pregnant normal mice [48]. It should be noted that loss of calcitriol is a more specific 
model than loss of VDR in that there could be a possibility that calcitriol might act on some 
unknown receptors. The functions of PTH and FGF23 in regulating intestinal phosphate 




PTH is synthesized in the parathyroid glands. PTH tightly maintains serum calcium 
concentrations. Hypocalcemia induces the production and secretion of PTH, which in turn 
increases serum calcium through several mechanisms. Calcium reversely acts as a suppressor of 
PTH by binding to calcium sensing receptors (CaSR), which inhibit a PTH synthesis and release. 
This negative feedback loop ensures that serum calcium concentrations stay within a tight range. 
 
The mineral and skeletal functions of PTH are through its actions on type 1 PTH receptors 
(PTH1R) that are highly expressed in the skeleton and kidneys. On one hand, activated PTH1R 
can modify the Gs protein, which in turn activates adenylate cyclase (AC). The activated AC 
synthesizes cAMP, which further activates protein kinase A (PKA), which regulates downstream 
transcriptional factors and gene expression. On the other hand, PTH1R modifies the Gq protein, 
which activates downstream PLC-IP3 and PLC-DAG-PKC pathways. The two pathways can 
further regulate downstream transcriptional factors and gene expression. Unlike PTH1R, type 2 
PTH receptors (PTH2R) are primarily located in the central nervous system, placenta, pancreas, 
and testis. PTH2R is involved in a variety of physiological functions, depending on where the 
receptor is [49].   
 
In terms of PTH-induced regulation of intestinal phosphate absorption, the current view is that 
PTH regulates NaPi2b gene expression in an indirect way – which is different from calcitriol that 
can place a direct effect on this process. That is, PTH indirectly stimulates NaPi2b by increasing 
calcitriol production and/or any other related regulators [50, 51]. As discussed above, 
biosynthesis of calcitriol in vivo is largely regulated by 1α-hydroxylase (encoded by Cyp27b1), 
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while the metabolism by 1,25-dihydroxyvitamin D3 24-hydroxylase (encoded by Cyp24a1). 
Many studies have shown that PTH is a strong activator of Cyp27b1 and a strong inhibitor of 
Cyp24a1[44, 52]. Calcitriol has an inhibitory effect on PTH production. This negative feedback 
loop ensures appropriate intestinal phosphate absorption.  
 
FGF23, which is discussed in details below, is known to reduce intestinal phosphate absorption.  
Studies have suggested that PTH can increase FGF23 production in both vivo and vitro. Lavi-
Moshayoff’s group reported that PTH infusion for 3 days increased circulating FGF23 in normal 
adult healthy mice and the treatment elevated calvarial Fgf23 mRNA expression. An in vitro 
experiment showed that PTH treatment increased Fgf23 expression in osteoblast-like UMR106 
cells [53]. DMP1-caPTHR1 is a transgenic mouse model that expresses a constitutively active 
human PTHR1 gene in osteocytes, causing increased bone mass and bone remodeling. Rhee 
showed that in DMP1-caPTHR1 transgenic mice Fgf23 expression in osteocytes was 
significantly elevated compared to normal WT mice [54]. PTH’s stimulatory effect on FGF23 
can be both direct as well as indirect through calcitriol. Lopez used parathyroidectomized rats to 
show that PTH replacement therapy was able to create a dose-dependent increase in both serum 
FGF23 and calcitriol in rats without the parathyroid glands. In this experiment, calcitriol plus 
PTH replacement highly increased serum FGF23 in parathyroidectomized rats. Although 
calcitriol alone also elevated serum FGF23, the level was below that achieved by calcitriol plus 
PTH replacement. [55]. Although many studies indicate PTH stimulates FGF23, further work is 
still needed to confirm this because some studies found that PTH did not change FGF23. For 
example, Saji showed in an in vitro study that calvarial cells receiving PTH treatment increased 




FGF23 is a phosphate-regulating hormone synthesized largely by osteoblasts and osteocytes 
[57]. Precursor proteins of FGF23 have 251 amino acids, which are modified by a cleavage of a 
24-amino acid signal peptide (AA1 – AA24) sequence before being secreted – thus secreted 
FGF23 has 227 amino acids. An intact structure of biologically active FGF23 consists of an N-
terminal fragment that is an FGF homology region (AA25 – AA179) and a C-terminal fragment 
(AA180 – AA251) [58]. Some FGF23 proteins are cleaved at AA179 by Furin (a type I 
precursor convertase), yielding separate N-terminal and C-terminal fragments [59]. It should be 
noted that it is intact FGF23 that is biologically active, whereas the N- and C-terminal fragments 
are not.  
 
The classic FGF23 signaling pathway involves three key elements: FGF23, FGF receptors 
(FGFRs), and a co-receptor called Klotho. There are four types of FGFRs: FGFR1, FGFR2, 
FGFR3, and FGFR4. These receptors belong to a tyrosine kinase superfamily. Like typical 
tyrosine kinase receptors, FGFRs have an extracellular domain to bind a ligand, a single 
transmembrane helix domain, and an intracellular domain associated with tyrosine kinase 
activity. A fifth type of FGFRs, FGFR5 (also known as fibroblast growth factor receptor-like 1), 
was recently identified. In contrast to FGFRs1-4, FGFR5 does not have a tyrosine kinase domain 
– it only has an extracellular ligand domain [60].  
 
Based on how FGFs conduct cell signals, the FGF superfamily is divided into two categories:  
paracrine FGFs and endocrine FGFs. The former includes the FGF1 family, the FGF4 family, the 
FGF7 family, the FGF8 family, the FGF9 family, and the FGF11 family. The latter (also known 
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as the FGF19 family) includes FGF19, FGF21, and FGF23. The key factor to differentiate the 
paracrine family and FGF19 family is the affinity to heparin sulfate proteoglycans (HSPGs, also 
known as heparin). Paracrine FGFs have a much stronger affinity to HSPGs than endocrine 
FGFs [61]. HSPG is thus claimed to serve as the “co-receptor” of paracrine FGFs [62]. Due to 
their loose affinities to HSPG, FGF19 family members can “escape” from local HSPGs and 
circulate to other locations to function.  
 
Klotho serves as a co-receptor of endocrine FGFs. Klotho is a single-pass transmembrane 
protein. It was initially discovered during a study in mice with a syndrome resembling rapid 
ageing [63]. The Klotho gene is expressed in various tissues, such as distal convoluted tubules in 
the kidneys, the parathyroid glands, and epithelial cells of the choroid plexus in the brain [64]. 
The essential role of Klotho in the classic FGF23 signaling pathway has been confirmed in 
several studies showing that adult mice with an inactivating mutation in Klotho had a identical 
phenotype as those with an inactivating mutation in Fgf23 except the former had extremely high 
FGF23 levels due to end organ resistance while the latter had none[65-68].  
 
Among the four types of FGFRs, the FGFR1c isoform (FGFR1c) is the principal receptor for 
FGF23 for phosphorus homeostasis [69, 70], while FGFR3 and FGFR4 are relatively 
unimportant [71]. When FGF23, FGFRs, and Klotho bind together to form a complex, 
downstream factors such as extracellular signal-regulated kinases (ERK), P38, c-Jun N-terminal 
kinases (JNK), and protein kinase B (PKB), are activated to trigger further signaling cascades 




FGF23’s main functions are to reduce serum phosphate and control phosphate supply at a 
mineralizing surface of the bones. Although the primary functional site of FGF23 is at the 
kidneys, this hormone can also indirectly inhibit intestinal phosphate absorption. Miyamoto 
showed that FGF23 injection reduced the amount of NaPi2b in the brush border membrane 
vesicles; however, the reduction disappeared in Vdr null mice – suggesting that FGF23 depends 
on VDR to inhibit NaPi2b [73]. FGF23 has been shown to suppress the production of PTH as 
well [74, 75]. The regulation of renal phosphate metabolism by FGF23 is discussed in Section 
1.2.2.3.4 titled “Regulation of Renal Phosphate Excretion and Reabsorption.” 
 
1.2.2.1.2.5 Other Hormones and Factors 
Besides the key players discussed above, other hormones and factors could also play roles in 
intestinal phosphate absorption to some extent. Secreted by various types of normal or malignant 
cells, parathyroid hormone related peptide (PTHrP) is a 139- or 173-amino acid peptide with N-
terminal homology to PTH. PTHrP is normally extremely low in adults; however, it can circulate 
at high levels in fetuses, lactating females, and patients with certain malignancies. When elevated 
in the circulation, PTHrP has a phosphaturic effect as a result of its N-terminal structural 
similarity as PTH. Dua’s group showed in a sheep study that after being injected by PTHrP, 
normal sheep had a significant increase in the absorption rate of calcium and phosphate from the 
reticulorumen [76]. In normal adults PTHrP does not regulate phosphate homeostasis. However, 
in patients with humoral hypercalcemia of malignancy, PTHrP is usually high, which can 
stimulate FGF23. Excess calcium forms un-absorbable compounds with phosphate in the 
intestines, leading to a reduction in phosphate intake [77]. Calcium can also suppress PTH, 
leading to a reduction in the renal synthesis of calcitriol. Xu showed that estradiol increased 
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active intestinal phosphate absorption by 45% in rats via increasing NaPi2b expression and its 
synthesis in the intestines [29]. Glucocorticoids have been suggested to inhibit intestinal 
phosphate absorption. In 4-week-old suckling rabbits, methylprednisolone injection significantly 
reduced an uptake of phosphate compared to rabbits treated with placebo [78]. Epidermal growth 
factor (EGF) has been illustrated to decrease NaPi2b mRNA levels via suppressing the activity 
of the gene’s promoter [27].   
 
1.2.2.2 Phosphate in the Bones 
As briefly mentioned above, the adult skeleton contains ~85% of the body’s phosphate content. 
One of the skeleton’s key functions is to serve as a reservoir of minerals, including phosphate. 
Therefore, in order to understand phosphate homeostasis, it is necessary to know how phosphate 
is handled within the bones.   
 
1.2.2.2.1 Phosphate-related Bone Metabolism 
Bone mineralization is an important step during skeletal development. Hydroxyapatite, a 
complex of calcium and phosphate, constitutes the majority of mineral content of the bones. 
Other contents normally include carbonate, magnesium, and acid phosphate. The chemical 
formation of hydroxyapatite initially occurs within matrix vesicles that originate from osteogenic 
cell membranes. These vesicles then migrate to extracellular skeletal matrix, where they attract 
phosphate to move into the vesicles, followed by a calcium influx [79].  Since ~85% of 
phosphate in vivo is stored in the bones in a form of hydroxyapatite, this acts as a reservoir of 




1.2.2.2.2 Regulation of Phosphate Storage and Release from the Bones 
After phosphate is absorbed in the intestines, most of it is stored in the bones. However, it should 
be noted that the bones are a less responsive organ to serum phosphate changes than the 
intestines and the kidneys (which is discussed in Section 1.2.2.3 titled “Phosphate Handling by 
the Kidneys). Factors that regulate the storage and release of phosphate from the bones are 
discussed below.  
 
1.2.2.2.2.1 FGF23  
FGF23 affects skeletal phosphate handling through changing the process of bone mineralization 
and bone resorption – bone mineralization consumes serum phosphate while bone resorption 
releases phosphate into the circulation. FGF23 can inhibit bone mineralization through both 
direct and indirect mechanisms. The indirect mechanism refers to FGF23’s effect to reduce 
circulating phosphate levels – thereby, making fewer minerals available for bone 
formation/mineralization. The direct mechanism is discussed below.  
 
FGF23 itself is an inhibitor of bone mineralization independent of circulating phosphate. The 
inhibitory effects have been shown in many studies. For example, when Fgf23 was 
overexpressed during osteoblast development in fetal rat calvaria cells, nodule formation and 
mineralization was inhibited. The inhibition could be ablated by an FGFR1 inhibitor, SU5402 
[80]. Similar results were demonstrated in Sitara’s and Shalhoub’s studies using primary 
calvarial osteoblast cell cultures and osteoblastic MC3T3 E1 cells, respectively [81, 82]. Yuan’s 
group showed that Fgf23/Pth double KO mice had improved trabecular bone volume and 
mineralized bone volume than Fgf23 mutant mice, indicating that a possible effect of FGF23 on 
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bone development is dependent of PTH but not phosphate[83]. 
 
Interestingly, some studies also suggest that FGF23 may have some positive effects on bone 
mineralization.  For example, mice with FGF23 deficiency had osteomalacia or osteodosis even 
though these mice exhibited hyperphosphatemia, hypercalcemia, decreased serum PTH, and high 
serum calcitriol. One potential explanation is that FGF23 could suppress osteopontin (OPN), 
which is a well-known inhibitor of bone mineralization [84, 85].     
 
1.2.2.2.2.2 PTH 
PTH indirectly stimulates osteoclasts by increasing secretion of receptor activator of nuclear 
factor kB (RANKL) by osteoblasts. RANKL acts on its receptor RANK on the surface of 
osteoclasts to activate the cells. During a process of bone resorption, phosphate and calcium are 
released into the circulation. Besides stimulating bone resorption, PTH can directly stimulate 
osteoblasts, which use phosphate to generate osteoid and thereby form bone.    
 
1.2.2.2.2.3 Calcitriol 
The effects of calcitriol on bone tissues are complex – calcitriol seems to be able to stimulate 
both bone resorption and mineralization independent of circulating phosphate [86].  
 
As to the effects on osteoclasts, Takahashi’s group showed that an addition of calcitriol to the co-
culture medium of osteoblasts and bone marrow cells enhanced the differentiation of osteoclasts 
[87]. An in vivo study demonstrated that calcitriol induced Rankl expression by osteoblasts, a 
critical step to stimulate the differentiation and activation of osteoclasts for bone resorption [88]. 
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Calcitriol’s stimulatory effects on osteoclastogenesis are thought to be through VDR in 
osteoblasts, because VDR is mainly expressed in osteoblasts, and  because studies showed 
conditional deletion of Vdr from osteoblasts ablated calcitriol’s stimulatory effects [89].  
 
As to calcitriol’s stimulatory effects on bone mineralization, most evidence suggests they are 
indirect. That is, calcitriol enhances bone mineralization by stimulating the intestinal absorption 
of calcium and phosphate. For example, Xue’s group demonstrated that global Vdr KO 
phenotypes were nearly prevented with a genetic reintroduction of Vdr into intestinal cells [90]. 
Another study showed a conditional KO of Vdr in the intestines had similar phenotypes as a 
global KO [91]. Interestingly, several recent studies illustrated that calcitriol could directly 
increase mineralization in the human pre-osteoblastic SV-HFO cell line by enhancing production 
of ALP-positive mature matrix vesicles [92].       
 
1.2.2.3 Phosphate Handling by the Kidneys 
1.2.2.3.1 Phosphate Physiology at the Kidneys 
Renal phosphate excretion is of particular importance for the maintenance of a phosphate 
balance, perhaps even more so than intestinal phosphorus absorption or bone formation and 
resorption [93]. In humans, approximately 20 g of phosphate is filtered by the kidneys per day, 
with 85% (~ 17 g) eventually reabsorbed [93]. In equilibrium, the amount of excreted phosphate 
should be equal to that of intestinal absorption; however, this is not always the case as renal 
handling of phosphate is subject to numerous factors. Main hormonal players in this process are 




1.2.2.3.2 Kidney Structure 
The kidneys are surrounded by a thin capsule, made of the connective tissues, which holds their 
shape and protects them. Inside the capsule is cortex, and deep inside that is medulla. The renal 
medulla is made of several pyramid-like structures, which consist of straight tubules and blood 
vessels. The apices of the renal pyramids are each connected to a minor calyx which merges with 
other calyces to form major calyces. The major calyces eventually merge into renal pelvis from 
where urine flows into the ureters.  
 
The functional unit of the kidneys is called nephron, which is located in the renal cortex. There 
are two types of nephrons: cortical nephrons which constitute ~85% of nephrons and are found 
in the renal cortex, and juxtamedullary nephrons which make up the remaining 15%, and are 
located near the renal medulla. Each nephron has three elements: a renal corpuscle, a tubule, and 
a capillary network. The renal corpuscle consists of a glomerulus and a Bowman’s capsule 
surrounding it. The glomerulus is linked to a long renal tubule that can be divided into three 
sections: the loop of Henle (also known as nephritic loop), a proximal tubule, and a distal tubule. 
The distal tubule is further connected to collecting ducts, which merge with other collecting 
ducts and enter into the papillae of the medullary section.  Urine flows through the glomerulus to 
be filtered and reabsorbed and then passes into the renal calyces and further into the bladder 
through the ureters.  
 
1.2.2.3.3 Renal Phosphate Reabsorption 
Renal phosphate reabsorption occurs at brush border membranes of proximal tubular cells. The 
process is thought to be sodium ion (Na
+
) dependent with no paracellular diffusion [94].  
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Chief co-transporters responsible for renal phosphate reabsorption are NaPi2a and NaPi2c. This 
has been confirmed in studies showing that adult mice with NaPi2a deficiency developed renal 
phosphate wasting and hypophosphatemia [95]. Similar results were observed when NaPi2c was 
knocked out [18]. Some studies suggest NaPi2a plays a larger role than NaPi2c. For example, the 
brush border membrane isolated from NaPi2a KO mice had a 70% reduction in the Na
+
 
dependent phosphate reabsorption [96]. Interestingly, NaPi2c was found to decrease with age in 
one study [97]. NaPi2a and NaPi2c have different transport stoichiometries as the former is 
electrogenic while the latter is electroneutral. NaPi2a displays a Na+:Phosphate stoichiometry of 
3:1, whereas NaPi2c shows 2:1 [93]. Some recent studies indicate that PiT2 should also be 
considered as a potential phosphate co-transporter since the protein was detected exclusively at 
the brush border membrane of proximal tubular cells [24, 93]. The process of phosphate 
reabsorption by proximal tubular cells is illustrated in Figure 2. How phosphate exits the tubular 














Figure 2: Renal Phosphate Reabsorption by Proximal Tubular Cells. Phosphate is 
transported across the brush border by NaPi2a and NaPi2c co-transporters. Phosphate enters the 
tubular cells and is transported across the basolateral membrane by a poorly understood 
mechanism. The Na/K -ATPase on the basolateral membrane (not shown in figure) pumps Na 














1.2.2.3.4 Regulation of Renal Phosphate Excretion and Reabsorption 
The regulation of renal phosphate reabsorption is through changes of the amount of NaPi2a and 
NaPi2c located on the brush border membrane of proximal tubular cells. The regulation process 
is complex and involves three major hormonal factors, including PTH, calcitriol, and FGF23. 
Interactions among the three hormones make the process even more complicated. Among the 
three players, PTH and FGF23 are thought to play more important roles. 
 
1.2.2.3.4.1 PTH and PTHrP 
PTH reduces renal phosphate reabsorption, causing an increase in the excretion of the mineral 
[2]. When PTH is missing, renal excretion of phosphate is highly reduced. A study conducted in 
the 1970s showed that parathyroidectomized starlings developed significant hyperphosphatemia 
and decreased clearances of phosphate [98]. More recent studies also illustrated that Pth null 
animals suffered from renal phosphate retention [75]. It has been well established for decades 
that hypoparathyroidism – whether congenital (due to inactivating Pth mutations) or acquired 
(e.g. from thyroid/parathyroid surgery) – leads to hyperphosphatemia with elevated renal 
phosphate reabsorption [99]. When PTH is at excess levels, the body tends to excrete too much 
phosphate.  Secondary hyperparathyroidism in vitamin D deficiency human patients was thought 
to be the cause of hyperphosphaturia [100].   
 
Primary hyperparathyroidism, which is due to a tumor of one parathyroid gland or hyperplasia of 
all four parathyroid glands, could increase renal phosphate excretion [101].  In addition, PTH 
analog injections (a treatment for osteoporosis) and PTH infusion (a diagnostic test for 
pseudohypoparathyroidism) can also lead to hyperphosphaturia. Several studies showed that a 
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low phosphate diet could reduce renal phosphate excretion because PTH was suppressed due to 
the body not being able to get a sufficient amount of phosphate [102].  
 
PTHrP and PTH have N-terminal homology that enables the two hormones to act on PTH1R to 
reduce renal phosphate reabsorption. It should be noted that PTHrP is normally undetectable in 
the circulation, suggesting it is unlikely to play a role in normal renal phosphate excretion. 
However, during lactation PTHrP levels in the blood are increased – a possible response in order 
to excrete excess phosphate through the kidneys because serum phosphate is highly elevated 
during lactation (as a result of elevated bone resorption) [103]. It should also be mentioned that 
during lactation PTH is normally at low levels, indicating the stimulatory effect on renal 
phosphate excretion is from PTHrP alone and not a combination of PTH and PTHrP. During 
fetal development, PTHrP is increased while PTH circulates at low levels.   
 
Some rodent studies showed that when PTH receptors were stimulated, within minutes the 
NaPi2a protein abundance in the brush border of proximal tubular cells decreased; however, the 
mRNA levels remained unchanged [104, 105]. Decreases in the protein level of NaPi2c were 
shown to take several hours [106, 107]. These results once again suggest that NaPi2a plays a 
more important role in renal phosphate reabsorption than NaPi2c.  
 
1.2.2.3.4.2 FGF23 
FGF23 reduces renal phosphate reabsorption through down regulation of NaPi2a and NaPi2c in 
the proximal tubules. Supporting evidence comes from prior studies in human patients who had 
tumor-induced osteomalacia (TIO), autosomal-dominant hypophosphatemic rickets (ADHR), 
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recessive hyperphosphatemic rickets (ARHR) and X-linked hypophosphatemic rickets (XLH). 
These patients had increased circulating levels of FGF23, phosphaturia and bone disorders [93]. 
Conversely, studies in tumor calcinosis (a disorder in which FGF23 is absent) patients showed 
that these patients usually developed hyperphosphatemia and had low phosphate excretion. 
Details of these human disorders are discussed in Section 1.2.3 titled “Phosphate Disorders in 
Human Adults”. 
 
Many in vitro studies suggest that FGF23’s phosphaturic effect is through a decrease in NaPi2a 
and NaPi2c in the kidneys [18, 108]. For example, isolated proximal tubular cells from rodents 
with a stable R176Q mutation had significantly reduced NaPi2a on the brush border. An R176Q 
mutation makes the FGF23 protein resistant to cleavage [109]. Shimada’s group previously 
showed that Fgf23 null mice developed hyperphosphatemia and increased renal phosphate 
reabsorption [110].  
 
Interestingly, some studies suggest that FGF23’s co-receptor, Klotho, could directly exert 
negative effects on NaPi2a. For example, Hu’s group illustrated that addition of Klotho in 
cultured proximal tubular cells first reduced the NaPi2a activity and then decreased its protein 
levels [111]. Even more interestingly, the Klotho gene was shown to be expressed in the renal 
distal convoluted tubules whereas phosphate reabsorption occurs in the proximal tubules [112]. 
How Klotho migrates from the distal tubules and acts in the proximal tubules remains unknown. 





First, whether calcitriol increases or decreases renal phosphate reabsorption remains 
controversial [113]. For example, thyroparathyroidectomized rats on chronic calcitriol treatment 
reportedly had reduced renal phosphate reabsorption [114]. In that study, the effect of PTH was 
excluded since the parathyroid glands were surgically removed. However, some other studies 
showed that mice with Vdr or Cyp27b1 knocked out had the same levels of NaPi2a in proximal 
tubular cells as WT mice, suggesting calcitriol may not have any effect on renal phosphate 
reabsorption [33, 115].  
 
Second, it is difficult to determine whether calcitriol regulates renal phosphate reabsorption in a 
direct or indirect manner, or both.  As described above, calcitriol interacts with FGF23 and PTH, 
both of which are important regulators of renal phosphate reabsorption. Repeated injection of 
calcitriol was shown to increase serum FGF23 levels in a rat study [116]. FGF23 was shown to 
reduce renal production of calcitriol by suppressing Cyp27b1 expression and by increasing 
Cyp24a1 expression [110, 117].     
 
1.2.3 Phosphate Disorders in Human Adults 
Serum minerals are tightly maintained within a proper range. Likewise, circulating phosphate 
needs to be regulated. Derangement in serum phosphate, either excess or deficiency, can cause 
severe human disorders. Here the phosphate related disorders, including both FGF23 dependent 




1.2.3.1 FGF23-Dependent Hypophosphatemic Disorders 
Defective bone mineralization results in rickets in childhood and osteomalacia in adulthood. 
There are many different causes of rickets and osteomalacia, but almost all share 
hypophosphatemia as a common pathophysiological denominator  [58]. Phosphate deposition is 
the first step required for skeletal mineralization; thus, low serum phosphate leads to an 
undermineralized skeleton.  
 
There are several kinds of hypophosphatemic rickets and osteomalacia associated with an excess 
FGF23 action, including XLH, TIO, and ADHR/ARHR. These disorders share not only 
relatively increased intact FGF23, but renal phosphate wasting, reduced renal calcitriol 
production, and low-to-normal serum calcitriol.  
 
1.2.3.1.1 XLH 
XLH is caused by an inactivating mutation in a phosphate-regulating gene with homologies to 
endopeptidases on the X chromosome – called the Phex gene [118]. Phex is expressed in 
osteocytes, osteoblasts, and odontoblasts [119]. Mutations in Phex indirectly lead to an increase 
in FGF23 serum levels, which results in renal phosphate wasting, hypophosphatemia, reduced 
renal synthesis of calcitriol and low-to-normal serum levels of calcitriol.  
 
The mechanisms whereby Phex regulates the Fgf23 expression remain to be elucidated. Initial 
studies suggested that the Phex protein cleaved FGF23 [120]. However, subsequent studies failed 
to prove the hypothesis as they showed that FGF23 was not a direct substrate of Phex [121]. 
Liu’s group showed that an inactivating mutation in Phex led to an increase in Fgf23 
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transcription, which suggests Phex is somehow involved in controlling the FGF23 biosynthesis 
[122].  
 
Some recent studies indicate that Phex and dentin matrix acidic phosphoprotein 1 (DMP1) share 
a common pathway to regulate Fgf23 expression. DMP1 belongs to a class of small integrin-
binding ligand, N-linked glycoprotein (SIBLING) proteins – SIBLING is a family of non-
collagenous proteins that are components of extracellular matrix of bone and dentin. Dmp1 is 
expressed by osteoblasts and osteocytes, and an inactivating mutation in Dmp1 can increase 
Fgf23 expression in the bones. The main function of DMP1 is to regulate mineralization of the 
extracellular matrix. A proposed mechanism of how DMP1 and Phex regulate Fgf23 expression 
is illustrated in Figure 3. In brief, the acidic serine-aspartate-rich motif (ASARM) at the C-
terminal of DMP1 binds to Phex located on the membrane of osteocytes, which subsequently 
inhibits expression of Fgf23. When there is a mutation on Phex, a biosynthesis of FGF23 is 







Figure 3: A Proposed Mechanism of How DMP1 Regulate the Fgf23 Expression. The 
ASARM motif at the C-terminal of DMP1 binds to the PHEX protein located on the membrane 
of osteocytes to inhibit the expression of Fgf23. Detailed intermediate mechanisms remain 













The development of TIO is usually associated with slow-growing, benign, mucinous tumors that 
are often pathologically classified as phosphaturic mesenchymal tumors. These tumors secrete 
FGF23 which is considered a causative factor for TIO [123]. Many clinical cases showed that 
once the tumors were surgically removed, serum FGF23, serum phosphate and renal phosphate 
handling were then normalized – TIO was cured [58]. Recent human studies also showed that 
treatment with an antibody against FGF23 led to resolution of TIO [124]. 
 
1.2.3.1.3 ADHR 
ADHR is a rare genetic disorder caused by mutations on Fgf23 [125]. Three missense mutations 
have been discovered to date, with each making the FGF23 protein resistant to cleavage – 
resulting in relative excess circulating FGF23, impaired mineralization of bone, rickets and/or 
osteomalacia, suppressed levels of calcitriol, renal phosphate wasting, and low serum phosphate. 
In clinical practice, calcitriol treatment – which is a common treatment for low serum phosphate 
– does not rescue hypophosphatemia in ADHR patients. Some studies showed that serum FGF23 
levels in some ADHR patients with hypophosphatemia were not always high and might fluctuate 
[126].   
 
1.2.3.1.4 ARHR 
ARHR is a rare genetic disorder that is often associated with increased serum FGF23, 
hypophosphatemia, low levels of serum calcitriol and hypophosphatemic rickets. Serum calcium, 
PTH and urinary calcium excretion in ARHR patients are normal [127, 128]. There are three 
types of ARHR, which are due to genetic mutations in Dmp1 (Type 1), Enpp1 (Type 2) and 
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Fam20c (Type 3), respectively[127, 128].  
 
1.2.3.2 FGF23-Dependent Hyperphosphatemic Disorders 
A common human disorder characterized by hyperphosphatemia is tumoral calcinosis (TC). 
Familial TC is a rare autosomal recessive disease in which patients have ectopic calcifications, 
especially on blood vessels and joints [129, 130]. Familial TC patients also develop 
hyperphosphatemia due to increased renal phosphate reabsorption and elevated serum calcitriol 
levels [130]. The development of familial TC is mainly caused by a disruption in the FGF23 
signaling pathway due to gene mutations – several responsible genes have been identified to 
date, including Galnt3, Fgf23, and Klotho [131-133]. Galnt3 encodes an enzyme involved in the 
glycosylation of FGF23 – mutations on Galnt3 result in higher sensitivity of FGF23 to cleavage 
before it can exit the cell of origin. Therefore, Galnt3 mutations can cause low serum intact 
FGF23 levels – which should have a similar phenotype as inactivating Fgf23 mutations [58].  
A KO mouse model – Fgf23 null – has been created to mimic inactivating Fgf23 mutations in 
humans. Those Fgf23 null mice exhibit growth retardation, hyperphosphatemia, increased 
calcium and calcitriol, and impaired bone mineralization and long bone growth in adulthood. 
Klotho gene mutations result in functional loss of the FGF23 signaling pathway. However, 
different from Galnt3 and Fgf23 mutations, Klotho mutations have high levels of serum FGF23, 
which is regarded as a compensatory response to hyperphosphatemia. 
 
1.2.3.3 FGF23-Independent Phosphate Disorders 
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare autosomal recessive 
disorder caused by mutations in NaPi2c [134].  HHRH patients normally develop urinary 
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phosphate wasting, hypophosphatemic rickets and appropriately elevated calcitriol.  The elevated 
calcitriol further results in hypercalciuria due to enhanced intestinal calcium absorption and 
reduced PTH-dependent renal calcium reabsorption that can cause kidney stones and/or 
nephrocalcinosis.  
 
Dent disease is an X-linked recessive chronic kidney disease that primarily affects males.  
It is mainly caused by mutations in either Clcn5 (Type I, 60% of cases) or Ocrl (Type II, 15% of 
cases). The remaining 25% of Dent disease cases are due to unknown genetic mutations.  The 
Clcn5 and Ocrl genes are involved in the production of proteins needed for normal kidney 
function, particularly in the proximal tubules where nutrients, water, and other substances are 
reabsorbed.  Mutations in the two genes impair the ability of the kidneys to reabsorb those 
substances.  Dent disease patients usually develop proteinuria, hypercalciuria, nephrocalcinosis 
and kidney stones. Some patients with Dent disease may also develop bone diseases such as 
osteomalacia and hypophosphatemic rickets (a condition caused by impaired phosphate 
reabsorption and altered calcitriol metabolism in the kidneys). 
 
Idiopathic infantile hypercalcemia (IIH) is a condition characterized by high levels of calcium in 
the blood. There are two types of IIH, which are caused by mutations in Cyp24a1 (Type I) and 
NaPi2a (Type II), respectively. Mutations in either of the two genes result in too much calcitriol 
in the blood, causing hypercalcemia that further leads to hypercalciuria, kidney stones, vomiting, 
polyuria, dehydration, constipation, poor feeding, weight loss, and an inability to grow. Patients 
with Type II IIH can also develop hypophosphatemia, while phosphate levels are typically 
normal in Type I patients. 
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1.3 Phosphorus Homeostasis in Fetal Life 
The preceding sections described regulation of phosphate homeostasis in young and adult stages. 
Phosphate metabolism during fetal development differs in several respects [135]. Normal human 
fetuses are hyperphosphatemic, with cord blood phosphate 0.5 mmol/L higher than maternal 
values; so are all mammals studied [135]. The fetal demand for phosphate is met by active 
transport across the placenta, which contributes to fetal hyperphosphatemia. Phosphate plays a 
significant role in fetal bone development. Renal and intestinal phosphate regulation during fetal 
life appears to be much less important than that in adulthood as a result of autophagia. That is, 
amniotic fluid (fetal urine) excreted by the fetal kidneys can be swallowed and absorbed by the 
intestines – it should be noted that intestinal absorption is a minor circuit and of little importance 
to fetal mineral homeostasis while this process is the primary and the only route of mineral 
delivery in the postnatal stage.    
 
1.3.1 Phosphate Handling by the Placenta 
By the time of this dissertation, few studies had been conducted to investigate placental 
phosphate transport. In this section, the current findings were summarized.  
 
1.3.1.1 Phosphate Transport across the Placenta 
Normally, two thirds of the phosphate stored in the human skeletons during fetal development is 
accreted within the third trimester [136]. Much evidence suggests that NaPi2b plays an important 
role in placental phosphate transport. For example, back in 1980s, Stulc’s group demonstrated 
that phosphate transport across the placenta was sodium (Na
+
) dependent in guinea pigs [137, 
138]. The rodent placenta was demonstrated to express Napi2a, NaPi2b, and NaPi2c, with the 
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levels of NaPi2a and NaPi2c lower than those of NaPi2b [139, 140]. In addition, global NaPi2b 
KO is lethal during mid-gestation [21].      
 
1.3.1.2 Regulation of Placental Phosphate Transport 
Many studies have been conducted to investigate factors that regulate how calcium crosses the 
placenta. However, there were few studies about phosphate. Prior to my Ph.D. project (one of 
experiments was to measure the effect of FGF23 excess or absence on placental phosphate 
transport), researchers had examined effects of several other hormones, including PTHrP, PTH, 
and calcitriol.   
 
1.3.1.2.1 PTHrP 
Multiple studies suggest that PTHrP is an important factor regulating placental calcium and 
magnesium transport. For example, Care’s group demonstrated that injections of a mid-region 
portion of PTHrP increased the rate at which the calcium concentrations increased (as measured 
by 45Ca/51Cr-EDTA) in the umbilical veins – suggesting PTHrP stimulates placental calcium 
transport [141]. Conversely, the N-terminal section of PTHrP was shown to have no effect on the 
process [135]. Dr. Kovacs’ group also independently showed that injections of mid-region but 
not N-terminal PTHrP could rescue a reduction in placental calcium transport in Pthrp null fetal 
mice [142]. Based on these observations, it should be logical to investigate whether mid-region 
PTHrP regulates placental phosphate transport; however, several studies in rats and ewes found 





That the PTH receptor gene, Pthr1, is highly expressed by intraplacental yolk sacs and 
trophoblasts in rodents strongly suggests that PTH plays certain roles in placental mineral 
transport [145]. However, most studies in fetal lambs suggest that PTH has no effect on placental 
phosphate transport [146]. Abbas, Care, and Rodda’s group independently showed that 
exogenous PTH did not change placental phosphate transport in thyroparathyroidectomized fetal 
sheep [141, 147, 148].  
 
For placental calcium transport, results are mixed. The studies by Abbas, Care, and Rodda’s 
groups in thyroparathyroidectomized fetal sheep showed PTH has no effect on this process, 
while Robinson’s group illustrated that exogenous N-terminal (1-34) PTH modestly increased 
calcium transport in the placenta from decapitated rat fetuses that mimicked parathyroidectomy 
[149]. Dr. Kovacs’ laboratory previously used Pth null and Gcm2 null fetuses to study potential 
effects of PTH on placental calcium transport. Gcm2 is a gene involved in the development of 
the parathyroid glands – knocking it out leads to the defective to absent parathyroid glands. 
Gcm2 null fetuses have a similar phenotype as Pth nulls, except the former have low but 
detectable serum levels of PTH. The results showed that placental calcium transport in Pth null 
fetuses appeared normal [150]. In subsequent studies, Pth null fetuses treated in utero with 
PTH1–84 increased the accumulation rate of 
45
Ca by 30%, indicating that exogenous PTH could 
stimulate placental calcium transport when endogenous PTH is absent. Different from Pth null 
fetuses, Gcm2 nulls had a significant increase in the rate of placental calcium transport, which 
was attributed to increased expression of Pth mRNA within the Gcm2 null placenta [150]. It is 
noteworthy that Pthrp null fetuses have decreased placental calcium transport despite a 3-fold 
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increase in PTH – therefore, PTH cannot make up for loss of PTHrP. 
 
To sum up, current available data suggest that PTH has no effect on placental phosphate transfer 
but that PTH may have a modest effect to stimulate placental calcium transport.    
 
1.3.1.2.3 Calcitriol 
Few studies directly examined whether calcitriol can regulate phosphate transport across the 
placenta. One group used an indirect method to measure the impact of calcitriol on this process 
in pregnant ewes. In this study, a single infusion of phosphorus isotope (
32
P) was injected into 
pregnant ewes that were later treated with either pharmacological doses of calcitriol or diluent 
(control) for one week. One week later, the amount of 
32
P in fetal ewes from the mothers treated 
with calcitriol was higher than that in fetal ewes from control mothers [151]. Placental calcium 
transport was also measured, showing similar results as phosphate. The same group conducted 
similar experiments in pregnant guinea pigs and obtained similar results – fetuses of the 




Ca compared to those of the control mothers 
[152].  
 
The results above appear to suggest that maternal calcitriol can increase the rate of placental 
phosphate transport. However, it should be noted that their experimental approaches were too 
indirect because external phosphate injection on pregnant mothers could increase phosphate 
availability to fetuses independent of calcitriol. In addition, just because pharmacological doses 
of calcitriol could increase the rate of placental phosphate transfer does not mean physiological 
doses would do the same. One study in Dr. Kovacs’ group demonstrated that Vdr null mouse 
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fetuses had no deficit in placental phosphate transport (unpublished data).These confounding 
results make the theory that calcitriol could regulate placental phosphate transport inconclusive.    
 
1.3.1.2.4 FGF23 
Prior to my Ph.D. program few studies were carried out to investigate the role of FGF23 in 
placental phosphate transport.  One study in Dr. Kovacs’ laboratory demonstrated that Fgf23 null 
fetuses had a similar rate of placental phosphate transport as WT fetuses, suggesting FGF23 
plays no role in this process [139]. In my present study, I investigated if excess FGF23 in Phex 
null fetuses would change the rate of placental phosphate transport.  Please refer to the results 
section of this dissertation.   
 
1.3.1.3 Summary of Key Points 
Active transport of phosphate across the placenta is required to meet fetal requirements for 
minerals; however, the mechanisms are not well established. The mid-section of PTHrP seems to 
be able to increase placental transport for calcium but not for phosphate. PTH and calcitriol were 
tested in rats and lambs – no solid conclusions have been reached as to whether the two 
hormones can regulate placental phosphate transport. FGF23 seems to have no effect in this 
process. 
 
1.3.2 Phosphate in Fetal Bone Development 
1.3.2.1 Overview of Fetal Bone Development 
There are two essential mechanisms involved in fetal bone development: intramembranous and 
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endochondral. Intramembranous bone formation involves deposits of mesenchymal cells in 
places where the axial and appendicular skeletons will form. Those mesenchymal cells will 
differentiate directly into osteoblasts that then form the intramembranous bones.  
 
Most of the fetal skeleton forms through endochondral bone formation, in which mesenchymal 
progenitor cells initially differentiate into proliferating chondroblasts and chondrocytes, forming 
a proliferating zone (Figure 4).  Cells located on the end of the proliferating zone secrete PTHrP 
and other signals to delay chondrocyte differentiation. As the distance increases from the zone of 
proliferating chondrocytes, older chondrocytes no longer receive the signals, so they start 
differentiating, forming a differentiation zone. After differentiation is complete, those 
differentiated chondrocytes become hypertrophic and a hypertrophic zone is then formed. 
Eventually hypertrophic chondrocytes undergo apoptosis and the dead cells and matrix are 
removed by chondroclasts, after which new blood vessels form and osteoblasts begin to lay 
down primary spongiosa. Interestingly, some studies suggest that hypertrophic chondrocytes 
could become osteoblasts and osteocytes in fetal and postnatal endochondral bone formation 
[153]. Endochondral bone formation occurs at the primary ossification centers during fetal bone 
development. It is not until the primary ossification centers have formed that the skeletons begin 





Figure 4: Endochondral Bone Formation. Mesenchymal progenitor cells initially differentiate 
into proliferating chondroblasts and chondrocytes (the proliferating zone).  The cells located on 
the end of the proliferating zone secrete PTHrP and other signals to prevent chondrocytes from 
differentiation. As the distance increases from the zone of proliferating chondrocytes, older 
chondrocytes no longer receive the signals, so they start differentiating (the differentiation zone). 
After the process of differentiation is complete, these chondrocytes become hypertrophic (the 
hypertrophic zone). Eventually hypertrophic chondrocytes undergo apoptosis and the dead cells 
and matrix are removed by chondroclasts, after which new blood vessels form and osteoblasts 










1.3.2.2 Regulation of Phosphate in Fetal Bone Development 
Phosphate is important in endochondral bone formation in fetuses – phosphate stimulates 
apoptosis of hypertrophic chondrocytes [154, 155] and it is deposited into osteoid before forming 
hydroxyapatite with calcium [156, 157]. Therefore, serum phosphate is an important factor in 
regulating fetal bone formation and mineralization. Studies in rodents, lambs, pigs, calves and 
foals suggest that serum phosphate is typically higher in fetuses than in pregnant mothers, which 
is critical to maintain the healthy bone formation in fetuses [135]. In fetuses with 
hypophosphatemia, apoptosis of differentiated hypertrophic chondrocytes is impaired, leading to 
an expanded hypertrophic chondrocyte layer of the growth plate, as well as reduced mineral 
deposits in the bones [154, 155]. 
 
1.3.2.2.1 PTH 
Studies in fetal sheep suggest that PTH is necessary for normal fetal bone development because 
previous studies in fetal lambs showed that surgical removal of the parathyroids resulted in 
undermineralized skeletons with increased bone volume, trabecular thickness and osteoid [158]. 
Compared to studies in fetal lambs, studies in fetal rats indicate that PTH is not required since 
fetal decapitation that mimics thyroparathyroidectomy had little impact on endochondral bone 
formation [159]. 
 
Studies utilizing various genetic KO mouse models have also been carried out to assess potential 
roles of PTH in fetal skeletal development. Knocking out Hoxa3 (a gene involved in the 
development of the parathyroid glands) causes absence of the parathyroid glands. Previous 
studies in Dr. Kovacs’ laboratory showed that Hoxa3 null fetuses had the normal long bones and 
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growth plate development, but their skeletons were significantly undermineralized [160]. 
Specifically, the total body ash weight, the calcium content and the magnesium content in Hoxa3 
nulls were reduced by approximately 10%, 20% and 10%, respectively. As to chondrocyte and 
osteoblast-specific genes, they were normally expressed. In Pth null fetuses, the skeletons were 
also undermineralized. However, unlike Hoxa3 nulls, Pth nulls showed slightly shortened long 
bones, abnormally formed skulls, smaller vertebral bodies, and shorter metacarpal and metatarsal 
bones [161]. In addition, the long bones of Pth nulls had an enlarged hypertrophic zone, 
increased cortical thickness, and decreased osteoblast number. As to osteoblast-specific genes, 
their expression was reduced in Pth nulls. 
 
A comparison between the phenotypes of Pth nulls and Hoxa3 nulls leads to a question – why a 
loss of PTH cause a bone phenotype which a loss of the parathyroid glands does not possess? 
Different genetic backgrounds could be an answer because Hoxa3 nulls in the study were 
generated in a Black Swiss background, while Pth nulls in C57BL/6 that is known to have lower 
levels of blood calcium compared to Black Swiss [162]. To resolve the puzzle, Pth nulls were re-
examined in a Black Swiss background in Dr. Kovacs’ laboratory. The results showed that Pth 
null fetuses had normal skeletal development, with a modestly reduced mineral content that was 
not as severe as in Hoxa3 nulls [142, 160]. The results indicate that a loss of PTH would cause a 
defective bone phenotype only in a C57BL/6 background, which is likely due to lower serum 
calcium in C57BL/6 mice than Black Swiss ones [163-166].  As to the osteoblast-specific genes 
that were reduced in Pth nulls with a C57BL/6 background, their expression was not altered in 





During fetal bone development, PTHrP is synthesized by chondrocytes in the proliferating zone. 
PTHrP’s N-terminal receptor, PTH1R, is located on the surface of  chondrocytes within the pre-
hypertrophic zone. Acting on the pre-hypertrophic chondrocytes, PTHrP delays their 
differentiation from proliferating to hypertrophic chondrocytes. That is, without PTHrP 
chondrocyte hypertrophy and the primary bone formation would occur prematurely, causing 
chondrodysplasia with shortened limbs [146, 167, 168]. Conversely, excess PTHrP during fetal 
bone development can result in the under-mineralized skeletons at birth (almost entirely 
cartilaginous) because endochondral bone development is so delayed [169, 170]. 
 
Previous animal studies showed that rodent Pthrp null fetuses developed hypocalcemia, 
hyperphosphatemia, and reduced placental calcium transport. Those null fetuses were originally 
expected to have reduced skeletal mineral content; however, they displayed normal skeletal ash 
weight and normal content of calcium and phosphate due to abnormally accelerated 
mineralization [160, 162]. In addition, not only the bones in utero were prematurely mineralized 
in Pthrp null fetuses, but some parts of their skeletons that normally remain cartilaginous – such 
as the sternal portions of the ribs – became the bones before birth. The expression of osteoblast-
specific genes (collagen I, collagenase-3, osteocalcin and osteopontin) was normal to increased 
in Pthrp nulls.  These results above confirm that PTHrP plays an important role in controlling 
bone mineralization (including phosphate) and growth plate development in fetuses.  
 
1.3.2.2.3 Combined Actions of PTH and PTHrP 
PTH and PTHrP share the same receptor, PTHR1. Knocking out Pthr1 causes characteristics 
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similar as combined phenotypes of PTH and PTHrP deficiencies. Pthr1 null fetuses have 
chondrodysplasia plus under-mineralization[171]. Hoxa3/Pthrp double KO fetuses have neither 
PTH nor PTHrP. They have a small body size, severe chondrodysplasia, and under-mineralized 
skeletons [160]. This model is essentially a sum of the phenotypes of Hoxa3 nulls and Pthrp 
nulls. Pthrp/Pth double KO fetuses show chondrodysplasia (observed in Pthrp nulls) combined 
with the under-mineralized bones (demonstrated in Pth nulls) [161].  
 
In summary, prior mouse studies demonstrated that Pth nulls and Hoxa3 nulls developed the 
under-mineralized bones; Pthrp nulls had normal skeletal mineral content but chondrodysplasia 
with shortened limbs; and Pthr1 nulls had a combined phenotypes of Pth nulls and Pthrp nulls. 
These results suggest that during fetal development PTHrP functions locally in the process of 
endochondral bone development to maintain the cartilaginous proliferating zone and delay their 
terminal differentiation, whereas PTH stimulates normal skeletal mineralization via maintaining 
serum mineral levels and acting on osteoblasts.  
 
1.3.2.2.4 Calcitriol 
Various animal studies have suggested calcitriol is not required for mineralization of 
endochondral ossification during fetal development. For example, fetal rats with vitamin D 
deficiency and fetal mice without Vdr had normal ash weight and skeletal mineral content [172-
175]. Specifically, the skeletons in Vdr null fetuses displayed no abnormalities – the length and 
morphology of the long bones in the appendicular skeleton were normal. Vdr null fetuses and 
their WT siblings had similar growth plates (length and morphology). As to expression of 
skeletal development-related genes [types I, II, and X collagens, H4 histone, cartilage matrix 
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protein, osteoblast markers (osteopontin, osteocalcin, interstitial collagenase, and alkaline 
phosphatase), osteoclast marker (92-kDa gelatinase or type IV collagenase or matrix 
metalloproteinase-9)], no differences were detected in Vdr nulls. 
 
It should be noted that Vdr null fetuses normally have high levels of calcitriol, which could 
potentially act on other receptors (not VDR) to regulate skeletal development and mineralization 
in fetuses. Recent studies using Cyp27b1 KO mouse model in Dr. Kovacs’ laboratory eliminated 
such possibility [176].  The results showed that Cyp27b1 null fetuses derived from Cyp27b1 null 
dams had normal skeletal mineral content and morphology relative to WT fetuses, which 
confirms that calcitriol is unimportant in regulating bone development and mineralization in 
fetuses.     
 
1.3.2.2.5 FGF23 
The role of FGF23 in regulating phosphate during fetal bone development had not been studied 
before my Ph.D. project was carried out. Concurrent with my Ph.D. project, one student in Dr. 
Kovacs’ laboratory carried out a study in Fgf23 null fetuses, which demonstrated that those nulls 
had normal mineral content (phosphate, calcium and magnesium) in their body ash prior to birth.  
In addition, other skeletal parameters were also normal in Fgf23 null fetuses.  Specifically, Fgf23 
null tibias showed normal endochondral development with no alteration in the lengths or cellular 
morphology of the cartilaginous or boney compartments, as well as a normal distribution of 
minerals [139]. In my present study, I investigated if excess FGF23 in Phex null fetuses would 
alter phosphate deposit during bone development, as well as other skeletal parameters.  Please 
refer to the results section of this dissertation. 
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1.3.2.2.6 Other Factors 
Animal and human studies indirectly suggest that sex hormones, including testosterone and 
estrogen, are not critical for fetal skeletal mineralization. Rodents and humans that have 
mutations in estrogen receptors or aromatase enzyme have normal bone morphology at birth and 
do not develop mineralization defects until older ages [177]. Calcitonin, which is encoded by the 
Ctcgrp gene, acts to lower serum calcium by preventing bone reabsorption. But calcitonin seems 
to be unimportant for fetal bone development and mineralization, as Ctcgrp null fetuses have 
normal endochondral skeletons (morphology, gene expression, and calcium and phosphate 
content) before birth [178].  
 
1.3.2.3 Summary of Key Points 
Phosphate plays an important role in fetal skeletal development and mineralization. Phosphate 
stimulates the apoptosis in hypertrophic chondrocytes during endochondral bone formation. 
When hypophosphatemia develops in fetuses, the apoptosis of differentiated hypertrophic 
chondrocytes is inhibited, leading to an expanded hypertrophic chondrocyte layer of growth 
plates and reduced mineral deposits in the bones. PTH and PTHrP are arguably the two most 
important hormones regulating fetal bone development and mineralization. PTHrP functions 
locally in the process of endochondral bone development to maintain the cartilaginous 
proliferating zone, whereas PTH stimulates normal skeletal mineralization via maintaining serum 
mineral levels and acting on osteoblasts. FGF23 does not seem to regulate phosphate during fetal 




1.3.3 Phosphate Handling by the Fetal Kidneys 
Although the kidneys play an essential role in maintaining mineral homeostasis in adults, their 
roles may be less important in fetuses for three reasons: first, the placenta is the main organ that 
supplies minerals to fetuses [179]; second, minerals (phosphate and calcium) that are excreted by 
the kidneys into amniotic fluid can be swallowed and absorbed (autourophagia), such that renal 
mineral excretion does not cause a permanent loss of mineral content [180]; and third, renal 
blood flow and glomerular filtration rates are low in fetuses until after birth, which contributes to 
relative inactivity of the kidneys during fetal development [181, 182].  
 
Whether the fetal kidneys play a role in mineral regulation remains inconclusive. Moore’s group 
and Ross’ group respectively conducted related experiments in fetal lambs – they surgically 
removed the bilateral kidneys, leading to hyperphosphatemia, hypocalcemia, an increase in PTH, 
and a 60% calcitriol decrease [183, 184]. A control procedure was conducted on additional fetal 
lambs by bilateral ureteral sectioning to permit fetal urine to drain into peritoneal cavity while 
presumably preserving normal renal function – the control procedure had no effect on fetal 
minerals and related hormones [183]. These observations led the researchers to believe it was the 
decrease in renal calcitriol production that resulted in the fetal mineral changes, but not the loss 
of the fetal kidneys. Moritz’s group nephrectomized five fetal lambs at 100 days of gestation 
(gestation in sheep normally varies from 142 to 152 days) and compared them to normal fetuses 
(control). The nephrectomized lambs displayed increased serum phosphate (two times as high as 
that in control), no changes in serum calcium, and a non-significant decrease in calcium 
excretion into amniotic fluid[185]. Unfortunately, calcitriol and PTH were not measured. Similar 
experiments have also been performed on fetal rats, with the results showing the same trend for 
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serum and amniotic fluid calcium but no phosphate changes[186].  
 
In summary, the kidneys play relatively minor roles in regulating fetal phosphate homeostasis 
because the placenta is the main organ of mineral delivery, fetuses can swallow amniotic fluid, 
and renal blood flow and glomerular filtration rate are low in fetuses. Several studies in fetal 
lambs suggest that the fetal kidneys may adjust serum phosphate through the renal production of 
calcitriol. However, more studies are needed.   
 
1.3.3.1 Regulation of Phosphate in the Fetal Kidneys 
1.3.3.1.1 PTH and PTHrP 
In fetuses, PTH appears to have some role in phosphate excretion. For example, 
thyroparathyroidectomized fetal lambs had hyperphosphatemia and reduced renal phosphate 
excretion. Hypocalcemia and increased calcium excretion were also noticed in them [187]. 
However, one previous study showed that a pharmacological dose of N-terminal fragments of 
PTH or PTHrP did not change serum or urine phosphate concentrations in normal fetal lambs 
[187, 188].  Fetal mice with mutations in Hoxa3, Gcm2, Pth1r, or Pth have hyperphosphatemia, 
which is likely contributed to reduced phosphate excretion [135, 150, 189].  
 
1.3.3.1.2 Calcitriol 
Functions of calcitriol in fetal phosphate regulation through the kidneys are inconclusive. One 
study in fetal lambs, which is discussed above in Section 1.3.3 titled “Phosphate Handling by the 
Fetal Kidneys,” concluded that a loss of renal production of calcitriol caused hypocalcemia and 
 
 46 
hyperphosphatemia – indicating renal phosphate excretion might be reduced without calcitriol 
[183]. Unlike nephrectomized fetal lambs, nephrectomized fetal rats had no changes in serum 
phosphate – indicating calcitriol might not be important in renal phosphate excretion [186]. In 
Vdr null fetuses (mice), serum ionized and amniotic fluid phosphate concentrations were not 
changed compared to WT, which also indicates kidney-produced calcitriol is relatively 
unimportant in renal phosphate regulation in mouse fetuses [175]. Cyp27b1 null fetuses had a 
similar phenotype – they had normal serum and amniotic fluid calcium and phosphate 
concentrations [190]. Why do rodent fetuses and fetal lambs show an opposite response to 
calcitriol deficiency? It is possibly because circulating calcitriol levels are relatively low in fetal 
rodents but high in fetal lambs [135]. 
 
1.3.3.1.3 FGF23 
Given that FGF23 regulates phosphate homeostasis in adults by suppressing renal phosphate 
reabsorption, FGF23 was initially expected to have an important role in fetuses. By the time 
when I started my Ph.D. project, there had been no relevant published data. One experiment 
(concurrent with my Ph.D. project) conducted in Dr. Kovacs’ Laboratory showed that phosphate 
and calcium in fetal amniotic fluid, which represents fetal urine, were not different between 
Fgf23 null and WT fetuses two days prior to birth. Renal expression of NaPi2a and NaPi2c was 
not altered in those nulls either.  These results suggest that FGF23 plays no role in regulating 
renal phosphate during the fetal stage. In my Ph.D. project, I studied amniotic fluid phosphate 
and calcium, as well as renal expression of NaPi2a and NaPi2c, in Phex null mouse fetuses 




1.3.3.2 Summary of Key Points 
The kidneys appear to be less important during fetal development because amniotic fluid (largely 
consisting of fetal urine) can be recycled through a process called autourophagia. The fetal 
kidneys are a likely source of low levels of calcitriol in the fetal circulation, and are capable of 
excreting and reabsorbing phosphate. Whether the fetal kidneys contribute importantly to fetal 
phosphate homeostasis is still uncertain.  Studies have been conducted to examine whether PTH, 
PTHrP and calcitriol can regulate renal phosphate regulation in fetuses, with no solid conclusions 
having been reached.  FGF23’s role was examined in this Ph.D. project, and the results were to 
be presented below in the results section.   
 
1.4 Phosphorus Homeostasis during the Neonatal Stage 
1.4.1 Serum Phosphate Changes during a Transition from Fetuses to Neonates 
After birth, a loss of the placenta forces a rapid change in mineral homeostasis because the 
source of minerals is lost and must be switched to intestinal absorption and renal reabsorption as 
quickly as possible.  
 
In rodents, serum phosphate decreases significantly in the first 2 – 4 hours after birth, then 
sharply increases by 6 hours, and again drops over the following days to normal neonatal levels 
[191]. The initial decline is largely due to a loss of the placental phosphate supply while uptake 
into bone continues; the subsequent rise corresponds to a transient hypoparathyroidism which is 
physiologically normal in newborns [135]. Why is there a transient hypoparathyroidism? In 
rodent fetuses, PTH circulates at lower levels because it is suppressed by hypercalcemia. After 
fetuses are delivered, fetal calcium falls immediately, which stimulates PTH release – but the 
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whole process to produce a sufficient amount of PTH takes time. Interestingly, some scant data 
from WT mice showed that FGF23 spiked to 10-fold higher than adult values within 12 hours 
after birth, concurrent with the transient increase in serum phosphate [192]. Contrary to rodents, 
neonatal lambs have elevated serum phosphate for more than one week [193]. Human babies 
undergo a similar transient hypoparathyroidism, with serum phosphate increasing over the first 
24 – 48 hours after delivery [194-196]. Subsequently, serum PTH rises and serum phosphate 
declines to adult levels [135].  
 
1.4.2 Intestinal Phosphate Absorption in Neonates 
Very few studies have been conducted to investigate intestinal phosphate absorption in neonates. 
However, how calcium is intestinally absorbed may give some insights as to how phosphate is 
absorbed because both minerals are related.  
 
In rodent neonates, intestinal calcium absorption occurs mainly in a passive manner and 
independent of calcitriol [197-199]. High levels of lactose contained in breast milk increase 
passive transport [135]. As days pass, intestinal epithelial cells start expressing necessary 
elements that drive active calcium absorption. These elements include VDR, calbindin-D9k, and 
transient receptor potential cation channel subfamily V member 6 (TRPV6).  
 
Studies have been conducted to investigate whether a disruption in the calcitriol pathway would 
cause a disturbance in intestinal calcium absorption in neonates. Experiments conducted by 
Halloran’s group showed that plasma calcium at 3 days postpartum was fairly normal in vitamin 
D-deficiency rat pups; however, plasma calcium decreased during the suckling period [199]. 
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Several mouse models with a disrupted vitamin D pathway were studied, which included four 
different types of Vdr null neonates [200-203] and two different types of Cyp27b1 null neonates 
[204, 205]. During the lactation period (first 2-3 weeks after birth), serum calcium and phosphate 
in Vdr nulls and Cyp27b1 nulls were normal. When it approached weaning, the null pups started 
to develop hypocalcemia, hypophosphatemia, secondary hyperparathyroidism and signs of 
rickets. When Vdr null and Cyp27b1 null pups were treated with a rescue diet made of increased 
content of calcium, phosphate and lactose, those pups could maintain normal serum calcium and 
phosphate and normal skeletal morphology and mineral content. The results described above 
suggest that passive calcium absorption (which may be stimulated by calcitriol to a small extent) 
progressively declines during the first 3 weeks after birth in rodent neonates, after which 
calcitriol-dependent active transport becomes the dominant way for calcium to be absorbed[135].  
 
In terms of phosphate, there is no specific data. It is expected that intestinal phosphate absorption 
in neonates follow a similar pattern as to what happens with calcium absorption, since calcitriol 
regulates both calcium and phosphate.  
 
In human neonates, calcium absorption is enhanced by lactose in breast milk, which is similar to 
rodent neonates [206, 207].  Intestinal absorption and retention of calcium increase with both 
postnatal age [135, 208, 209]. These findings suggest that intestinal absorption in human 
neonates develops toward an active, calcitriol-dependent process – which is what is seen in older 
children and adults. Much evidence suggested that the intestines in premature babies are 
unresponsive to calcitriol. A small study in preterm babies compared human milk, human milk 
plus vitamin D, and human milk plus vitamin D and phosphorus, and found that only the group 
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receiving phosphorus supplementation had a significant increase in calcium retention, suggesting 
there is a lack of effect of vitamin D/calcitriol to increase calcium absorption and retention in the 
preterm intestines [210]. An interventional study found that preterm infants showed no calcemic 
response to short courses of supraphysiological doses of calcitriol, also suggesting the preterm 
intestines are refractory to calcitriol [211]. It should be noted that these data could infer that the 
intestines in human neonates go through progressive up-regulation of Vdr expression.  However, 
data of longitudinal changes in Vdr expression has not been available. Similarly, it is unclear 
when the intestines in neonates change from passive to active absorption. One study 
demonstrated the responsiveness to calcitriol at four weeks of age, which may indicate that 
active absorption should have occurred by that age [212].  Some human data from premature 
neonates highlights potential impacts of intestinal absorption on skeletal development. Studies 
demonstrated that prematurely born babies required more minerals to support bone development 
than what the intestines can possibly absorb. Thus, parenteral administration of minerals is 
needed to prevent premature rickets [213-215]. 
 
1.4.2.1 Regulators of Intestinal Phosphate Absorption in Neonates 
1.4.2.1.1 Calcitriol 
In adults, calcitriol is required to facilitate active phosphate transport across the intestines. Due to 
a lack of specific data in neonates, it is expected that calcitriol may not be important until after 
weaning when the active phase of intestinal phosphate absorption is more evident. This is 
partially supported by the fact that serum calcitriol does not elevate until the 3
rd
 week after birth 
when lactation is almost over – calcitriol is barely synthesized before weaning [191, 216]. In 
newborn lambs, calcitriol is not produced until up to 11 days after birth, even in response to PTH 
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administration [191, 217].    
 
1.4.2.1.2 FGF23 
Scant data is available regarding the role of FGF23 in intestinal mineral absorption in neonates. 
Studies have shown Fgf23 null neonates (mice) developed hyperphosphatemia and increased 
calcitriol at 10 days after birth, as well as hypercalcemia by 2 weeks – these data suggests that 
FGF23 could suppress phosphate and calcium absorption in the intestines; however, whether the 
effects are mediated through calcitriol is still unknown as there have been no studies 
investigating if FGF23 could directly regulate NaPi2b in the neonatal intestines [110]. 
 
1.4.2.1.3 PTH and PTHrP 
PTH and PTHrP could affect intestinal phosphate absorption in neonates via changing renal 
calcitriol synthesis. Studies of the PTH1R signaling pathway, comparison of crystal structures of 
PTH and PTHrP, and clinical studies suggest that PTH is a more potent simulator of the calcitriol 
synthesis than PTHrP in humans and rodents [218-221]. However, the kidneys of neonatal lambs 
have a resistance to PTH during the first 11 days after birth [217]. Whether PTHrP is directly 
involved in the renal calcitriol synthesis in neonates is unknown. PTHrP disappears from the 
circulation at some time point postnatally, which suggests that PTHrP is unlikely to be involved 
in renal production of calcitriol. The parathyroids are important for mineral homeostasis in 
neonates since removal of the organ increases serum phosphate and decreases calcium. However, 




1.4.2.1.4 Phosphate Content in Food 
Mineral content of food sources affect mineral intestinal absorption. Over 90% of the phosphate 
content in breast milk is absorbed through the intestines. More importantly, studies showed that 
neonates consuming formula with a higher phosphate content had serum phosphate doubled 
compared to ones consuming breast milk [135]. This is reasonable because phosphate absorption 
is proportional to intake when it is initially absorbed via a passive transport mechanism.  
 
1.4.2.2 Summary of Key Points 
Calcium studies suggest that intestinal mineral absorption (including phosphate) is through 
passive transport during the stage of breast feeding, after which minerals are actively transported 
across the intestines in a calcitriol-dependent manner. PTH is also an important hormone in this 
process as PTH is a potent stimulator of renal calcitriol production. Based on these conclusions 
from calcium studies in neonates, it is speculated that intestinal phosphate absorption follows a 
similar mechanism as calcium, and calcitriol and PTH are two critical hormones regulating the 
process after breast feeding.  
 
1.4.3  Skeletal Phosphate Metabolism in Neonates 
It is known that skeletal development in neonates highly depends on the efficiency of intestinal 
mineral absorption. Neonatal rodents normally do not develop any skeletal abnormality before 
weaning because minerals are passively absorbed during this stage. After weaning, intestinal 
mineral absorption becomes a calcitriol-dependent, active process, in which the neonatal 
skeleton will develop deficits in mineral content if there are conditions of hypoparathyroidism, 
vitamin D deficiency, and/or a loss of VDR. As to the skeletal phosphate content, it is highly 
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dependent on the intestinal supply after weaning, as well as, the ability to reabsorb phosphate in 
the kidneys. Thus, any phosphate deficiency in the diet, inability to absorb sufficient phosphate 
from the diet, or renal phosphate wasting will cause neonatal rickets. It also should be noted that 
infants and neonates normally tend to have higher serum phosphate concentrations than adults, 
which is believed to be important to maintain healthy bone development. Factors that regulate 
intestinal phosphate absorption should have a significant impact on skeletal phosphate deposits 
in neonates.   
 
1.4.4 Renal Phosphate Excretion in Neonates 
Renal regulation of phosphate in neonates needs further studies. Available data from rat studies 
showed that the neonatal kidneys started actively excreting or reabsorbing minerals within a few 
days after birth [222]. In addition, elements responsible for renal calcium reabsorption, such as 
TRPV6 and calbindin-D9k, showed a progressive expression increase, reaching maximum at the 
third week after birth [223]. Human data showed that renal phosphate excretion was low at birth 
and gradually increased with age [182, 224]. Longitudinal changes of NaPi2a and NaPi2c in the 
human neonatal kidneys have not been studied.  
 
1.4.4.1 Regulators of Renal Phosphate Excretion in Neonates 
1.4.4.1.1 PTH 
PTH reduces renal phosphate reabsorption in adults. But whether PTH affects the process in 
neonates remains inconclusive. In vitro studies demonstrated that PTH treatment in renal cells 
from rodent neonates generated less cAMP (an important element in the PTH signaling pathway) 
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than in fetal renal cells, indicating PTH is of less importance in the neonatal kidneys [225]. 
Human data showed that there was an increasing trend in serum PTH after birth, which coincided 
with the elevation of renal phosphate excretion [182, 224]. Term and preterm infants also 
showed a developmental increase in the cAMP synthesis after PTH treatment, likely suggesting 
that PTH begins to suppress renal phosphate reabsorption during the neonatal stage in humans 
[226].  
 
Some interesting data from studies in neonates with congenital hypoparathyroidism suggests that 
PTH may have a different effect on renal phosphate excretion between animals and humans. For 
example, animal pups with hypoparathyroidism had hypocalcemia, hyperphosphatemia, and 
impaired skeletal mineralization at birth; while human babies with hypoparathyroidism at birth 
did not develop hyperphosphatemia until later in childhood [135] [227-229].  
 
1.4.4.1.2 Calcitriol 
Potential roles of calcitriol in renal phosphate excretion in neonates have not been studied 
specifically. Rat kidneys do not begin expressing Vdr or responding to calcitriol until the third 
week after birth, suggesting that calcitriol does not function at the kidneys until after weaning 
[222]. Other studies have suggested that a gradual increase in renal calcitriol production in 
neonates is likely to due to an increasing responsiveness to PTH [225].    
 
1.4.4.1.3 FGF23 
Until recently, very limited data have been available pertaining to the role of FGF23 in renal 
phosphate regulation in neonates.  One mouse study demonstrated that reduced renal phosphate 
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excretion was present at 3 weeks after birth in Fgf23 KO neonates – this timing was the earliest 
time point that had been studied until this project [81]. Those nulls also displayed 
hyperphosphatemia, increased calcitriol, and hypercalcemia. In Phex mutant neonates, serum 
phosphate surprisingly increased modestly from 2 hours to 10 hours after birth, and then dropped 
– causing hypophosphatemia at 24 hours after birth [192]. At the same time that 
hypophosphatemia developed, serum FGF23 and PTH in those Phex mutant neonates were 
elevated, and calcitriol was reduced. These results suggest that FGF23 starts playing a role in the 
neonatal kidneys within the first day after birth.   
 
In humans, TC commonly presents during the first twenty years of life. In some cases, it has 
presented as early as 18 days after birth and as late as 65 years old [230-232]. XLH patients have 
been recognized to have hypophosphatemia during the first year after birth if there is family 
history that led to increased surveillance [233]. Without a family history, XLH with 
hypophosphatemia is often diagnosed at 2 or 3 years of age [234-236]. In one study involving 
four patients who were diagnosed early because of family history, all had hypophosphatemia 
between 2 and 6 weeks of age, one had reduced renal phosphate reabsorption at 9 days of age, 
and the rest did not have it until 6 months old [233]. 
 
1.4.4.2 Summary of Key Points 
The neonatal kidneys start actively excreting and reabsorbing phosphate within a few days after 




1.5 Summary of Animal Models 
In this Ph.D. project, three main mouse models were applied, including Phex null model, Fgf23 
KO model, and Klotho KO model. Main phenotypes of each model were summarized below.  
 
Phex null mice have naturally occurring mutations in the Phex gene located on Chromosome X, 
which leads to abnormally high serum levels of FGF23.  Adult Phex nulls had impaired 
mineralization (rickets or osteomalacia), which occur as a consequence of excess renal phosphate 
excretion, reduced calcitriol and reduced intestinal phosphate absorption.  
 
Fgf23 null mice have mutations in the Fgf23 gene located on chromosome 6, leading to loss of 
FGF23 in the blood. Adult Fgf23 nulls develop hyperphosphatemia and extraskeletal 
calcifications, which occur as a result of impaired urine phosphorus excretion, increased 
calcitriol, and increased intestinal phosphorus absorption. Although PTH also lowers serum 
phosphate, it is unable to correct the hyperphosphatemia caused by absence of FGF23 in the null 
mice.  
 
Klotho null mice have mutations in the Klotho gene located on chromosome 5. Adult Klotho 
nulls have a similar phenotype as Fgf23 nulls except that the former has high levels of serum 
FGF23.   
 
1.6 Overview of Ph.D. Project 
In adults, FGF23 is a phosphate-regulating hormone produced largely by osteocytes and 
osteoblasts. It controls a supply of phosphate at a mineralizing surface of the bones through 
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actions on distal tissues. Within proximal renal tubules FGF23 down-regulates expression of 
NaPi2a and NaPi2c. FGF23 also inhibits renal expression of Cyp27b1, increases expression of 
Cyp24a1, and inhibits intestinal expression of NaPi2b. The combined effects of these actions 
lead to increased renal phosphate excretion and reduced active intestinal absorption of calcium 
and phosphate. 
 
A loss of FGF23 causes hyperphosphatemia, extraskeletal calcifications, and early mortality, 
which occur as a result of impaired urine phosphate excretion, increased calcitriol, and increased 
intestinal phosphate absorption. Although PTH can also lower serum phosphate, PTH is unable 
to correct hyperphosphatemia caused by an absence of FGF23. Excess FGF23 leads to opposite 
phenotypes – hypophosphatemia with impaired mineralization (rickets or osteomalacia) and 
myopathy, which occur as a consequence of excess renal phosphate excretion, reduced calcitriol, 
normal-to-low PTH, and reduced intestinal phosphate absorption. 
 
My Ph.D. project was to study potential effects of FGF23 on fetal phosphate regulation and 
skeletal development. In this project, I hypothesized that FGF23 could regulate fetal phosphate 
metabolism through actions on the placenta, kidneys, and skeletons. The whole project was 
divided into four aims. Each aim is briefly described below: 
 Aim 1: To study effects of excess FGF23 on fetal phosphate metabolism and skeletal 
development by using the Phex null model; 
 Aim 2:  To study effects of a loss of Klotho on fetal phosphate metabolism and skeletal 
development by using the Klotho KO model;  
 Aim 3: To study combined effects of PTH and FGF23 losses on fetal phosphate metabolism 
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and skeletal development by using the Pth/Fgf23 double KO (DKO) model; and  
 Aim 4: To determine effects of excess FGF23 and a loss FGF23 on neonatal phosphate 
metabolism by using the Phex null model and the Fgf23 KO model, respectively.  The Klotho 
KO model was also applied in this aim.  
 
It should be noted that little had been known about the role of FGF23 in fetal and neonatal 
development by the time when this project was carried out. Concurrent with my studies, Dr. 
Samaraweera in Dr. Kovacs’ laboratory measured effects of a loss of FGF23 on fetal phosphate 
regulation and skeletal development by utilizing Fgf23 KO mouse model. Some of her results 
were cited in earlier subsections. Here I briefly summarized all of her results. In Dr. 
Samaraweera’s project [139], Fgf23 null fetuses were confirmed to have undetectable serum 
FGF23 on embryonic day (ED)18.5 compared to WT fetuses. Fgf23 heterozygous (HET) dams 
had significantly higher serum FGF23 than fetuses of all genotypes. In adults, FGF23 inhibits the 
synthsis of calcitriol, so it was originally expected that a loss of FGF23 would lead to an increase 
in calcitriol in fetuses. However, serum calcitriol on ED 18.5 in Fgf23 nulls was not changed. In 
terms of serum and plasma PTH, Fgf23 null fetuses had numerically lower levels than WTs. As 
to phosphorus and total calcium in serum and amniotic fluid, placental phosphate transport, and 
skeletal mineral content (phosphate, calcium and magnesium) and bone morphology, there were 
no significant differences in Fgf23 nulls. Placental and renal expression of Fgf23 and Fgf23-
targeted genes (Klotho, NaPi2a, NaPi2b, NaPi2c, Cyp27b1, Cyp24a1, and Fgfr1 – 4) in Fgf23 
null fetuses on ED 18.5 was also studied by Dr. Samaraweera. The WT placenta showed a low 
level of Fgf23 expression that was absent (no signal) in the null placenta. Those Fgf23-targeted 
genes were each expressed within the placenta, with Klotho and NaPi2b displaying the most 
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abundant expression. However, there were no significant differences between the WT and Fgf23 
null placenta in their expression. Fgf23 was not expressed within the WT and null fetal kidneys 
whereas each of the Fgf23-targeted genes was well expressed. Cyp24a1 expression was reduced 


















2 Materials and Methods 
2.1.1 Mouse Models Used in My Ph.D. Project 
All experiments were approved by Institutional Animal Care Committee of Memorial University 
of Newfoundland. 
 
2.1.1.1 Phex Null Model  
Phex null mice (AKA Hyp mice) bear spontaneous mutations on the Phex gene that is located on 









 (Figure 5).  The Phex model I used is based on the Phex
Hyp-2J
 
mutation. Adult Phex mutant mice develop excess FGF23, which causes hypophosphatemia, 
reduced renal phosphate reabsorption, low serum levels of calcitriol, reduced intestinal 
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2.1.1.2 Fgf23 KO Model 
The generation of Fgf23 null mice was previously described [237]. In brief, the Exon 1-3 coding 
region of the Fgf23 gene is replaced with the lacZ gene and the neomycin (neo) gene (Figure 6). 
Adult Fgf23 null mice develop FGF23 deficiency, which leads to hyperphosphatemia, increased 
renal phosphorus reabsorption, increased serum levels of calcitriol, increased intestinal 

















Figure 6: The Generation of Fgf23 Null Mice. The Exon 1-3 coding region of the Fgf23 gene 
















2.1.1.3 Klotho KO Model 
Klotho null mice were generated by an insertion of two unique plasmids, E50 and E70, which 
can trigger an 8-kb deletion of the Klotho gene, resulting in a functional loss of the gene [63] 
(Figure 7). Adult Klotho null mice have a similar phenotype as Fgf23 nulls – 
hyperphosphatemia, increased renal phosphate reabsorptionexcretion, high calcitriol, increased 
intestinal phosphorus absorption and skeletal abnormalities.  Different from Fgf23 nulls, Klotho 












Figure 7: The Generation of Klotho Null Mice. An insertion of two unique plasmids, E50 and 
















2.1.1.4 Fgf23/Pth Double KO Model  
The Fgf23/Pth double KO mice were generated in Dr. Kovacs’ Laboratory (Figure 8). In brief, 






















), as well as 5 
other genotypes that weren't relevant to current project. The generation of the Pth KO model was 
previously described [161]. In brief, part of Exon 3 of the Pth gene is replaced by a neo gene via 










Figure 8: The Generation of Fgf23/Pth Double Mutant Mice. Fgf23 HET mice were mated 




). The double HET mice were 






























Figure 9: The Generation of Pth Null Mice. To generate Pth null mice, part of the coding 
sequence of the Pth gene on Exon 3 is replaced with a neomycin-resistant gene via a homologous 































2.2 Description of Experiments in Aim 1 
All mice used in Aim 1 were raised on standard laboratory mouse diet (1% calcium, 0.75% 
phosphorus) and maintained in the Animal Care Facility at Memorial University of 
Newfoundland. Males and females were weaned at 3 weeks old. To generate experimental 
fetuses, 7-week-old female HET (♀ Phex
+/-
) and male WT (♂ Phex 
+/
) mice were mated 
overnight and then separated the next morning. The female mice were checked for a mucus plug, 
which is a sign that mating has occurred. Those females with a mucus plug were put into 
separate cages and the day was marked as Day 0.5 of pregnancy (ED 0.5). 
 
2.2.1 Experiments on ED17.5 
On ED 17.5, the pregnant mothers were sacrificed to collect amniotic fluid from each fetus. The 
amniotic fluid was frozen at -20˚C for future phosphorous and calcium measurements. 
 
2.2.2 Experiments on ED18.5 
On ED18.5, the pregnant mothers were sacrificed to harvest fetuses. Serum from each fetus was 
collected and frozen immediately for subsequent phosphorous, calcium and hormone (FGF23, 
PTH and calcitriol) measurements. After blood collection, carcasses were frozen at -20˚C for 
subsequent skeletal mineral and morphological analysis. The placenta and kidneys of each fetus 
were harvested and snap frozen for future expression analysis of FGF23-targeted genes by qPCR 
and microarray. On ED18.5, the amount of phosphorous transferred across the placenta from a 




2.3 Description of the Experiments in Aim 2 
To generate experimental fetuses, 7-week-old female HET (♀ Klotho
+/-
) and male HET (♂ 
Klotho
+/-
) mice were mated. Sample collection details are the same as those in Aim 1. 
 
2.4 Description of the Experiments in Aim 3 




) and male 




) were mated. On ED17.5, the pregnant mothers were sacrificed to 
harvest fetuses, following which serum of each fetus was collected and frozen immediately for 
future phosphate measures.  The bodies of the used fetuses were frozen for later mineral content 
measures.  
 
2.5 Description of the Experiments in Aim 4 
For the Phex mutant model, 7-week-old female HET (♀ Phex
+/-
) and male WT (♂ Phex 
+/
) mice 









) mice were mated. Neonatal 
serum and urine were collected and frozen on postnatal day 1 (PD 1, within 24 hours after birth), 
PD 3, PD 5, PD 7, and PD 10. Serum and urine phosphorous concentrations were later measured. 
The neonatal kidneys were harvested at the postnatal day when urine phosphorous of null pups 
showed a significant difference. qPCR was used to measure NaPi2a and NaPi2c mRNA 





Polymerase chain reaction (PCR) was carried out to determine mice genotypes. The genotyping 
process included tagging and tailing, DNA extraction, PCR, and gel electrophoresis. 
 
2.6.1 Tagging and Tailing 
Mice were briefly anaesthetized with isoflurane (Baxter, Toronto). Their right ear was pierced 
with an ear tag containing a unique number and a 0.5 cm tail clipping was collected and put into 
a sterile Eppendorf tube.  
 
2.6.2 DNA Extraction 
The Puregene Mouse Tail Kit (Qiagen, Toronto) was used to extract genomic DNA from tail 
clippings. Details can be found in the kit insert (see Appendix).  
 
2.6.3 PCR 
PCR was carried out on genomic DNA extracted from mouse tails. PCR conditions and primer 
sequences for each study are described below. 
 
2.6.3.1 PCR Programs for the Phex Mutant Model 
To identify male fetuses in the litter, PCR for the Sry gene was used to distinguish between male 
and females, with β-actin used as a positive control.  
 
The Sry primers were:  
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 Forward 5’-GAG AGC ATG GAG GGC CAT-3’,   
 Reverse 5’-CCA CTC CTC TGT GAC ACT-3’ (product size 200bp).  
 
The β-actin primers were:  
 Forward 5’-TGT GAT GGT GGG AAT GGG TCA G-3’, 
 Reverse 5’-TTT GAT GTC ACG CAC GAT TTC C-3’ (product size 514bp).  
 
The PCR program was as follows: 
 Initial denaturation at 95°C for 5 minutes 
 Denaturation at 94°C for 5 seconds  
 Annealing at 60°C for 30 seconds 
 Extension at 72°C for 30 seconds 
 Repeat for 30 cycles 
 Final extension at 72°C for 5 minutes 
 
To distinguish between null and WT, male fetuses were then genotyped by PCR to detect Exon 
15 (absent in Phex male nulls) and Exon 11 (present in both WTs and nulls and used as a 
positive control).  
 
 The Exon 15 primers were [238]:  
 Forward 5’-AGT CTT GCC AAA CTG TGC TC-3’, 




The Exon 11 primers were:  
 Forward 5’-GAC TGG TGT GGG ATG GAA TC-3’, 
 Reverse 5’-TCT TGT CTG TCA GAT CTG CC-3’ (product size 280bp).  
 
The PCR program was as follows:  
 Initial denaturation at 95°C for 5 minutes 
 Denaturation at 95°C for 30 seconds  
 Annealing at 60°C for 30 seconds 
 Extension at 72°C for 30 seconds 
 Repeat for 35 cycles 
 Final extension at 72°C for 5 minutes 
 
Because the mutation is X-linked, males are either null or WT and these 2 genotypes can be 
easily distinguished using primers to detect Exon 15 (above). But HET females mated to WT 
males can bear WT or HET fetuses and we were unable to distinguish between these 2 genotypes 
with the Exon 15 primers, which only allow us to detect the presence or absence of Exon 15 but 
not to distinguish between one copy of Exon 15 (as in HET) vs 2 copies (in WT). The Phex gene 
has not been sequenced adjacent to Exon 15 to enable efficient primer design to be used in 
conventional PCR genotyping. Instead, RNA extracted from female tails was first reverse-
transcribed to create cDNA and then amplified by PCR using primers designed to detect the 
Phex sequence. Female WTs (Phex
+/+
) should have a single band while female HETs (Phex
+/-
) 
should have two bands that include a normal band and a shorter mutant band. RNA extraction 
and cDNA synthesis steps are explained in the qPCR section below.  
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The specific PCR primers for on cDNA Exon 15 primers were:  
 Forward 5’-GGC AAC GTA CTG CAA ACC CGC-3’, 
 Reverse 5’-CCA CAG ACC ACC ACG GAT CAA GG-3’.  
 
The Exon 11 primers (positive control) were: 
 Forward 5’-GAC TGG TGT GGG ATG GAA TC-3’, 
 Reverse 5’-TCT TGT CTG TCA GAT CTG CC-3’ (product size 280bp).  
 
The PCR program was as follows:  
 Initial denaturation at 95°C for 5 minutes 
 Denaturation at 95°C for 15 seconds  
 Annealing at 68°C for 30 seconds 
 Extension at 68°C for 1 minute 
 6 cycles, -1°C/cycle 
 Denaturation at 95°C for 15 seconds  
 Annealing at 62°C for 30 seconds 
 Extension at 68°C for 1 minute 
 Repeat for 35 cycles 




2.6.3.2 PCR Programs for the Klotho KO model 




), and null (Klotho
-/-
). 
The GKL-01 and GKU01 primers detected the mutant allele while GKL-02 and GKU01 detected 
the WT allele. 
 
 GKU01 sense primer: 5’-TTG TGG AGA TTG GAA GTG GAC GAA AGA G-3’ 
 GKL-01 null antisense primer: 5’-CGC CCC GAC CGG AGC TGA GAG TA-3’ (product 
size 491bp) 
 GKL-02 wildtype antisense primer: 5’-CTG GAC CCC CTG AAG CTG GAG TTA C-3’ 
(product size 815bp) 
 
The PCR Procedure was as follows: 
 Initial denaturation at 94°C for 5 minutes 
 Denaturation at 94°C for 30 seconds  
 Annealing at 60°C for 1 minute 
 Extension at 72°C for 45 seconds 
 Repeat for 30 cycles 
 Final extension at 72°C for 10 minutes 
 
2.6.3.3 PCR Programs for the Fgf23 KO Model 




), and null (Fgf23
-/-
). The 
Fgf23 primers (forward and reverse) detected Fgf23 WT allele while the Fgf23 forward primer 
and the LacZ primer detected the mutant allele. 
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 Fgf23 forward primer: 5’-AGT CTT GCC AAA CTG TGC TC-3’  
 Fgf23 reverse primer: 5’-GTC ACT TAC ATT GAA AAC ACT C-3’ (product size 252 bp)  
 LacZ primer: 5’-TCT TGT CTG TCA GAT CTG CC-3’ (product size 366 bp)  
 
The PCR program was as follows: 
 Initial denaturation at 94°C for 5 minutes 
 Denaturation at 94°C for 1 minute  
 Annealing at 62°C for 1 minute 
 Extension at 72°C for 1 minute 
 5 cycles, -1°C/cycle 
 Denaturation at 94°C for 1 minute  
 Annealing at 56°C for 1 minute 
 Extension at 72°C for 1 minute 
 Repeat for 35 cycles 
 Final extension at 72°C for 5 minutes 
 
2.6.3.4 PCR Programs for the Fgf23/Pth Double KO Model 








) as parents. The same technique was also used to 
determine genotypes of the offspring. Fgf23 genotyping was done using the same primer set and 
procedure described above. Pth genotyping was performed using the following 3-primer system:  
 Pth common primer: 5’-AAG ATG ATG TCT GCA AAC ACC GTG G-3’  
 Pth wildtype primer: 5’-GGT GTT TGC CCA GGT TGT GCA TAA-3’ (product size 250bp)  
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 Pth mutant primer: 5’-TCC AGA CTG CCT TGG GAA AAG CGC-3’ (product size 200bp)  
 
The Pth PCR program was as follows: 
 Initial denaturation at 94°C for 5 minutes 
 Denaturation at 94°C for 1 minute  
 Annealing at 63°C for 1 minute 
 Extension at 72°C for 1 minute 
 Repeat for 34 cycles 
 Final extension at 72°C for 10 minutes 
 
2.6.4 Gel Electrophoresis 
Horizontal gel electrophoresis was used to separate and visualize PCR products. The 1.2% 
agarose gel in TAE buffer was made as follows: 1.2 g agarose (Invitrogen, Toronto) was 
dissolved by heating in 100 ml 1X TAE buffer (10ml 10x Tris-acetate-EDTA (TAE) buffer 
[0.12M EDTA, 0.40M Tris, 11.5% Glacial Acetic Acid, pH 8.0], 90 ml deionized water). 10μL 
SYBR Safe DNA Gel Stain (Invitrogen, Toronto) was added. Once slightly cooled, the gel was 
poured into the gel casting tray with comb in place and allowed to solidify.  
 
1X TAE was used as the gel running buffer (10X TAE diluted to 1X by adding 70ml to 630ml 
distilled water). 4μL of 6X gel loading dye (2% coomassie blue, 2% xylene cyanol, 30% 
glycerine) was added to the 20μL PCR product and mixed well. 15μL was pipetted into each 




The gel was imaged under UV excitation using Gel Doc
TM
 XR+ with Image Lab
TM
 Software 
(BIO-RAD, Toronto) to visualize the bands.  
  
2.7 Fetal Serum Mineral and Hormone Analysis 
2.7.1 Fetal Serum Collection 
Fetal serum was collected on ED 18.5. Pregnant dams were first anesthetized with isoflurane and 
then sacrificed by cervical dislocation. A Caesarean section (C-section) was performed to 
remove fetuses. Fetal whole blood was collected by severing the carotid artery and collecting 
blood using microhematocrit capillary tubes (Fisher Scientific, Toronto).    
     
To separate serum, the capillary tubes containing whole blood were centrifuged at 14,000 rpm 
for 20 minutes in the Micro-MB microcentrifuge (Thermo Scientific, Toronto). A glass cutter 
was used to cut the capillary tubes at the interface between serum and clotted blood. The serum 
in each capillary tube was decanted into 0.6 ml tubes and stored at -20 °C.  
 
2.7.2 Serum Mineral Analysis 
Serum phosphorous and calcium were measured using commercial assays (Sekisui Diagnostics, 
Charlottetown). In terms of the mechanism of the phosphorus kit, inorganic phosphorus reacts 
with ammonium molybdate in the presence of sulfuric acid to produce an unreduced 
phosphomolybdate complex. The increase in absorbance at 340 nm is directly proportional to the 
concentration of phosphomolybdate complex, which also reflects the concentration of inorganic 
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phosphorus in the sample. In terms of the mechanism of the calcium kit, calcium reacts with 
Arsenazo III [2,2'-(1,8-dihydroxy-3,6-disulfonaphthylene-2,7-bisazo) bisbenzenearsonic 
acid] in an acid solution to form a blue-purple complex. The color developed has a maximum 
absorbance at 650 nm and is proportional to the calcium concentration in the sample. The 
experimental procedure followed the product inserts (see Appendix). Samples were analyzed 
using the Ultrospec 2000 UV spectrophotometer (Pharmacia Biotech, Toronto).    
 
2.7.3 Serum Hormone Analysis 
PTH, FGF23, and calcitriol concentrations in fetal serum were measured using commercial 
ELISA kits for mouse use (Immutopics Inc., CA; Kainos Laboratories Inc., Japan; and 
Immunodiagnostic Systems, UK; respectively).  
 
In the two-site rat intact PTH ELISA kit two different goat polyclonal antibodies to rat intact 
PTH have been purified by affinity chromatography. The antibody which recognizes epitopes 
within the mid-region/C-terminal portion (39-84) of the peptide is biotinylated for capture. The 
other antibody which recognizes epitopes within the N-terminal region (1-34) is conjugated with 
the enzyme horseradish peroxidase (HRP) for detection. A sample containing PTH is incubated 
simultaneously with the biotinylated capture antibody and the HRP conjugated antibody in a 
streptavidin coated microtiter well. Intact PTH (1-84) contained in the sample is 
immunologically bound by the capture antibody and the detection antibody to form a “sandwich” 
complex: Well/Avidin-Biotin Anti-Rat PTH — Rat Intact PTH — HRP Anti-Rat PTH. At the 
end of this incubation period, the well is washed to remove any unbound antibody and other 
components. The enzyme bound to the well is then incubated with a substrate solution in a timed 
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reaction and then measured in a spectrophotometric microtiter plate reader. The enzymatic 
activity of the antibody complex bound to the well is directly proportional to the amount of PTH 
in the sample. 
 
The FGF23 kit follows a similar mechanism as the PTH kit. Two specific murine monoclonal 
antibodies bind to full-length FGF23.  One antibody is immobilized onto the microtiter plate well 
for capture. The other antibody is conjugated to HRP for detection. In enzyme reaction, a 
“sandwich” complex immobilized on the well is incubated with a substrate solution and then 
measured by a spectrophotometric microtiter plate reader. The enzymatic activity of the complex 
bound to the well is directly proportional to the amount of FGF23 in the sample.  
 
The calcitriol kit is a complete assay system for the purification of calcitriol in samples by 
immunoextraction followed by quantitation by EIA. Samples are delipidated and calcitriol 
extracted from potential cross-reactants by incubation for 90 minutes with a highly specific solid 
phase monoclonal anti-calcitriol. The immunoextraction gel is then washed and purified 
calcitriol eluted directly into glass assay tubes. Reconstituted eluates and calibrators are 
incubated overnight with a highly specific sheep anti-calcitriol. A portion of this is incubated for 
90 minutes with shaking in microplate wells which are coated with a specific anti-sheep 
antibody. Calcitriol linked to biotin is then added and the plate shaken for a further 60 minutes 
before aspiration and washing. HRP labelled avidin is added and binds selectively to complexed 
biotin and, following a further wash step, colour is developed using a chromogenic substrate. 
The absorbance of the stopped reaction mixtures are read in a microtitre plate reader, colour 
intensity developed being inversely proportional to the concentration of calcitriol in the sample. 
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The procedure of each experiment followed the product manual (see Appendix).         
 
2.8 Amniotic Fluid Collection and Mineral Analysis 
2.8.1 Amniotic Fluid Collection 
Amniotic fluid was collected because it essentially represents fetal urine. On ED17.5, when 
amniotic fluid is more plentiful and less viscous, pregnant dams were anesthetized with 
isoflurane and then sacrificed by cervical dislocation. C-section was performed to reveal fetuses 
in their amniotic sacs. Amniotic sacs were lanced with a sterile blade, and the fluid was collected 
into microhematocrit capillary tubes which was then transferred to 0.6 ml tubes and stored at -20 
°C. 
 
2.8.2 Amniotic Fluid Mineral Analysis 
Amniotic fluid phosphorous and calcium were measured using the same commercial assays used 
for serum measurements. Samples were analyzed using the Ultrospec 2000 UV 
spectrophotometer (Pharmacia Biotech, Toronto). 
 
2.9 Fetal Skeletal Mineral Analysis 
2.9.1 Fetal Ash Collection 
Previously genotyped fetuses were weighed in crucibles (wet weight) and were reduced to ash in 
a furnace (make and manufacturer) at 500°C for 24 hours. The ash was then weighed (dry 
weight) and this represented the total amount of mineral in the fetuses. Samples were transferred 
to 20 ml scintillation vials and stored at room temperature.  
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2.9.2 Skeletal Mineral Analysis 
Fetal ash was dissolved in 253 μl of nitric acid. The samples were left at room temperature for 
one week until all ash was dissolved after which 10 ml of deionized water was added to each 
vial. Ash calcium and magnesium was measured by flame atomic absorption spectrophotometry 
on the 2380 Atomic Absorption Spectrophotometer (Perkin-Elmer, MA) while phosphorous 
content was measured using the same commercial phosphorous assay that was used to measure 
serum phosphorous. Samples were diluted 1:10 in distilled water prior to measurement. The 
measuring procedure followed the manual of the atomic absorption spectrophotometer. Five 
measurements per sample were done and averaged. Samples were further diluted 1:5 for 
phosphorous measurement.  
 
2.10 Placental Phosphorus Transfer 
Placental phosphorus transfer methodology was adapted from our previously reported placental 
calcium transfer procedure [162]. On ED 17.5 pregnant dams were anesthetized with isoflurane 
and given an intra-cardiac injection of 50 µCi 
32
P and 50 µCi 
51
Cr-EDTA in 0.9% saline. EDTA 
is passively transferred and serves as a blood diffusional marker. The mothers were then placed 
in a lead-coated box. After 5 minutes the mothers were sacrificed by cervical dislocation, and a 
C-section was performed to remove the fetuses from amniotic sacs. Fetal tails were collected for 
genotyping and the fetuses were placed in 12 mm x 75 mm disposable round bottom polystyrene 
culture test tubes (Fisher Scientific), and their brains were pithed using forceps. The tubes were 
then capped and the 
51
Cr-EDTA activity in each fetus was measured using a 1480 Wizard 
automatic γ counter (Perkin Elmer, MA). To dissolve the fetuses, 1 ml of Scintigest (Fisher 
Scientific, Toronto) was added to each tube and the tube was vortexed until to loosen the fetus so 
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that it could be transferred to a 20 ml scintillation vial (Fisher Scientific. A further 9 ml of 
Scintigest was added. All vials were incubated at 55°C in an isotherm oven (Fisher Scientific) 
for 24-48 hours, with periodic vortexing to aid in solubilization. When the fetuses were fully 
solubilized, the tubes were removed from the oven, and 10 ml of ScintiVerse (Fisher Scientific) 
and 5 drops of glacial acetic acid (Fisher Scientific) were added to each vial. The vials were 
wrapped in aluminum foil and placed in the dark for 24 hours to reduce bioluminescence. The 
activity of 
32
P was then measured using an LS 6500 Multi-Purpose Scintillation Counter 
(Beckman Coulter, CA). The ratio of 
32
P activity to 
51
Cr-EDTA activity for each fetus was 
calculated to determine the rate of phosphorous transfer from mother to fetus. The ratio of each 
fetus was normalized to the mean HET value within its litter for the Klotho fetuses or to the 
mean male null value within its litter for the Phex fetuses. Normalization allowed aggregate 
results from different litters to be analyzed. In addition, 
32
P activity alone (not as a ratio to
51
Cr-
EDTA) was analyzed after normalization. 
 
2.11 Fetal Tibial Morphology  
On ED 18.5, at the time of fetal serum collection, tibias were also removed, stored in 10% 
buffered formalin and subsequently embedded in paraffin for sectioning. 5 µm sections were cut 
and collected. The slides were placed on a slide warmer (Fisher Scientific, Toronto) for 30 
minutes and were deparafinized and rehydrated using the following series: xylene for 2 minutes 
(2x), 100% Ethanol for 2 minutes (2x), 95% ethanol for 2 minutes, 70% Ethanol for 2 minutes, 
50% ethanol for 2 minutes, and distilled water for 1 minute. Von Kossa staining for mineral was 
then conducted.  The steps were explained here. The sections were placed in a 1% aqueous silver 
nitrate solution and exposed to direct light for one hour. The sections were then washed 3 times 
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with distilled water, 2 minutes per wash. Sections were  transferred to a 2.5% sodium 
thiosulphate solution for 5 minutes, and then washed three times (2 minutes per wash) in distilled 
water. The sections were counterstained with methyl green (Sigma, Toronto) for 2 minutes. 
Excess dye was blotted from the slides, which were then washed in 1- butanol (Fisher Scientific, 
Toronto) for 10 seconds, (2X), and then in xylene for 10 seconds (2X). Permount (Fisher 
Scientific, Toronto) was then added to the slides to mount the coverslips. 
 
2.12 Microarray 
Placental RNA samples were shipped on dry ice to The Centre for Applied Genomics, 
Microarray Facility, at the Hospital for Sick Children (Toronto, ON). The Affymetrix GeneChip 
Mouse Gene ST 2.0 Array (Affymetrix, CA), which is a whole-transcript array that includes 
probes to measure both mRNA and long intergenic non-coding RNA transcripts (lincRNA) 
(lincRNA transcripts can impact the mRNA expression profile), was then utilized to assess gene 
expression in the placenta of Fgf23 WT, Fgf23 null, Phex WT and Phex null fetuses. In total, 16 
arrays were conducted, which included 4 samples in each of the 4 groups. Raw data obtained 
from the Mouse Gene ST 2.0 Arrays, which summarizes all probes into a single gene expression 
value, were analyzed by a third-party person hired by Dr. Kovacs’ Laboratory. Raw data were 
normalized in R Version 3.2.1 (R Foundation for Statistical Computing) using the robust multi-
array average algorithm. Differentially expressed genes were identified using the Local-Pooled-
Error Test. False discovery rate, which is commonly used to evaluate statistical significance, was 
set at 0.01 such that genes with adjusted p-values < 0.01 were considered statistically significant. 
In this method, errors within genes and between replicate arrays for genes in which expression 
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values are similar are pooled, and it has been shown to have an advantage in identifying subtle 
changes in gene expression. 
 
2.13 Neonatal Urine Collection  
Neonatal urine was collected at the time of neonatal serum collection. The abdomen of each 
neonate was resected to reveal the bladder, which was removed intact and transferred to a clean 
0.6 mL tube. Within the tube, the bladder was pierced to release the urine. Bladder tissue was 
then removed. Phosphorous in the neonatal urine was measured.  
 
2.14 FGF23-Targeted Gene Expression Analysis on the Placenta and on the Fetal and Neonatal 
Kidneys 
2.14.1 Placenta and Fetal and Neonatal Kidneys Collection  
The placenta and fetal kidneys were collected on ED18.5, at the time of fetal blood collection. 
Placentas were removed, immediately snap-frozen in liquid nitrogen and stored at -70 °C. 
Immediately after fetal blood was collected, the abdomen of the fetuses was resected to reveal 
the kidneys. The kidneys were removed, immediately snap-frozen in liquid nitrogen and stored at 
-70°C. A similar procedure was carried out to collect the kidneys in neonates at the time point 
when neonatal urine phosphorous was analyzed.  
 
2.14.2 Real-time Quantitative RT-PCR (qPCR) 
qPCR was used to measure differential expression of select FGF23-targeted genes in the placenta 
and kidneys of Phex and Klotho null fetuses compared to their respective WT fetuses. qPCR was 
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also used to determine differential expression in the kidneys of Phex, Klotho, and Fgf23 null 
neonates compared to their respective WT littermates. FGF23-targeted genes measured in the 
fetal kidneys included Fgf23, Cyp27b1, Cyp24a1, NaPi2a, NaPi2b, NaPi2c, Fgfr1, Fgfr2, Fgfr3, 
Fgfr4, and Klotho. In the neonatal kidneys, expression of Napi2a and Napi2c was measured.  
 
Differential gene expression analysis consisted of three separate steps: RNA extraction from 
tissue samples, cDNA synthesis and finally, qPCR.  
 
2.14.2.1 RNA Extraction 
To extract RNA from the placenta and fetal kidneys, the snap frozen organs were first transferred 
to clean tubes containing Qiazol (Qiagen, Toronto), which was followed by tissue disruption and 
homogenization using the Precellys system (Bertin Instruments, MD). Then, the RNeasy Midi 
Lipid Kit (Qiagen, Toronto) and RNeasy Mini Lipid Kit (Qiagen, Toronto) were applied to 
extract total RNA from placentas and fetal kidneys, respectively. The experimental steps 
followed the manual in each kit. RNA was quantified and the the RNA Integrity Number (RIN) 
was determined for each sample using the Agilent 2100 Bioanalyzer platform (Agilent 
Technologies, CA).  
 
2.14.2.2 cDNA Synthesis 
cDNA was synthesized from 2 μg of RNA using the Superscript III First-strand Synthesis Kit 
(Invitrogen, Toronto). The synthesis program was as follows:  
 Step 1: 25°C for 10 minutes  
 Step 2: 37°C for 2 hours  
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 Step 3: 85°C for 5 minutes  
 Step 4: 4°C indefinitely 
 
2.14.2.3 Quantitative Real Time RT-PCR (qPCR)  
Differential gene expression analysis was done by qPCR using Taqman® Gene Expression 
Assays (commercially available manufactuer’s pre-designed primers and probes for optimal 
amplification) (Life Technologies, Toronto) and Taqman Fast Advanced Master Mix (Life 
Technologies, Toronto). Briefly, a minor groove binder (MGB) probe with a 6-
carboxyfluorescein (FAM) reporter dye at the 5' end and a non-fluorescent quencher at the 3' end 
is used in the assay. When targeted cDNA is amplified, the MGB probe is digested by DNA 
polymerase and the FAM reporter dye is released. Florescence from the free FAM reporter dye is 
detected by a real-time PCR system. The intensity of florescence is directed to the concentration 
of the targeted cDNA within proper range.  
 
Samples were prepared using the Fast Advanced Master Mix kit (Life Technologies, Toronto). 
All samples were run in triplicate and the threshold cycle value (CT) was used as an indicator of 
gene expression. Gapdh was used as an endogenous control. All samples were run on the ViiA
TM
 
7 Real-Time PCR System (Life Technologies, Toronto). qPCR results were analyzed using the 




2.15 Statistical Analysis 
All experimental results (except the qPCR results) were expressed as mean ± standard error (SE). 
The results were analyzed using StatPlus:Mac Professional 2009, Build 6.0.3 (AnalystSoft Inc). 
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ANOVA was used for analysis of the following experiments, with a post-hoc Tukey test 
conducted to determine which pairs of means differed significantly: fetal serum and amniotic 
fluid chemistries, fetal serum hormones, fetal ash and mineral content, and placental phosphate 
transport. qPCR data was analyzed using the comparative CT method (2
ΔCT
) with two-tailed 
probabilities reported as mean ± SD. In the graphs of all results, significant differences were 
denoted and the number of the samples studied was indicated in parentheses. 
 
Based on experience from previous studies in Dr. Kovacs’ laboratory, the minimum sample size 
per group to find significant differences in the studies of serum chemistries, urine chemistries, 
serum hormones and bone mineral content is six. For qPCR experiments, the minimum sample 
















3.1 Results from Phex Null Fetuses 
In this aim, I mainly examined whether excess FGF23 would impact fetal phosphate homeostasis 
and skeletal development, as well as placental phosphate transport by studying Phex null male 
fetuses. In contrast to the Phex null model, Fgf23 null fetuses were studied in a simultaneous 
project carried out by Dr. Samaraweera in Dr. Kovacs’ laboratory.  To complement the studies in 
Fgf23 nulls, I would also investigate phosphate-related phenotypes in Klotho null fetuses in 
which the FGF23 pathway is blocked (see results in Aim 2 below). If Phex null fetuses 
demonstrate an opposite phenotype against Fgf23 nulls and Klotho nulls, it would imply FGF23 
plays some critical roles in regulating fetal phosphate homeostasis.  If Phex null fetuses have a 
similar phonotype as Fgf23 nulls and Klotho nulls, it would imply FGF23 is relatively 
unimportant in this process.    
 
3.1.1 Serum Hormones in Phex Fetuses on ED18.5  
Serum FGF23 in Phex
+/-
 female fetuses (Phex ♀) and male null fetuses was up to 8-fold higher 
than that in WT fetuses (♂ and ♀) – which confirmed the effect of the Phex mutation was active 
in utero, but more importantly, proved that this model was valid in studying the effect of excess 
FGF23 in fetal phosphate regulation because FGF23 was increased up to 8-fold in Phex nulls 
(Figure 10). It should be noted that FGF23 was also increased over 7-fold in Phex
+/-
 dams 
compared to WT fetuses.  Despite the high maternal value, the FGF23 levels in WT fetuses were 
largely in-line with those in fetuses from WT dams – implying that FGF23 is unlikely going to 




Fetal serum calcitriol, as well as serum PTH, was measured to determine if there was any 
compensatory mechanism when serum FGF23 was ultra-high. FGF23 is known to inhibit 
calcitriol in adult mice – therefore, I expected serum calcitriol levels to be low in male Phex 
nulls. The results were in-line with my expectation, which showed that calcitriol was 
significantly reduced more than 30% in male Phex nulls compared to male WT fetuses (Figure 
11). Calcitriol in Phex
+/-
 dams was at least 5 times as high as in fetuses regardless their 
genotypes.  
 
In terms of serum PTH, it showed no response to higher FGF23 in male Phex null fetuses as both 
WT and null fetuses had identical levels (Figure 12). Fetal serum PTH appeared to be about 8 
fold as high as in Phex
+/-
 dams, although the differences were non-significant. The high 
concentrations of serum PTH in fetuses was opposite of what was originally expected as PTH is 










Figure 10: Serum FGF23 in Phex Fetuses on ED18.5. Fetal serum FGF23 on ED 18.5 was 
significantly increased in Phex
+/-
 (Phex ♀) and male null (Phex ♂) fetuses compared to WT (♂ 
and ♀) fetuses. Phex
+/-
 dams on ED 18.5 had significantly higher FGF23 than WT fetuses. The 













































(5)          (2)                              (5)                              (6)
p < 0.001
p < 0.001





Figure 11: Serum Calcitriol in ED18.5 Phex Fetuses. Serum calcitriol in male Phex null 
fetuses (Phex ♂) on ED 18.5 was significantly lower than that in male WTs (WT ♂). Phex
+/-
 
dams had higher serum calcitriol than all fetuses. The numbers in parentheses indicate the 




































(5)                                (7)                               (7)
p < 0.02
p < 0.001 
p < 0.001 




Figure 12: Serum PTH in ED 18.5 Phex Fetuses. On ED 18.5, male Phex null fetuses (Phex 
♂) had similar levels of serum PTH as male WT fetuses (WT ♂). Fetal serum PTH appeared to 
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WT ♂ Phex Phex+/- Dam
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3.1.2 Serum Chemistries in Phex Fetuses on ED18.5 
FGF23 lowers serum phosphate in adults. If FGF23 acts in fetuses in the same way, I expected 
serum phosphate to decrease in Phex null fetuses. Opposite to my original expectation, the 
results demonstrated that fetal serum phosphorus among Phex WT ♂, WT ♀, Phex ♀, and Phex 
♂ was not significantly different on ED 18.5 (Figure 13). Serum phosphorus in fetuses was 
significantly 2.5-fold higher than that in Phex
+/-
 dams on ED 18.5 – which was expected as 
higher levels of phosphate are normally seen in fetuses. Since there were no differences in serum 
phosphorus between WT ♂ and WT ♀, data from these two groups were pooled together for an 
analysis – serum phosphorus of Phex WT fetuses was still not significantly different from that in 
Phex ♀ or Phex ♂ (Figure 14). On ED 18.5, Phex WT (♂ and ♀), Phex ♀, and Phex ♂ fetuses 
had similar levels of serum total calcium. Phex
+/-
 dams had non-significantly higher levels of 
serum total calcium (Figure 15). Normally, fetuses have hypercalcemia compared to dams when 
the ionized form of calcium is measured. The results shown in Figure 15 represent the total 










Figure 13: Serum Phosphorus in Phex Fetuses on ED18.5 (Data of WT ♂ and WT ♀ Were 
Separated). Fetal serum phosphorus was not significantly changed in Phex ♀ and Phex ♂ 
fetuses when compared to WT ♂ and WT ♀ fetuses. The numbers in parentheses indicate the 















































WT ♂ WT ♀ Phex ♀ Phex ♂ Phex+/- Dam    
(4)                        (4)                         (4)                      (9)                      (8)    
p < 0.001 
p < 0.001 
p < 0.001 




Figure 14: Serum Phosphorus in Phex Fetuses on ED18.5 (Data of WT ♂ and WT ♀ Were 
Pooled). There were no significant differences in serum phosphorus on ED 18.5 among Phex 
WT, Phex ♀, and Phex ♂ fetuses. Fetal serum phosphorus was higher than Phex
+/-
 dams’. The 












































(8)                                 (4)                            (9)                                 (8)    
p < 0.001 
p < 0.001 
p < 0.001 




Figure 15: Serum Total Calcium in Phex Fetuses on ED18.5. There were no significant 
differences in serum total calcium on ED 18.5 among Phex WT, Phex ♀, and Phex ♂ fetuses. 
Regardless of genotypes, fetuses normally have hypercalcemia compared to dams when the 
ionized form of calcium is measured. The results presented here represent serum total calcium 
that include both free ionized calcium and albumin-binding calcium. The numbers in parentheses 
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WT (♂ and ♀)                 Phex ♀ Phex ♂ Phex+/- Dam 
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3.1.3 Amniotic Fluid Chemistries in Phex Fetuses on ED17.5 
Amniotic fluid is mainly made of fetal urine. It is commonly used to measure minerals that the 
fetal kidneys excrete. Based on previous studies in Dr. Kovacs’ laboratory, the amount of 
amniotic fluid on ED 18.5 is too thick and scant. Thus, I used amniotic fluid on ED 17.5 to 
measure concentrations of phosphorus and calcium. It is known that FGF23 decreases renal 
phosphate reabsorption in adults. If FGF23 has the same effect in fetuses, phosphorus in 
amniotic fluid from Phex null fetuses should increase. However, the results showed that WT (♂ 
and ♀), Phex ♀, and Phex ♂ fetuses had no significant differences in amniotic fluid phosphorus 
on ED 17.5 (Figure 16). The levels of total calcium in amniotic fluid on ED 17.5 were also 






Figure 16: Amniotic Fluid Phosphorus in Phex Fetuses on ED17.5. There were no significant 
differences in amniotic fluid phosphorus on ED 17.5 among WT (♂ and ♀), Phex ♀, and Phex ♂ 
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Figure 17: Amniotic Fluid Total Calcium in ED 17.5 Phex Fetuses. Compared to WT fetuses, 
Phex ♂ had similar levels of amniotic fluid total calcium on ED 17.5. The numbers in 
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3.1.4 Placental Phosphate Transport in Phex Fetuses on ED17.5 
The placenta is arguably the most important organ in fetal development as it represents the only 
source of input from mothers. Prior to this project, little had been known about potential roles of 
FGF23 in placental phosphate transport. FGF23 could conceivably stimulate or even inhibit this 
process. In this study, I measured the amount of 
32
P relative to 
51
Cr-EDTA transferred from dams 
to each of their fetuses in a 5-minute period following a maternal intracardiac injection. Because 
51
Cr-EDTA only diffuses across the placenta passively, it serves as a control for differences in 
the flow rate among individual placentas in one litter. 
32
P, however, is actively transported across 
the placenta from dams to fetuses. Thus, by normalizing for the rate of diffusion (using 
51
Cr-
EDTA) the relative rate of placental phosphate transfer in each fetus in the same litter can be 
determined. The results seemed to suggest there was no effect of FGF23 on placental phosphate 
transport as this process was not changed in Phex ♂ fetuses relative to WT ♂ fetuses (Figure 
18). The placental transfer of 
32
P without normalization to 
51
Cr-EDTA was also measured, 
















Cr-EDTA) in ED 17.5 Phex Fetuses. When 
normalized to 
51
Cr, placental phosphate transfer on ED 17.5 was not different in Phex ♂ fetuses 












































Figure 19: Placental Phosphate Transport (
32
P) in ED17.5 Phex Fetuses. Without 
normalization to 
51
Cr, placental phosphate transfer on ED 17.5 was not changed in Phex ♂ 
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3.1.5 Skeletal Mineral Content in Phex Fetuses on ED18.5 
The results above demonstrated that serum and amniotic fluid phosphate was not significantly 
changed in Phex ♂ fetuses, as well as placental phosphate transport. It could be possible that the 
methods of measuring serum/amniotic phosphate levels and placental phosphate transport were 
not sensitive enough to detect small differences that were present between Phex nulls and WT.  
If there were true differences between the two genotypes, the skeletal mineral content would be 
more likely to show a difference since it represents the net effect of phosphate metabolism over 
gestation, especially the last five days of it. Additionally, high levels of FGF23 are known to 
cause hypophosphatemic rickets and osteomalacia in adults.  If excess FGF23 in fetuses has 
similar skeletal effects as in adults, skeletal mineral content and morphology in fetuses should be 
significantly altered. In this section, fetal bodies on ED 18.5 were reduced to ash in order to 
assess their mineral content. The results were presented by mineral content normalized to dry 
weights in order to eliminate the impact of different body weights. The results showed that Phex 
WT (♂ and ♀), Phex ♀ and Phex ♂ had identical body ash weight; more importantly, there were 
no significant changes in skeletal mineral content (phosphate, calcium and magnesium) in Phex 
♂ fetuses compared to WT fetuses (Figures 20 – 23).  Body ash weight and skeletal phosphate 
content of the fetuses of the Phex null model were also largely in-line with those of the fetuses of 









Figure 20: Body Ash Weight in ED 18.5 Phex Fetuses. There were no significant differences 
in body ash weight among Phex WT (♂ and ♀), Phex ♀ and Phex ♂ fetuses on ED 18.5.  The 
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Figure 21: Skeletal Phosphate Content in ED 18.5 Phex Fetuses. Compared to WT fetuses, 
Phex ♂ fetuses demonstrated no significant changes in the skeletal content of phosphate on ED 
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Figure 22: Skeletal Calcium Content on in ED 18.5 Phex Fetuses. Compared to WT fetuses, 
Phex ♂ fetuses had similar skeletal content of calcium on ED 18.5. The numbers in parentheses 
indicate the number of fetuses studied.  
 






































Figure 23: Skeletal Magnesium Content in ED 18.5 Phex Fetuses. There were no significant 
differences in skeletal magnesium content among Phex WT, Phex ♀ and Phex ♂ fetuses. The 
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3.1.6 Bone Morphology and Mineralization in Phex Fetuses on ED18.5 
It is known that phosphate stimulates apoptosis of hypertrophic chondrocytes during 
endochondral bone formation in fetuses – which is a critical step to ensure the bone develops 
robustly. In fetuses with hypophosphatemia, apoptosis of differentiated hypertrophic 
chondrocytes is impaired, leading to an expanded hypertrophic chondrocyte layer of the growth 
plate, as well as reduced mineral deposits in the bone. I originally expected the growth plate 
would be abnormal and mineral deposits would be highly decreased in Phex null fetuses; 
however, the results showed that the skeletal morphology and the mineralization pattern of Phex 
♂ fetuses on ED 18.5 appeared similar to those of WT fetuses (Figure 24), suggesting that the 
skeletal scaffold of Phex ♂ fetuses develops robustly before birth, with normal tibial length and 
diaphysis and appropriate mineralization. The cellular morphology and growth plates were 
largely identical in Phex WT and Phex ♂ fetuses. In addition, both genotypes had no obvious 
differences in mineral deposition (the black areas in Figure 24 represent von Kossa’s stain). It 
should be noted that the skeletal morphology and mineralization results were confirmed by the 
skeletal mineral (phosphate, calcium, and magnesium) content data discussed above, which 
demonstrated that Phex ♂ fetuses had similar content of phosphate, calcium, and magnesium as 







Figure 24: Skeletal Morphology and Mineralization in ED 18.5 Phex Fetuses. Compared to 
WT fetuses, Phex ♂ fetuses appeared normal in terms of the amount of mineral deposition (the 
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3.1.7 Gene Expression Analysis on the Phex Placenta and Kidneys on ED18.5 
FGF23 was significantly elevated in Phex ♂ fetuses, which might alter expression of its targeted 
genes. I examined expression of FGF23-targeted genes in the placenta and kidneys because the 
placenta represents the only source of phosphate to fetuses and the kidneys the only exit for 
phosphate – if excess FGF23 could impact serum phosphate in fetuses, the placenta and kidneys 
should be the most likely organs to act on.  Although FGFR1 is the main receptor for FGF23, I 
also studied gene expression of the other three types of FGFR (FGFR2 – 4) as FGF23 might act 
on them when its serum concentrations were ultra-high in Phex ♂ fetuses. Normally, Fgf23 
expression in the placenta is low, which has been confirmed by the study conducted in the Fgf23 
KO model [139]. In the present experiment, the Phex ♂ placenta showed an increase in Fgf23 
expression, which approached statistical significance (p = 0.054). Fgf23 expression was absent in 
the kidneys of WT and male null fetuses. In terms of FGF23-targeted genes, Cyp24a1 expression 
was significantly increased in the Phex ♂ kidneys and placenta – which might explain why 
serum calcitriol was significantly reduced in Phex ♂ fetuses (Figure 11) The majority of the 
remaining target genes showed no significant expression changes in the Phex ♂ kidneys and 
placenta, except for Klotho and Fgfr2 in the kidneys (Table 1). However, the changes in these 
two genes were of small magnitude and questionable physiological significance – these changes 









Table 1: List of FGF23-Targeted Genes in Placentas and Fetal Kidneys between Phex WT 
and Null Fetuses. 
 
 Placenta Fetal Kidneys 
Gene Phex
 
WT (♂) Phex ♂ p value Phex
 
WT (♂) Phex ♂ p value 
Fgf23 1.00±0.87 3.15±1.94 0.054 Undetectable Undetectable N/A 
Klotho 1.00±0.16 1.17±0.12 0.103 1.00±0.18 0.59±0.19 0.014 
NaPi2a 1.00±0.35 1.16±0.12 0.348 1.00±0.09 0.98±0.25 0.867 
NaPi2b 1.00±0.31 1.01±0.29 0.953 1.00±0.20 0.81±0.05 0.071 
NaPi2c 1.00±0.48 0.98±0.27 0.953 1.00±0.10 0.86±0.38 0.446 
Cyp24a1 1.00±0.36 7.00±3.54 0.030 1.00±0.46 5.58±1.77 0.001 
Cyp27b1 1.00±0.17 1.10±0.35 0.495 1.00±0.34 1.05±0.48 0.637 
Fgfr1 1.00±0.19 0.85±0.08 0.276 1.00±0.09 0.87±0.11 0.068 
Fgfr2 1.00±0.12 0.97±0.10 0.776 1.00±0.08 0.83±0.08 0.011 
Fgfr3 1.00±0.40 0.76±0.07 0.357 1.00±0.11 0.89±0.19 0.283 





Fgf23 Fibroblast growth factor 23
Klotho Klotho
NaPi2a or Slc34a1 Sodium-dependent phosphate transporter 2A or Solute carrier family 34 member 1
NaPi2b or Slc34a2 Sodium-dependent phosphate transporter 2B or Solute carrier family 34 member 2
NaPi2c or Slc34a3 Sodium-dependent phosphate transporter 2C or Solute carrier family 34 member 3
Cyp24a1 1,25-dihydroxyvitamin D(3) 24-hydroxylase
Cyp27b1 25-hydroxyvitamin D-1 alpha hydroxylase
Fgfr1 Fibroblast growth factor receptor 1
Fgfr2 Fibroblast growth factor receptor 2
Fgfr3 Fibroblast growth factor receptor 3
Fgfr4 Fibroblast growth factor receptor 4
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3.1.8 Control Studies in Phex WT Dams on ED18.5 
In the studies above, the Phex
+/-
 dams were abnormal because serum FGF23 was highly 
increased and serum phosphours was reduced. In order to determine if maternal phenotypes 
would have an impact on fetuses via serum phosphours and FGF23 or somehow via the 
genotypes, I measured serum phosphours and FGF23 in fetuses derived from WT females mated 
to Phex null males – the genotypes of offspring included Phex WT ♂ and Phex ♀ fetuses.    
 
As to serum FGF23 in Phex WT ♂ and Phex ♀ fetuses, the results showed that serum FGF23 in 
the latter was 10 fold as high as that in the former.  In addition, serum FGF23 in Phex ♀ fetuses 
was highly increased compared to values of WT dams. Serum FGF23 in WT dams at late 
pregnancy (LP) on ED 18.5 was 2.5 fold as high as that in WT dams at baseline (BL) – which 
was consistent with what Dr. Kovacs’s Laboratory has previously reported that maternal intact 
FGF23 doubled during pregnancy compared with pre-pregnant values [165] (Figure 25). 
 
As to serum phosphorus, there were no significant differences between WT ♂ and Phex ♀ 
fetuses (Figure 26). Serum phosphorus in fetuses was significantly higher than that in WT dams. 








Figure 25: Serum FGF23 in Phex Fetuses from WT Dams Mated to Phex Null Males. Phex 
♀ fetuses from WT dams mated to Phex null males had significant higher serum FGF23 than 
WT ♂ siblings, Phex
+/+
 (WT) dams at baseline (BL), and at late pregnancy on ED 18.5 (LP). 




































p < 0.001 p < 0.001 
p < 0.001 




Figure 26: Fetal Serum Phosphorus of Fetuses from Phex WT Dams Mated to Phex Null 
Males. WT ♂ and Phex ♀ fetuses from WT dams mated to Phex null males had similar levels of 
serum phosphorus. Fetal serum phosphorus was significantly higher than WT dams’. The 
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p < 0.001 
p < 0.001 
WT ♂ Phex ♀ Phex+/+ Dam
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3.1.9 Microarray Analysis on the Phex and Fgf23 Null Placentas 
To confirm that excess or deficient FGF23 does not importantly alter placental expression of 
Fgf23-targeted genes (apart from the change in Cyp24a1 expression), genome-wide microarray 
analyses were carried out on the Fgf23 null, Phex null and matching WT littermate placentas. No 
significant changes in gene expression were noted between the Phex null and WT placentas, or 
between the Fgf23 null and corresponding WT placentas (data not shown). It should be noted 
that p<0.01 was used in the microarray analysis to determine whether a gene expression change 
was significant.  Although qPCR analysis showed the expression of Cyp24a1 in the Phex null 
placenta was significantly increased (Table 1), the p value in that experiment was only 0.03.  It 
could be the reason why microarray analysis did not show a significant change in placental 














3.2 Results from Klotho Null Fetuses 
In the experiments above, it was shown that excess FGF23 in Phex null fetuses did not change 
any parameter of fetal mineral homeostasis, including serum and amniotic fluid phosphate, 
skeletal morphology, skeletal mineral content, and placental phosphate transport. Although 
Cyp24a1 was significantly increased in the Phex null placenta and fetal kidneys, the increase in 
gene expression did not disturb any parameter related to phosphate. It is also discussed in the 
introduction section that loss of FGF23 in Fgf23 null fetuses did nothing to phosphate 
metabolism and fetal bone development either, although expression of Cyp24a1 in the Fgf23 null 
kidneys was significantly reduced. The purpose of studying phosphate related phenotypes in 
Klotho null fetuses was to confirm that loss of Klotho should be equivalent to loss of FGF23, as 
well as, to ensure that another FGF would not be compensating for absence of FGF23 by acting 
on Klotho.     
 
3.2.1 Serum Hormones in Klotho Fetuses on ED18.5  
Serum FGF23 is significantly increased in adult Klotho nulls to compensate a disruption in the 
FGF23 pathway. Therefore, I originally expected serum FGF23 to behave in the same way in 
Klotho null fetuses. Contrarily, there were no significant differences in serum FGF23 on ED 18.5 
among WT, HET, and null fetuses (Figure 27). Klotho HET dams on ED 18.5 had significantly 
higher FGF23 compared to fetuses of all genotypes. Similar to calcitriol in Fgf23 null fetuses, 
calcitriol in Klotho null fetuses was not altered onED18.5 either (Figure 28). As to serum PTH, 
it was numerically decreased in Klotho null fetuses compared to WT on ED18.5 (Figure 29). In 
adults PTH is normally suppressed in Klotho nulls due to hypercalcemia as a result of high 




Figure 27: Serum FGF23 in ED18.5 Klotho Fetuses. There were no significant differences in 
serum FGF23 on ED 18.5 among Klotho WT, HET, and null fetuses. Klotho HET dams on ED 
18.5 had significantly higher FGF23 than all fetuses. The numbers in parentheses indicate the 



































(5)         (5)                               (5)                             (5)
p < 0.001 
p < 0.002 
p < 0.001 




Figure 28: Serum Calcitriol in ED18.5 Klotho Fetuses. Serum calcitriol in Klotho null fetuses 
was not different as compared to that in WTs. The numbers in parentheses indicate the number 
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Figure 29: Serum PTH in ED 18.5 Klotho Fetuses. On ED 18.5, Klotho null fetuses had 
numerically lower serum PTH than WT fetuses (non-significant). The numbers in parentheses 







































(7)         (7)                                           (6)
Klotho+/+ (WT)                   Klotho+/- (HET)                       Klotho-/- (Null)
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3.2.2 Serum Chemistries in Klotho Fetuses on ED18.5 
Klotho nulls develop hyperphosphatemia postnatally as the FGF23 pathway does not function. I 
originally expected serum phosphorus to increase in Klotho null fetuses.  However, results 
demonstrated that Klotho null fetuses on ED 18.5 had similar levels of serum phosphorus as WT 
and HET fetuses – a similar case as in Fgf23 null fetuses (Figure 30). Fetuses of all genotypes 
had hyperphosphatemia compared to HET dams (1.94±0.04 mmol/L), which was physiologically 
normal. Klotho WT, HET, and null fetuses on ED 18.5 had the same levels of serum total 
calcium (Figure 31). HET dams had non-significantly higher serum total calcium than all 










Figure 30: Serum Phosphorus in ED 18.5 Klotho Fetuses. There were no significant 
differences in serum phosphorus on ED 18.5 among Klotho WT, HET, and null fetuses. All 
Klotho fetuses had hyperphosphatemia compared to HET dams. The numbers in parentheses 















































(10)                             (22)                           (10)                             (4)
p < 0.001 
p < 0.001 
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Figure 31: Serum Total Calcium in ED 18.5 Klotho Fetuses. There were no significant 
differences in serum total calcium on ED 18.5 among Klotho WT, HET, and null fetuses. HET 
dams had non-significantly higher serum total calcium than all fetuses. The numbers in 
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Klotho+/+ (WT)         Klotho+/- (HET)        Klotho-/- (Null)        Klotho+/- Dam 
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3.2.3 Amniotic Fluid Chemistries in Klotho Null Fetuses on ED17.5 
Because amniotic fluid is largely fetal urine and because renal phosphate excretion is largely 
reduced in Klotho nulls postnatally, I originally expected loss of Klotho to lead to a reduction in 
amniotic fluid phosphorus in Klotho null fetuses. However, the results demonstrated that there 
were no significant differences in amniotic fluid phosphorus among Klotho WT, HET, and null 
fetuses (Figures 32). 
 
As to calcium, it is not impacted during postnatal period by lack of Klotho. Therefore, I did not 
expect amniotic fluid calcium to be changed in Klotho null fetuses – the results were in-line with 
my expectations. It should be pointed out that if the non-significant reduction in PTH observed in 
Klotho nulls is real (Figure 29), amniotic fluid calcium should increase – however, this was not 
seen in Figure 33, suggesting the observed reduction in PTH in Klotho nulls is just a numerical 














Figure 32: Amniotic Fluid Phosphorus in ED 17.5 Klotho Fetuses. Klotho WT, HET, and null 
fetuses had similar levels of amniotic fluid phosphorus on ED 17.5. The numbers in parentheses 
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Figure 33: Amniotic Fluid Total Calcium in ED 17.5 Klotho Fetuses. There were no 
significant differences in amniotic fluid calcium on ED 17.5 among Klotho WT, HET, and null 
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Klotho+/+ (WT)                   Klotho+/- (HET)                     Klotho-/- (Null) 
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3.2.4 Placental Phosphate Transport in Klotho Fetuses on ED17.5 
The rate of placental phosphate transport was measured in two ways: with a 
51
Cr-EDTA 
correction and without the correction. Because 
51
Cr-EDTA only diffuses across the placenta 
passively, it serves as a control for differences in flow rate among individual placentas in one 
litter. 
32
P, however, is actively transported across the placenta from dams to fetuses. Thus, by 
normalizing for the rate of diffusion (using the 
51
Cr-EDTA) the relative rate of placental 
phosphate transfer in each fetus in the same litter can be determined. The results demonstrated 
that placental phosphate transport as measured by 
32
P normalized to 
51
Cr in Klotho null fetuses 
was not changed compared to WTs and HETs. Without 
51
Cr normalization, the results were the 















Cr) in ED 17.5 Klotho Fetuses. Klotho WT, 
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Figure 35: Placental Phosphate Transport (
32
P) in ED 17.5 Klotho Fetuses. Klotho WT, 














































(15) (32)                                          (12)
Klotho+/+ (WT)                 Klotho+/- (HET)                   Klotho-/- (Null) 
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3.2.5 Skeletal Mineral Content in Klotho Fetuses on ED18.5 
Since the skeleton contains the largest amount of phosphate in the body, any difference in 
serum/amniotic fluid phosphate or placental phosphate transport should lead to a change in ash 
weight and, more specifically, skeletal phosphate content. In adult Klotho null mice, skeletal 
phosphate content is increased due to hyperphosphatemia. Based on the adult phenotype, I 
originally expected body ash weight and skeletal phosphate content to increase in Klotho null 
fetuses – however, the results showed that there was no difference between WT and null, which 
was consistent with no changes in serum/amniotic fluid phosphate or placental phosphate 
transport. Skeletal content of calcium and magnesium was not altered in Klotho null fetuses 
either. It is noteworthy that if there were any extraskeletal calcium/phosphate deposits, they 
would be registered in body ash weight measurement because the minerals all remained behind 
regardless of whether they were in the skeleton or not. The results showed Klotho WT and null 
fetuses had equal weight of body ash – confirming the total amount of phosphate in the null was 
not changed (Figures 36 – 39). Body ash weight and skeletal phosphate content of the fetuses of 
the Klotho model were also largely in-line with those of the fetuses of the Fgf23 KO model 
[139].   
 
 









Figure 36: Body Ash Weight in ED 18.5 Klotho Fetuses. There were no changes in body ash 
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Figure 37: Skeletal Phosphate Content in ED 18.5 Klotho Fetuses. Klotho null fetuses 
demonstrated no significant changes in the skeletal content of phosphate on ED 18.5. The 
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Figure 38: Skeletal Calcium Content on in ED 18.5 Klotho Fetuses. Klotho null fetuses had a 
similar skeletal content of calcium on ED 18.5. The numbers in parentheses indicate the number 
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Figure 39: Skeletal Magnesium Content in ED 18.5 Klotho Fetuses. There were no significant 
differences in the skeletal magnesium content among Klotho WT, HET, and null fetuses. The 













































(14)                                        (30)                                          (19)
Klotho+/+ (WT)                      Klotho+/- (HET)                       Klotho-/- (Null) 
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3.2.6 Bone Morphology and Mineralization in Klotho Fetuses on ED18.5 
Phosphate stimulates apoptosis of hypertrophic chondrocytes during endochondral bone 
formation in fetuses, a critical step to ensure robust bone development. Fetuses with 
hyperphosphatemia develop premature apoptosis of hypertrophic chondrocytes – leading to a 
shortened growth plate, as well as impaired mineral deposits. Based on this, I originally expected 
the growth plate would be impaired and mineral deposits would be increased in Klotho null 
fetuses; however, the results showed Klotho WTs and nulls on ED18.5 had a largely identical 















Figure 40: Skeletal Morphology and Mineralization in ED 18.5 Klotho Fetuses. Klotho WT 
and null fetuses appeared to have a similar pattern of the growth plate morphology and 









Klotho+/+ (WT) Klotho-/- (Null)
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3.2.7 Gene Expression Analysis on the Klotho Placenta and Kidneys on ED18.5 
It is known that in Klotho null adults serum FGF23 is significantly increased due to a 
compensatory mechanism. In contrast, Figure 27 demonstrated that serum FGF23 was only 
numerically elevated in Klotho null fetuses.  While the increase in the fetuses was not as 
profound as that in the adults, it might still be able to alter expression of FGF23-targeted genes in 
the placenta and kidneys. The placenta represents the only source of phosphate to fetuses and the 
kidneys the only exit for phosphate – if loss of Klotho could alter serum phosphate in fetuses, 
FGF23-targeted gene expression should be changed on the two organs. The results first showed 
that Klotho WT fetuses had robust Klotho expression in the placenta and kidneys, which was 
absent in the null organs – confirming the Klotho KO model was valid. FGF23-targeted genes 
(NaPi2a, NaPi2b, NaPi2c, Cyp27b1, Cyp24a, and Fgfr1– 4) were each expressed within the WT 
and null placentas, with NaPi2b displaying the most abundant expression among the sodium-
phosphate co-transporters. Originally, I expect the expression of Cyp27b1 to increase and the 
expression of Cyp24a1 to decrease as calcitriol in adult Klotho nulls is elevated. I also expected 
the expression of NaPi2a and NaPi2c to increase as renal phosphate excretion in adult Klotho 
nulls is reduced. However, the results in Klotho null fetuses demonstrated the expression of none 
of those genes was altered (Table 2). A very low level of Fgf23 expression (near the limit of 
detection) was detected in the WT and null placentas, which was also confirmed in the Fgf23 KO 
model.  
 
Since the Fgf23 null kidneys showed a modest reduction in Cyp24a1 expression that reached the 
threshold of statistical significance, and since the Phex null kidneys (and the placenta) showed 
opposite, and since the Klotho null kidneys showed no changes, I repeated the qPCR analysis 
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using a larger sample size of the fresh kidneys from Fgf23 null, Klotho null, and Phex null 
fetuses. The results confirmed that the Cyp24a1 expression was significantly increased in the 
Phex null kidneys. However, the expression was not changed in the Fgf23 null or Klotho null 






















Table 2: List of FGF23-Targeted Genes in Placentas and Fetal Kidneys between Klotho WT 
and Null Fetuses. 


















Fgf23 1.00±0.25 1.00±0.22 0.917 Undetectable Undetectable N/A 
Klotho 1.00±0.22 Undetectable 0.000 1.00±0.11 Undetectable 0.000 
NaPi2a 1.00±0.23 1.00±0.38 0.825 1.00±0.10 1.20±0.20 0.109 
NaPi2b 1.00±0.08 0.90±0.24 0.559 1.00±0.10 1.00±0.00 0.673 
NaPi2c 1.00±0.16 1.10±0.15 0.431 1.00±0.30 1.20±0.30 0.258 
Cyp24a1 1.00±0.20 0.80±0.36 0.364 1.00±0.10 1.10±0.30 0.537 
Cyp27b1 1.00±0.00 0.90±0.00 0.379 1.00±0.30 1.20±0.70 0.614 
Fgfr1 1.00±0.08 1.20±0.33 0.341 1.00±0.20 1.20±0.10 0.225 
Fgfr2 1.00±0.14 1.10±0.19 0.284 1.00±0.20 1.20±0.10 0.080   
Fgfr3 1.00±0.21 1.00±0.27 0.881 1.00±0.30 1.20±0.10 0.323 





Fgf23 Fibroblast growth factor 23
Klotho Klotho
NaPi2a or Slc34a1 Sodium-dependent phosphate transporter 2A or Solute carrier family 34 member 1
NaPi2b or Slc34a2 Sodium-dependent phosphate transporter 2B or Solute carrier family 34 member 2
NaPi2c or Slc34a3 Sodium-dependent phosphate transporter 2C or Solute carrier family 34 member 3
Cyp24a1 1,25-dihydroxyvitamin D(3) 24-hydroxylase
Cyp27b1 25-hydroxyvitamin D-1 alpha hydroxylase
Fgfr1 Fibroblast growth factor receptor 1
Fgfr2 Fibroblast growth factor receptor 2
Fgfr3 Fibroblast growth factor receptor 3




Figure 41: Expression of Cyp24a1 in the Fgf23, Phex, and Klotho Fetal Kidneys. Phex ♂ 
kidneys had significantly higher expression of Cyp24a1 while no changes were detected in Fgf23 
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3.3 Results from Pth/Fgf23 DKO Fetuses  
PTH and FGF23 both regulate serum phosphate and both hormones affect the same renal genes 
postnatally. It was previously found in Dr. Kovacs’ Laboratory that unlike Fgf23 nulls, Pth null 
fetuses on ED18.5 had increased serum phosphorus compared to WT siblings; meanwhile, those 
nulls had significantly reduced serum FGF23[139, 150]. Therefore, two questions were raised: 
(i) in Fgf23 nulls and Klotho nulls, could PTH somehow compensate to keep phosphorus normal 
even though there was no increase in PTH in either model? (ii) conversely, could FGF23 
compensate in utero for loss of PTH? To answer the two questions, the approach was to take the 
hyperphosphatemic Pth null fetus and to see if hyperphosphatemia would worsen with absence 
of FGF23. If PTH could compensate loss of FGF23, Fgf23/Pth DKO fetuses should have a 
phenotype different from Fgf23 nulls; if PTH could not, the DKO should have an identical 
phenotype as Fgf23 nulls. If FGF23 could compensate loss of PTH, Fgf23/Pth DKO and Pth null 
fetuses should have a different phenotype; if FGF23 could not, the DKO should have an identical 
phenotype as Pth nulls. 
 
3.3.1 Serum Phosphorus in Fgf23/Pth DKO Fetuses on ED18.5 
My results in Figure 42 showed that Pth nulls had significantly increased serum phosphorus 
relative to the normal fetal hyperphosphatemia – which was consistent with what was observed 
previously in Dr. Kovacs’ Laboratory. If FGF23 could compensate for loss of PTH, Fgf23/Pth 
DKO should have an even higher serum phosphorus than Pth nulls – however, there was no 
significant difference between the values. In fact, serum phosphorus was non-significantly lower 




As discussed above, serum phosphorus was not altered in Fgf23 nulls relative to WT [139].  
In this experiment, serum phosphorus in Fgf23 nulls was only numerically decreased when 
compared to DKO, suggesting there is lack of any synergistic effect of PTH and FGF23 being 
both absent, which further indicates that PTH is likely not compensating for loss of FGF23 in 













Figure 42: Serum Phosphorus in Fgf23/Pth DKO Fetuses. DKO and Pth null fetuses had 
increased serum phosphorus compared to WT siblings. However, no differences were detected 
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(WT)                         (DKO)                      (Fgf23 Null)                  (Pth Null)
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3.3.2 Skeletal Mineral Content in Fgf23/Pth DKO Fetuses on ED18.5 
The skeleton contains the largest amount of phosphate in the body, so any difference in 
serum/amniotic fluid phosphate or placental phosphate transport should cause a change in  
ash weight and, more specifically, skeletal phosphate content. As discussed in the introduction 
section, skeletal mineral content was not altered in Fgf23 nulls – thus, in this study I explored if 
this was due to a compensatory mechanism by PTH. The calcium content is known to be reduced 
in Pth null fetuses.  My results showed that the calcium content was significantly reduced in both 
DKO and Pth nulls, with no differences between the two genotypes – suggesting no added 
change in calcium content due to loss of FGF23 (Figure 43B). The phosphate content was 
significantly increased in Fgf23 nulls compared to WTs (Figure 43A) – which was different 
from the results of a prior study with a much bigger sample size showing the phosphate content 





), the skeletal phosphate content in Fgf23 nulls was modestly 
increased, just reaching statistical significance. No changes in the magnesium content were 
observed among genotypes (Figure 43C). Other analyses as in the Phex null and Klotho KO 
models were not done in the DKO model because: (i) serum phosphate and skeletal mineral 
content in Fgf23/Pth double null fetuses were not changed compared to Pth nulls – suggesting 
that no further insights are likely to be gained and that it would be low yield to further pursue 
those experiments, and (ii) those studies are quite time consuming and expensive because of the 







Figure 43: Skeletal Mineral Content in ED17.5 Fgf23/Pth DKO Fetuses. (A) Fgf23 null 
fetuses had increased skeletal phosphate content as compared to their WT siblings. (B) DKOs 
and Pth nulls had a higher skeletal calcium content than WT fetuses; however, there were no 
differences between DKOs and Pth nulls. (C) No different skeletal magnesium content was 
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P < 0.04
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p = 0.05
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Fgf23+/+/Pth+/+ Fgf23-/-/Pth-/- Fgf23-/-/Pth+/+ Fgf23+/+/Pth-/-





3.4 Results from Postnatal Phex Null, Fgf23 Null, and Klotho Null Pups 
The results in Phex null and Klotho null fetuses, as well as previous data in Fgf23 null fetuses, 
suggest that FGF23 has no role in fetal phosphate regulation. However, it is well known that 
excess or deficient FGF23 will cause marked abnormalities postnatally – so, when does FGF23 
become important postnatally? In this aim, I investigated when serum and urine phosphorus, as 
well as renal expression of NaPi2a-c, would be changed in postnatal Phex, Fgf23 and Klotho 
null pups. I considered the first time point to be within 12 hours of birth because dams usually 
delivered pups at midnight and the experiments were conducted between 10 a.m. and 12 p.m.  
Serum phosphours was significantly decreased 30% within approximate 12 hours of delivery [i.e. 
postnatal day (PD) 1] in Phex ♂ pups (Figure 44). At the same time point, urine phosphorus was 
analyzed. Due to a limit of urine volume available, creatinine was not measured to normalize 
urine phosphorus. Within PD 1, Phex ♂ pups had significantly increased renal phosphate 
excretion by 2.5 fold (Figure 45) relative to WT pups. To confirm the observed changes of renal 
phosphate excretion, I analyzed renal expression of NaPi2a, NaPi2b, and NaPi2c, concurrently 
with the urine phosphate measures. The results demonstrated that in Phex ♂ pups within PD 1, 
renal expression of both NaPi2a and NaPi2c was significantly reduced while expression of 
NaPi2b was not altered (Table 3). 
 
Conversely, absence of FGF23 or Klotho had a slower onset to effects in neonatal pups. The 
results showed that serum phosphorus was not increased until PD7 and PD5 in Fgf23 nulls and 
Klotho nulls, respectively (Figures 46 – 47. On PD 7, Fgf23 null pups started to have a modest 
but significant 10% reduction in renal phosphate excretion (Figure 48). On PD 5, Klotho null 
pups had a non-significant downward trend in renal phosphate excretion (Figure 49). I also 
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measured urine phosphorus levels after PD 5 in Klotho null pups, with no significant differences 
from the levels in WTs (data not shown). The failure to detect the urine phosphorus changes in 
Klotho nulls might be due the technical aspect of not being able to normalize for urine 
concentration by correcting for urine creatinine. To complement the urine phosphorus results, 
renal expression of NaPi2a, NaPi2b, and NaPi2c was analysed in Fgf23 nulls on PD 7 and 
Klotho nulls on PD 5. The results showed that the expression of NaPi2a and NaPi2c was 
significantly elevated while there was no change in NaPi2b (Table 4). 
 
Fgf23 and Klotho null neonates did not have increased serum phosphorus immediately after birth 
– therefore, I wondered if PTH would transiently compensate loss of the FGF23 pathway, given 
the fact that PTH decreases serum phosphate in adults. The results showed that serum PTH in 
Fgf23 nulls did not differ as compared to that in WTs at any postnatal time points, nor did serum 
PTH in Klotho nulls (Figure 50). The only significant trend observed was that serum PTH 












Figure 44: Serum Phosphorus in Phex Neonates. Phex null pups demonstrated decreased 
serum phosphorus immediately after birth (PD 1). The numbers in parentheses indicate the 
















































(9)         (8)                     (6)        (4)                     (6)        (6)                      (6)        (4)
Postnatal D1                  Postnatal D3                   Postnatal D5                 Postnatal D7          
p < 0.001 p < 0.001 p < 0.001 p < 0.001




Figure 45: Urine Phosphorus in Phex Neonates. Phex null pups had a significant increase in 














































(10) (12)  
p < 0.05
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NaPi2a 1.00±0.08 0.78±0.17 < 0.03 
NaPi2b 
 
1.00±0.08 1.04±0.04 NS 
NaPi2c 
 












Figure 46: Serum Phosphorus in Fgf23 Neonates. Fgf23 nulls did not have increased serum 










































Postnatal D1         Postnatal D3                 Postnatal D5            Postnatal D7            Postnatal D10 
(5)   (11)  (9)           (10)   (9)   (3)           (15)  (5)  (8)           (8)     (5)  (6)           (12)   (14)  (10)
p < 0.001 p < 0.001




Figure 47: Serum Phosphorus in Klotho Neonates. Klotho nulls did not have increased serum 















































(6)   (5)  (6)             (5)   (13)  (6)           (4)   (10)  (7)           (6)    (11) (6)           (6)   (13)  (8)
Postnatal D1             Postnatal D3            Postnatal D5            Postnatal D7            Postnatal D10
p < 0.002 p < 0.001 p < 0.001




Figure 48: Urine Phosphorus in Fgf23 Neonates. Fgf23 nulls had a modest but significant 
reduction in renal phosphorus excretion at PD 7. The numbers in parentheses indicate the 









































(10)          (16)                                           (12)                
p < 0.05




Figure 49: Urine Phosphorus in Klotho Neonates. Klotho nulls had a non-significant trend for 













































Klotho+/+ (WT)                     Klotho+/- (HET)                      Klotho-/- (Null)




Table 4: Renal Expression of NaPi2a, NaPi2b and NaPi2c in Fgf23 and Klotho 
Neonates. 


















NaPi2a 1.00±0.08 1.39±0.12 < 0.05 1.00±0.29 1.67±0.36 < 0.02 
NaPi2b 1.00±0.23 1.30±0.29 NS 1.00±0.29 1.05±0.26 NS 

















Figure 50: Serum PTH in Fgf23 and Klotho Neonates. (A – B) PTH did not differ between 
genotypes at any postnatal time points in Fgf23 and Klotho neonates. Serum PTH decreased 
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P < 0.05
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It has been established that FGF23 plays important roles in regulating phosphate homeostasis in 
adults – it decreases serum phosphate mainly by reducing renal phosphate reabsorption and 
reducing renal production of calcitriol, which in turn decreases intestinal phosphate absorption. 
This Ph.D. project examined potential roles of FGF23 in fetal-placental phosphate and bone 
metabolism as little had been known about expression of Fgf23 and its target genes in the 
placenta or fetal kidneys, or whether FGF23 plays a significant role in regulating fetal phosphate. 
It was initially hypothesized that FGF23 plays an important role in regulating not only fetal 
blood phosphate and skeletal development, but also placental phosphate transfer. However, 
results of this project demonstrated that: (i) neither excess FGF23 nor loss of Klotho disturbed 
fetal-placental phosphate parameters, (ii) loss of FGF23 did not further alter phosphate 
homeostasis in Pth null fetuses, but (iii) excess FGF23 altered serum and urine phosphate within 
12 hours of birth while loss of FGF23 or Klotho took 5-7 days to change serum and urine 
phosphate. The following sections discuss those results in detail. 
 
4.1 Excess FGF23 Does Not Disturb Fetal Phosphate Metabolism 
In adults excess FGF23 causes a severe disruption in phosphate metabolism, mainly including 
hypophosphatemia, renal phosphate wasting and osteomalacia or rickets. Extrapolating those 
findings in adults to fetuses, I initially hypothesized that FGF23 would also be a critical 
phosphate regulator through reducing serum phosphate, decreasing renal phosphate reabsorption 
and lowering placental phosphate transport during fetal development.  However, I found in Phex 
null fetuses that excess FGF23 resulted in no disturbance in serum and amniotic fluid (fetal 
urine) phosphate and calcium, placental phosphate transport, skeletal morphology, or skeletal ash 
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weight and mineral content. WT, Phex null male, and Phex
+/-
 female fetuses were able to 
maintain normal phosphate parameters despite marked hypophosphatemia in their Phex
+/-
 dams. 
These results were surprisingly the opposite of what was expected initially, suggesting that 
FGF23 did not regulate phosphate homeostasis or bone development in fetuses – this is in sharp 
contrast to its critical roles in regulating phosphorus and skeletal metabolism in adults and 
children. 
 
It should be noted that a Japanese group also conducted mice studies in Phex male null fetuses 
independently [239]. Their key findings are summarized here. The protein expression of FGFR1 
and Klotho was initially confirmed in the WT placenta by immunohistochemical analysis. This 
group next examined potential effects of excess FGF23 in male Phex null fetuses derived from 
the Phex
+/-
 (HET) female and Phex
+/
 (WT) male mating. Specifically, plasma FGF23 in Phex
+/-
 
dams was significantly elevated by 10 fold than that in normal WT dams. FGF23 in male Phex 
null fetuses was about 20-fold higher than that in Phex
+/-
 dams, as well as 100-fold higher than 
that in male WT fetuses. The Japanese group also found that Cyp24a1 expression was 
significantly increased in the placenta of fetuses (including both null and WT) from Phex
+/-
 dams 
when compared with WT fetuses from normal WT dams; however, there was no significant 





The Japanese group then did an experiment in which they directly injected FGF23 into the WT 
placentas from normal WT dams, which led to an increase in Cyp24a1expression. In the fetal 
kidneys, Cyp24a1 expression was significantly increased in male Phex nulls than in male WT; 
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however, serum calcitriol in male Phex nulls was only decreased numerically (non-significantly) 
when compared to that in male WT fetuses. It should be noted that despite those changes in male 
Phex nulls, serum phosphate and calcium, as well as amniotic fluid phosphate, were not altered. 
The Japanese group then did an in vitro organ culture experiment with the WT placenta (from 
normal WT dams). In this experiment, treatment with plasma from Phex
+/-
 dams significantly 
increased placental Cyp24a1expression, which was abolished by a simultaneous addition of an 
anti-FGF23 antibody.  
 
In the end, the Japanese group concluded that excess FGF23 in pathological conditions (such as 
in male Phex null fetuses) exerted direct effects on the placenta and affected fetal vitamin D 
metabolism via the up-regulation of Cyp24a1 expression. Comparing my results and the 
Japanese group’s, I noticed that we both observed that excess FGF23 in male Phex null fetuses 
did not cause changes in phosphate metabolism. The Japanese group did some experiments in 
which exogenous FGF23 treatment was introduced to change Cyp24a1 expression. My study 
should be more complete as I directly measured the rate of placental phosphate transport and 
phosphate deposits in the fetal skeleton. What is quite interesting is that this Japanese group 
claimed that FGF23 seemed important in fetal phosphate homeostasis – a conclusion that was 
based solely on some modest changes in placental gene expression. It would be the same as I 
were to claim FGF23 is important due to a few modest changes in gene expression that I found. 
However, I know that those important physiological parameters (serum phosphate, amniotic fluid 




PTH is known to reduce serum phosphate via suppressing its renal reabsorption in adults. It is 
also known from other in vitro studies that excess FGF23 inhibits PTH.  However, in the present 
study serum PTH levels were not different between WT male and Phex null male fetuses, 
suggesting there is no interaction between FGF23 and PTH in fetuses.  
 
Interestingly, I found that increased FGF23 in Phex null male fetuses resulted in an increase in 
Cyp24a1 expression in the fetal kidneys and placenta, which may explain the small but 
statistically significant reduction in serum calcitriol in Phex null male fetuses.  I also found that 
expression of Klotho and Fgfr2 was significantly reduced in the Phex null kidneys. Overall, these 
results suggest that fetal kidneys are likely to respond to high FGF23 levels as they do in adults 
by increasing Cyp24a1 expression and reducing renal calcitriol production. However, these 
changes did not cause any detectable disturbance in renal phosphate handling or serum 
phosphate, indicating that calcitriol is not an important phosphate regulator in fetuses either and 
that the kidneys only play a very minor role during fetal development. Studies in Dr. Kovacs’ 
laboratory previously demonstrated that neither loss of VDR nor loss of calcitriol would disturb 
fetal phosphate regulation – thus, it is not surprising that modest lowering of calcitriol in Phex 
null male fetuses had no effect [175, 176]. Fgfr2 expression was reduced only 17% in the Phex 
null kidneys, and so this may not be a physiologically significant difference.  It would be 
interesting to study the phenotype of Fgfr2 null fetuses; however, knocking out the gene is fetal 




4.2 Neither FGF23, Calcitriol nor PTH Is Required to Maintain Fetal Phosphate Homeostasis 
As presented in the introduction section, it was recently discovered in Dr. Kovacs’ Laboratory 
that loss of FGF23 did not cause any significant disturbance in phosphate metabolism in Fgf23 
null fetuses, except a modest reduction in renal Cyp24a1 expression which did not alter serum 
calcitriol.  These data suggest that FGF23 is not required to maintain phosphate homeostasis 
during fetal development. Based on these results, I then hypothesized that there could be other 
FGF members compensating FGF23 deficiency in fetuses by acting on the FGFR/Klotho 
receptor complex. In order to address this hypothesis, I studied phenotypes of Klotho null fetuses 
in Aim 2. The results demonstrated that Klotho null fetuses had a similar phosphate and bone 
development phonotype as Fgf23 nulls – thus, my hypothesis should be rejected.  
 
Gene expression analysis showed that Klotho expression was absent in the Klotho null placenta 
and kidneys and that Klotho nulls had normal renal expression of Cyp24a1 – which was different 
from Fgf23 nulls that had decreased expression. It should be noted that studies in Phex null 
fetuses suggest calcitriol is not important in fetal phosphate homeostasis – thus, the Cyp24a1 
expression difference between Klotho null and Fgf23 null is physiologically unimportant. 
Additionally, upon a repeat assessment with the new placentas from WT and Fgf23 nulls in a 
larger sample size, I found Cyp24a1 expression was not reduced in the Fgf23 null placenta – 
confirming neither an absence of FGF23 or Klotho alters Cyp24a1expression, which is 
consistent with lack of changes in serum calcitriol in both genotypes. Collectively, these results 
indicate that calcitriol does not compensate to regulate phosphate in fetuses when the FGF23 




PTH is well known to decrease renal phosphate reabsorption in adults, leading to increased renal 
excretion of the mineral. However, in my fetal experiment, serum PTH levels were not 
significantly altered in Klotho nulls. Similar results were also observed in Fgf23 nulls. These 
results should reinforce the notion that fetal phosphate homeostasis is not altered by absence of 
Klotho or FGF23 since PTH did not need to increase to compensate. It was previously observed 
in Dr. Kovacs’ laboratory that both Pth null and Gcm2 null fetuses developed 
hyperphosphatemia, reduced body ash weight and reduced skeletal calcium and magnesium 
content.  Although skeletal phosphorus content was not measured, the mineral would be highly 
likely reduced in the bone as the calcium content was lower. These results imply that PTH could 
potential lower blood phosphate by stimulating bone mineralization in fetuses. In the present 
study (Aim 3), by comparing Pth nulls and Fgf23/Pth DKO fetuses in Aim 3, I found that 
whereas loss of PTH had its previously established effect to cause hyperphosphatemia and 
reduced the skeletal calcium content, simultaneous loss of FGF23 did not potentiate those 
effects. These results further support the notion that PTH does not compensate loss of FGF23 to 
regulate phosphate homeostasis in fetuses, otherwise there would be phenotype differences 
between Pth nulls and DKOs. Meanwhile, the lack of difference between Pth nulls and 
Fgf23/Pth DKO once again highlighted that FGF23 is not important in regulating fetal 
phosphate. 
 
4.3 Maternal Phenotype Does Not Affect Fetal Phenotype  
My results confirmed that Phex
+/-
 dams have lower serum phosphate than WT dams during 
pregnancy.  To determine whether hypophosphatemia in Phex
+/-
 dams would affect fetal serum 
phosphate, I studied serum FGF23 and phosphate in fetuses (WT male and Phex
+/-
 female) from 
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Phex WT dams mated to Phex null males. The results showed that fetal serum phosphate was no 
different across genotypes (WT vs. Phex
+/-
). More importantly, the results demonstrated that WT 
fetuses from the WT dams and WT fetuses from the HET dams had similar levels of serum 
phosphate, and that HET fetuses from the WT dams and HET fetuses from the HET dams had 
similar levels of serum phosphate as well. In terms of FGF23, it was significantly increased in 
Phex
+/-
 female fetuses when compared to WT males.  What is more important is that when 
comparing serum FGF23 between fetuses from Phex WT dams vs. HET dams, I noticed that 
serum FGF23 was unaltered by maternal genotypes. Additionally, in Dr. Samaraweera’s studies 
WT fetuses from Fgf23
+/-
 dams (which had FGF23 deficiency) had largely identical serum 
phosphate and FGF23 as WT fetuses from Fgf23
+/+
 dams [139]. Overall, these results suggest 
that fetal phenotypes of serum phosphate and FGF23 are independent of maternal phenotypes.  
This is similar to what was previously found about fetal serum calcium in Dr. Kovacs’ laboratory, 
that fetal serum calcium was generally set and maintained independent of maternal levels. It is 
also noteworthy that a recent project carried out in Dr. Kovacs’ laboratory using WT dams 
(mated with WT males) demonstrated that altering maternal serum phosphate through low, 
normal or high phosphate diets did not change fetal serum phosphate either (data not published). 
For details, please refer to the first point discussed in the “Future Directions” section below.  
 
4.4 Why Were Fetal PTH Values High in My Study? 
PTH is normally suppressed at a relatively low level in fetuses. However, it was observed in Aim 
1 and Aim 2 that fetuses had higher-than-expected serum PTH. It could be due to a problem with 
the mouse PTH enzyme immunoassay (EIA) I used – it might measure fragments of PTH at 
times rather than true intact PTH because such fragments may accumulate in the fetal circulation. 
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Human PTH assays have gone through an evolution of becoming more and more specific to 
measure intact PTH without binding to the N-terminal or C-terminal fragments of PTH that are 
not biologically active. Unfortunately, this has not been done with rodent assays which still 
measure N-terminal PTH but not full-length – that is, current rodent PTH kits still include 
measuring inactive PTH fragments which the human assays now exclude. It should be pointed 
out that recent experiments in Dr. Kovacs’ laboratory using the mouse PTH EIA kits that were 
ordered recently saw appropriately low fetal PTH values – however, this did not occurred in the 
past by using the PTH EIA kits that were ordered earlier.  The variation from batch to batch 
could suggest there are between-kit problems. Additionally, a mouse PTH EIA kit is also not as 
specific or reliable as a rat/rodent PTH immunoradiometric assay (IRMA) kit. Earlier studies in 
Dr. Kovacs’ laboratory and others used the rat/rodent IRMA kit for measurements in mice and 
later switched to the mouse EIA kit – that is when this kit-to-kit variability started. I’ve been 
tempted to look at this in more details by comparing the IRMA and EIA, mouse and rat, but it 
would be expensive. 
 
Another explanation for high PTH in those fetuses is that maternal HET phenotype may be 
affecting serum levels of PTH in fetuses. Why? It is known that Phex
+/-
 dams have 
hypophosphatemia, which may require fetuses to up-regulate the mechanisms responsible for 
placental phosphorus transport in order to obtain the needed amount of phosphorus. Conceivably, 
secondary hyperparathyroidism in fetuses may stimulate placental phosphate transport. However, 
other studies of the perfused placenta from fetal lambs demonstrated that exogenous PTH or 




Regardless of PTH being higher than maternal levels or lower (as it is supposed to be), readers 
should know that PTH was not changed between the fetal genotypes in the Fgf23, Phex and 
Klotho KO models. Therefore, whether high levels of fetal PTH in my studies are an assay 
problem or due to some aspects of maternal genotypes/phenotypes, it is not an issue of any of the 
fetal genotypes. However, the possibility that variability of the mouse PTH EIA (as explained 
earlier) might mask some true differences in serum PTH between WT and null fetuses cannot be 
completely ruled out.      
 
4.5 Potential Effects of Genetic Backgrounds on Fetal FGF23   
Serum FGF23 was previously measured in WT fetuses of Pth
+/-
 dams in Dr. Kovacs’ Laboratory 




 dams, and 
Fgf23
+/-
 dams, I observed that Pth WT fetuses had higher serum FGF23 than Phex WT and 
Fgf23 WT fetuses [139]. At this time, I do not have a solid reason to explain why there was such 
a difference. The lower FGF23 in the latter two ones may be due to genetic background 
differences as the Phex null and Fgf23 KO models are based on the C56BL/6 background while 
the Pth KO model on the Black Swiss. It has been known that Black Swiss fetuses have higher 
ionized calcium  and bone mineral density than C57BL/6 fetuses [162]. The genetic differences 
between the Black Swiss and C57BL/6 may impact the overall physiology of fetuses and result 
in phenotypic differences. As a result, FGF23 in Black Swiss fetuses was higher than that in 
C57BL/6 fetuses. It should also be pointed out that there are even significant phenotypic 
differences between Black Swiss-based and C57BL/6-based Pth null fetuses. For example, 
C57BL/6-based ones are modestly abnormal in skeletal development (i.e. slightly shortened long 
bones, shorter metacarpals and tetatarsals) while Blass Swiss-based ones are normal in those 
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parameters. Clearly, other factors, besides genetic differences, may also contribute to higher 
FGF23 observed in Pth WT fetuses. More studies are needed to identify them.   
 
4.6 Calcitriol Does Not Respond to FGF23 during Pregnancy 
I did not comprehensively examine maternal physiology during pregnancy in the Phex null and 
Klotho KO models. However, I noted in Aim 1 that 7-fold increased FGF23 in Phex
+/-
 dams did 
not suppress maternal serum calcitriol during pregnancy – suggesting that Cyp27b1 and Cyp24a1 
do not respond to FGF23 in pregnant dams and that whatever stimulates Cyp27b1 and inhibits 
Cyp24a1 should be more powerful than the effects of high FGF23 that normally suppresses 
Cyp27 and stimulates Cyp24a1. It should be pointed out that increased calcitriol during 
pregnancy is likely not due to contributions from the placenta and other fetal sources. Calcitriol 
normally increases 2- to 5-fold during pregnancy, primarily as a result of increased production 
within the maternal kidneys and without the need for stimulation by PTH [165, 242]. The 
placenta normally contributes little if any calcitriol to the maternal circulation, as shown by an 
anephric woman who had low calcitriol before and during a pregnancy and by 30-fold higher 
expression of Cyp27b1 in the maternal kidneys vs. placenta in mice [48, 165, 176, 243]. 
 
4.7 Why Does an Abnormal FGF23 Signaling Pathway Fail to Alter Fetal Phosphate 
Parameters? 
There are two key points to answer this question – first, the placenta is the main organ for 
regulating phosphate in fetuses; and second, the placenta does not depend upon FGF23 to 
regulate phosphate transport. Active transport of phosphate across the placenta is the main route 
of phosphate delivery to fetuses. The fetal kidneys and intestines provide only a route for 
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recycling of minerals that come across the placenta, are excreted by the kidneys into amniotic 
fluid, and are then swallowed and reabsorbed. This is evidently a trivial route compared with the 
substantial forward flow of phosphate across the placenta. Other studies have demonstrated that 
the fetal kidneys have a reduced glomerular filtration rate and blood flow relative to the neonatal 
kidneys, and that maturational changes in glomerular filtration and renal blood flow after birth 
lead to an improved ability to reabsorb and excrete minerals[135]. A combination of all these 
pieces of evidence suggests that the placenta is the main organ to regulate phosphate (as well as 
other minerals) in fetuses while the kidneys and intestines play a much less important role. In 
terms of FGF23, it is evidently not a major regulator of active placental transport of phosphate as 
studies in Aims 1 & 2, as well as studies by Dr. Samaraweera, demonstrated neither excess 
FGF23 nor an impaired FGF23 pathway altered placental phosphate transport or placental gene 
expression of any of the sodium-phosphate co-transporters. As discussed in the introduction 
section, FGF23 acts primarily on the kidneys and to a lesser extent on the intestines to regulate 
phosphate metabolism in adults and children (postnatally). But during fetal development the 
kidneys and intestines provide only a trivial route for mineral exchange. 
 
Besides the two points discussed above, the normally low concentrations of intact FGF23 in fetal 
mice of the C57BL/6 background may also be contributing to why the absence of FGF23 or 
Klotho has no effect; in other words, low concentrations of FGF23 in normal fetal mice may 
imply that FGF23 per se is relatively unimportant for fetal mineral homeostasis. However, it 
should be pointed out that fetal mice in the Black Swiss background were found to have intact 
FGF23 concentrations equal to the maternal values[139], and another study found fetal intact 
FGF23 concentrations to equal maternal values in the C57BL/6 background[239]. Moreover, low 
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levels of FGF23 in normal fetuses aren’t the sole explanation for why FGF23 absence has no 
effect, because the absence of Klotho did not disturb fetal serum FGF23 concentrations, whereas 
it led to 1000- to 5000-fold higher levels in neonates and adults[74, 244, 245]. Taken together 
with the fact that high levels of FGF23 do not disturb fetal phosphate parameters but begin to do 
so within 12 hours after birth, it is clear that the fetal-placental unit is unresponsive to FGF23 or 
a loss of Klotho. The microarray studies in the placentas of WT, Fgf23 null, and Phex null male 
placentas (in Aim 1) revealed no evidence of compensatory changes in phosphate-regulating or 
other genes. The lack of changes in the phosphotrophic hormone PTH (in Aims 1 & 2 and Dr. 
Samaraweera’s studies) is further evidence that the compensatory changes do not occur during 
fetal development when FGF23 or Klotho is absent, or when FGF23 excess is present. In a real 
sense, fetuses do not care about a loss of FGF23 signaling, nor about excess FGF23 signaling, 
whereas neonates are adversely affected. 
 
It is noteworthy that in my studies, as well as in Dr. Samaraweera’s studies, the pregnant dams 
were on normal phosphate diet. Since their fetuses would also get a normal phosphate load, 
maybe that is why there was no FGF23 response. It is possible that hyperphosphatemia in 
pregnant dams as a result of phosphate-rich diet would trigger a FGF23 response in fetuses. 
 
My experiments do not rule out the potential importance of the sodium-phosphate co-transporters 
(mainly NaPi2b) in regulating placental phosphate transport, because their expression was 
normal in Klotho null, Fgf23 null, and Phex null male placentas. Instead, factors other than 
FGF23 must be regulating their expression during normal fetal development. Mouse fetuses with 
a global KO of Napi2b die at mid-gestation[246], but whether this is due in part to altered 
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placental phosphate transport is unknown. In addition, there are other possibilities that may 
explain why abnormal FGF23 fails to alter fetal phosphate metabolism. First, FGF23 might be 
different in fetal life from postnatal life in terms of its structure. That is, the structure of the 
FGF23 protein could be modified in fetuses to have no effect in phosphate regulation. Second, 
actions of FGF23 in fetal life may be blocked by some other undiscovered agents. Third, 
receptors of FGF23 (mainly FGFR1) may be altered or expressed at low protein levels even 
though my experiments showed that gene expression of Fgfr1 – 4 was normal in the fetal 
kidneys and placenta. Fourth, the FGF23 assay is known to measures intact FGF23 which is 
biologically active. However, whether the assay can capture the first two N-terminal acids of 
FGF23 is unknown. If the assay does not, then there is a possibility that “intact” FGF23 that I 
measured in those Phex and Klotho fetuses was not intact at all or biologically active. That is, 
whether the two models are truly valid is unknown. A similar situation happens with PTH where 
loss of the first two amino acids of the protein causes inactivity but the protein is picked up as 
intact by most assays. Fifth, we know that the C-terminal fragment levels of FGF23 (biologically 
inactive) are higher in fetuses. If those fragments can block the action of intact FGF23, intact 
FGF23 cannot function properly in fetuses.   
 
4.8 FGF23 Is Important in Neonatal Phosphate Regulation 
Since the results in Aims 1-3 suggest FGF23 is not an important regulator in phosphate 
homeostasis in fetuses, I further hypothesized that FGF23 would start being critical in this 
process during the neonatal stage. The results in Aim 4 demonstrated that by PD5 in Klotho 
nulls, and by PD7 in Fgf23 nulls, serum phosphate became significantly increased, whereas the 
urine phosphate showed a slight decrease that was statistically significant in Fgf23 nulls but not 
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significant in Klotho nulls. The non-significance of the urine phosphate results in Klotho nulls 
may be due to lack of the creatinine correction which likely increased the variability of the urine 
phosphate results (I did not measure the creatinine concentrations in urine because obtainable 
urine volumes from mouse neonates were too small). This apparent reduction in renal phosphate 
excretion in both Fgf23 nulls and Klotho nulls was accompanied by an increase in renal 
expression of NaPi2a and NaPi2c, which was not present at ED 18.5. Collectively, these results 
suggest that my hypothesis should be accepted – that is, FGF23 is required during the neonatal 
stage to maintain normal phosphate homeostasis. The renal gene expression changes in NaPi2a 
and NaPi2c indicate that the kidneys start becoming an important organ to regulate phosphate 
excretion in neonates – which is strikingly opposite to what happens in fetuses where the kidneys 
only play some minor roles. My results in Aim 4 also showed that Klotho nulls appeared to have 
an earlier onset of hyperphosphatemia (day 5 vs. day 7) than Fgf23 nulls but whether this is a 
real or chance difference from the Fgf23 null phenotype is not certain; PD6 was not assessed.  
 
In contrast to the slow emergence of hyperphosphatemia in Fgf23 null and Klotho null neonates, 
excess FGF23 in Phex null males caused a reduction in serum phosphate and a significant 
increase in urine phosphate within 12 hours after birth. These results once again indicate that a 
normal level of FGF23 is important in maintaining phosphate homeostasis in neonates. 
Accompanying with the urine phosphate results, renal expression of NaPi2a and NaPi2c was 
significantly reduced, as compared with no difference 24 hours earlier (ED 18.5) – suggesting 
the kidneys in neonates become important and responsive to FGF23 within 12 hours after birth 




The results also demonstrated that Phex null neonates had much earlier onset of phosphate 
abnormalities than Fgf23 nulls and Klotho nulls, which could be due to a compensatory increase 
of PTH in the latter two ones.  However, measurements of PTH in neonatal Fgf23 nulls and 
Klotho nulls showed this hormone was not significantly altered – thus, such possibility should be 
ruled out.  That is, the delayed onset of the Fgf23 null and Klotho null phenotypes was not due to 
compensatory secondary hyperparathyroidism. FGF23 could be modified or blocked by other 
agents in fetuses, therefore ultra-high FGF23 in Phex null fetuses did not exert any effect on 
phosphate regulation. Once the fetus is delivered, the modification or blockade of FGF23 would 
disappear within several hours after birth. Therefore, Phex null pups demonstrated 
hypophosphatemia and increased renal phosphate excretion. There is also a possibility that intact 
FGF23 could be interfered by high levels of the C-terminal fragment of FGF23. A Japanese 
group previously reported that the C-terminal fragment was abundant in normal human cord 
blood despite low levels of intact FGF23 [247]. Once a fetus is delivered, the high levels of the 
C-terminal fragment of FGF23 should be cleared, which could allow FGF23 to begin acting on 
the kidneys of the pup right away. Another potential explanation for why Fgf23 and Klotho null 
pups showed the abnormalities several days later than Phex null pups is that immediately after 
birth there is a very high need for phosphate in the developing skeleton, therefore, from a 
developmental perspective, an early neonate does not need to excrete phosphate but instead 
needs to hold on to it – so FGF23 normally do not begin to act until days later. The high demand 
of phosphate is especially seen in premature neonates where dietary calcium/phosphate intake is 
not sufficient, the neonates have to be treated parenterally to get enough calcium/phosphate to 




4.9 Clinical Implication 
There have been no systematic studies of serum phosphate or urine phosphate excretion in 
human fetuses and/or neonates that are homozygous for mutations that lead to loss of 
biologically active FGF23 or Klotho; this is because their autosomal recessive inheritance leads 
to unexpected, sporadic appearance of affected offspring. Based on my Ph.D. project, it can be 
predicted that phosphate should be normal in cord blood of human fetuses that have null 
mutations in Fgf23, Klotho, and/or other genetic causes of hyperphosphatemic tumor calcinosis. 
Human conditions with a calcific mass and hyperphosphatemia (such as TC) can be presented as 
early as 18 days after birth – which is quite similar to the phenotypes observed in Fgf23 null and 
Klotho null mouse neonates [230, 231].  
 
In the opposite condition of excess FGF23, XLH (due to the Phex mutation) in humans can be 
diagnosed as early as the first year if there is a positive family history of the condition. Some 
abnormalities in this disorder, such as reduced but normal renal phosphate reabsorption, can be 
observed as early as 9 days of age – humans seem to have a slower occurrence of symptoms than 
what would be predicted from the Phex null model, likely due to a species difference between 
humans and rodents. Generally speaking, the human data, although limited, suggest a similar postnatal 
onset of FGF23 action as predicted in the mouse model. 
 
4.10 Study Limitations 





First, the technique used to measure placental phosphate transport (studies in Aims 1 – 2) may 
not count the effect of 
32
P backflux (flow of phosphate from fetuses to dams) – which might 
mask true differences in placental phosphate transport between WT and null fetuses. Previous 
studies in Dr. Kovacs’ Laboratory in Pthrp KO mice showed that extending the time between 
calcium isotope administration and surgical removal of fetuses could increase the relative 
differences in placental calcium transfer between the genotypes – which may indicate that the 
longer the interval, the more likely that placental mineral transport results would show 
significant differences. With only a 5-minute interval, there could be less time for 
32
P transferred 
from the maternal to the fetal side; in addition, a certain amount of 
32
P could cross the placenta to 
dams – the net result is a dilution in circulating phosphate in fetuses which could mask a small 
but true difference in placental phosphate transport between WT and null. It should be noted that 
in my studies, the NaPi2b gene expression was not significantly changed in Phex null or Klotho 
null placentas.  Since there could be post-transcriptional modifications in NaPi2b, a protein 
analysis should be conducted to confirm there are no real changes in NaPi2b on protein levels.   
 
Second, the measured urine phosphate concentrations in neonatal pups (studies in Aim 4) were 
not normalized by creatinine concentrations – this is likely the reason why no significant 
differences in urine phosphate between Klotho WT and null pups across all postnatal timepoints 
were detected. Normally, urine mineral concentration measures should be normalized by 
creatinine concentrations to eliminate the confounding effect of urine volume. However, urine 
volume available for collection in my postnatal experiments was too small to support creatinine 
measurements. It should be noted no creatinine correction may not be a big limitation, since 
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significant differences in urine phosphate without being corrected by creatinine were detected in 
Phex null and Fgf23 null neonates. 
 
Third, KO mouse models are great tools to investigate potential effects of certain gene(s) on 
physiological activities in vivo, especially given the fact that certain studies cannot be conducted 
in human bodies.  However, there are various structural differences between rodents and humans, 
which may cause findings in mouse models to be inapplicable to humans. Take the placenta for 
example, rodents have a haemotrichorial placenta, while humans have a haemomonochorial 
placenta [248]. In addition, rodents have an intricate labyrinth where the maternal and fetal blood 
contact closely, whereas in humans villi from the fetal side extend into the intervillous maternal 
blood-filled space and float freely [249]. Due to these structural differences, it is possible that the 
human and rodent placenta function differently – however, it remains unknown. Therefore, our 
findings in mouse models may not necessarily be applicable to humans. 
 
Fifth, in this project KO mouse models allowed me to investigate the potential roles of FGF23 in 
fetal phosphate regulation. However, there are limitations when using such models. One 
challenge is that when a gene of interest is knocked out, another hormone or mechanism may be 
triggered to compensate the loss of such gene. Moreover, a phenotype due to the knockout of a 
gene of interest might not be directly related to the gene loss. That is, knocking out a gene of 
interest may change expression of another gene, which in turn leads to a certain genotype.   
 
Sixth, PTH normally circulates at low levels in fetuses; however, in studies in Aim 1 fetal PTH 
levels were unexpectedly high compared to the maternal values.  It could be due to our mouse 
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PTH kit not being reliable, because one batch had given low PTH values in fetuses (which is 
what is expected) and then another had given high levels (based on our historical use 
experience). The PTH kit may vary in its sensitivity and specificity, and may pick up inactive 
PTH fragments in fetuses at times. The mouse PTH kits do not seem to be subjected to the same 
quality control that human kits are. 
 
4.11 Future Directions 
My Ph.D. project suggests that FGF23 is not an important regulator in phosphate homeostasis 
and skeletal development in fetuses. Further efforts should still be taken to discover potential 
important regulators in this process.  
 
First, dams’ diet during pregnancy could be an important factor that would potentially change the 
process of fetal mineral metabolism. Few studies have been carried out to determine potential 
effects of low-phosphate diet on fetal phosphate regulation and bone development. In my Ph.D. 
project, all fetuses were delivered from dams on regular diet – thus, all fetuses got a normal 
phosphate load, which could be a potential reason that there were no FGF23 responses in Phex 
null, Fgf23 null or Klotho null fetuses.  Two studies were conducted in Dr. Kovacs’s Laboratory 
to investigate if maternal hyperphosphatemia that was induced by phosphate-rich diet would 
provoke FGF23 responses in fetuses [250, 251].  The first study examined whether serum 
phosphate in WT fetuses from WT dams (mated to WT males) responds to different maternal 
phosphate diets (low vs. normal vs. high with corresponding effects on maternal serum 
phosphate).  In this study, 30 WT C57BL/6 dams received low, normal or high phosphate diets 
prior to mating. The results showed that increasing phosphate intake led to progressively higher 
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maternal serum phosphate and FGF23 during pregnancy, while PTH stayed suppressed. As to 
fetal serum phosphate, there were no differences among fetuses from the dams on high, normal, 
low phosphate diets – that is, serum phosphate in fetuses was maintained independent of 
maternal serum phosphate. Fetal FGF23 and PTH remained low and unchanged. There were no 
differences in fetal ash weight, phosphate, or calcium content either; and no changes in placental 
expression of genes relevant to phosphate transport or FGF23 physiology. The second study 
examined whether serum phosphate in fetuses from Fgf23
+/-
 dams (mated to Fgf23
+/-
 males) 
responds to different maternal phosphate diets (normal vs. high).  In this study, 20 Fgf23
+/-
 dams 
received normal or high phosphate diets prior to mating. The results showed that high phosphate 
diet increased maternal FGF23 while PTH stayed suppressed.  Similar to the results in the WT 
C57BL/6 fetuses, there were no differences in serum phosphate, FGF23 or PTH between WT 
fetuses from the dams on high and normal phosphate diets. What was interesting was that Fgf23 
null fetuses from mothers on the high phosphate diet had very high serum phosphate compared 
to Fgf23 null fetuses from dams on the normal diet.  Additionally, in the Fgf23 null placenta 
from the high phosphate diet, Cyp27b1 was down-regulated. There were no differences across 
genotypes or diets in fetal ash weight, phosphate, or calcium content. In general, combined 
results from both studies suggest that fetal phosphate is independent of maternal phosphate levels 
and that fetal FGF23 is only required to defend against hyperphosphatemia induced by maternal 
phosphate loading. I studied fetuses from Phex
+/-
 dams and WT dams which were all fed with 
normal phosphate diets – that is, I examined the effect of low vs. normal maternal serum 
phosphate on WT fetuses.  As discussed above, there was no difference in serum phosphate 
between WT fetuses from the Phex
+/-
 dams and WT fetuses from the WT dams.  Comparing my 
results and the results in the first study, we had a similar observation that abnormal levels of 
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maternal serum phosphate (either due to genetic mutations or phosphate diets) had no effect on 
fetal serum phosphate. Comparing my results and the results in the second study, we had a 
similar observation in WT fetuses, which was also similar to the first study.  Although the results 
in the second study suggest potential effect in null fetuses due to high maternal phosphate diets, 
these results do not conflict with my data.  
 
Second, the phenotype of Klotho null fetuses of the HET dam (Klotho
+/-
) on high-phosphate diet 
should also be explored in comparison to Klotho null fetuses of the HET dam on regular 
phosphate diet. If results replicate what was observed in the second study discussed in the last 
paragraph (i.e. hyperphosphatemia and reduced placental expression of Cyp27b1 in the null 
fetuses of the dam on high phosphate diet), it should suggest that the potential role of fetal 
FGF23 in defending against hyperphosphatemia induced by maternal phosphate loading is 
through the classic FGF23/FGFR/Klotho pathway.  If the null fetuses of the dam on high 
phosphate diet show a same phenotype as the null fetuses of the dam on regular phosphate diet, it 
should imply that the potential role of fetal FGF23 in defending against hyperphosphatemia 
could be through a Klotho-independent pathway.   
 
Third, fetuses of the Phex HET dam (Phex
+/-
) were able to defend their serum phosphate levels 
against maternal hypophosphatemia, implying that when pregnant dams are hypophosphatemic, 
the rate of placental phosphate transport could potentially be increased to fulfill normal 
hyperphosphatemia in fetuses. A placental 
32
P transport study could be conducted to compare the 
rate of phosphate transport between WT fetuses of the Phex HET dam and those of the Fgf23 
HET dam.  If the fetuses of the Phex HET dam accumulate more 
32
P than those of the Fgf23 
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HET dam within a period of time, it should suggest the placenta can self regulate the rate of 
phosphate transport to defend against maternal phosphate abnormalities. Additionally, an 
exploratory experiment could be conducted to mine potential changes on both gene expression 
(mircroarray and/or RNAseq) and protein (proteomics) levels between the placenta of WT 
pregnant dams on regular diet vs. on low-phosphate diet. Significant changes in a gene or protein 
imply this candidate may play roles in regulating placental phosphate transport, which may 
further impact fetal phosphate homeostasis and bone development.  
 
Fourth, previous studies showed that Pth null fetuses had increased serum phosphate 
concentrations by ED18.5, which suggests that PTH could be a critical regulator of fetal 
phosphate homeostasis. However, placental phosphate transport was not measured in Pth null 
fetuses. It would be interesting to see if a loss of PTH could change this process.  
 
Fifth, as discussed above, the sequence and structure of the FGF23 protein in fetal stage could be 
different from those in the adult stage – if so, FGF23 might have no effect in regulating 
phosphate metabolism in fetuses. In order to address this possibility, fetal FGF23 and adult 
FGF23can be extracted and purified to analyze their amino acid sequences, respectively, 
followed by bioinformatics analysis that compare their structure.  In addition, although our gene 
expression and microarray analysis showed that Fgfr1 (FGF23’s main receptor) was not changed 
in Phex null fetuses, it cannot be ruled out that the protein levels of FGFR1 could be low, leading 
to no effect of ultra-high levels of FGF23 in the nulls. Western blot can be applied to study the 




Sixth, FGF23 could be bound by other agents (proteins) that block its functions in Phex null 
fetuses. If so, the complex should have a higher molecular weight than FGF23. Proteomics 
techniques can be applied to study whether FGF23 interacts with other proteins in Phex null 
fetuses.    
 
Seventh, as discussed above, the C-terminal fragment of FGF23 is known to be high in human 
cord blood. High serum levels of the C-terminal fragment could act on FGF23’s receptors to 
block intact FGF23. Whether the C-terminal fragment is also high in rodents is unknown, which 
is worth being measured. Additional studies should also be conducted to study if there is an 
interaction between the C-terminal fragment and FGFR1 in the placenta. If so, it could explain 
why abnormally high FGF23 in the Phex null placenta had no effect in placental phosphate 
transport.   
 
4.12 Summary and Conclusion 
In summary, Deletion of Klotho, as well as 7.8-fold higher serum FGF23 due to a mutation in 
Phex, does not disturb any measured parameters of fetal mineral homeostasis, including serum 
and amniotic fluid phosphate, skeletal morphology, skeletal mineral content, and placental 
phosphate transport. It is only after birth that disturbance in FGF23 signaling begins to 
significantly alter phosphate homeostasis. In neonates, excess FGF23 exerts its effects as early as 
12 hours after birth; whereas a loss of Klotho or FGF23 has no effect until 5 to 7 days after birth. 
My results predict that human babies with abnormalities of FGF23 signaling will be normal at 





In conclusion, my original hypothesis (FGF23 was important in regulating not only fetal serum 
phosphate and skeletal development, but also placental phosphate transport) was rejected. 
Although intact FGF23 is present in the fetal circulation at levels that range from low to equal to 
adult values, and although there is robust expression of FGF23-targeted genes in the placenta and 
kidneys, FGF23 itself is not an important regulator of fetal phosphate metabolism. Instead, 
factors other than FGF23 must dominate to regulate the transport of phosphate across the 
placenta, as well as expression of the sodium-phosphate co-transporters. The magnitude of 
phosphate delivery across the placenta may override any effect that an absence of FGF23 or 
Klotho, or excess FGF23, might otherwise have on the fetal kidneys. It is in hours to days after a 
loss of placental phosphate pump that FGF23 becomes an important regulator of renal phosphate 
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6.1 Mouse Tail DNA Extraction Protocol 
1. Cut 5 mm (5–10 mg) fresh or frozen mouse tail tissue into small pieces. 
2. Dispense 300 μl Cell Lysis Solution into a 1.5 ml microcentrifuge tube and add the tissue from 
the previous step. 
3. Add 1.5 μl Puregene Proteinase K to the lysate, and mix by inverting 25 times. 
4. Incubate at 55°C overnight or until the tissue has completely lysed. Invert tube periodically 
during the incubation. 
5. Optional: If RNA-free DNA is required, add 1.5 μl RNase A Solution (cat. no. 158922), and 
mix by inverting 25 times. Incubate for 15–60 min at 37°C. Incubate for 1 min on ice to quickly 
cool the sample. 
6. Add 100 μl Protein Precipitation Solution, and vortex vigorously for 20 s at high speed. 
7. Centrifuge for 3 min at 13,000–16,000 x g. The precipitated proteins should form a tight pellet. 
If the protein pellet is not tight, incubate on ice for 5 min and repeat the centrifugation. 
8. Pipet 300 μl isopropanol into a clean 1.5 ml microcentrifuge tube and add the supernatant 
from the previous step by pouring carefully. Be sure the protein pellet is not dislodged during 
pouring. 
9. Mix by inverting gently 50 times. 
10. Centrifuge for 1 min at 13,000–16,000 x g. The DNA may be visible as a small white pellet. 
11. Carefully discard the supernatant, and drain the tube by inverting on a clean piece of 
absorbent paper, taking care that the pellet remains in the tube. 
12. Add 300 μl of 70% ethanol and invert several times to wash the DNA pellet. 
13. Centrifuge for 1 min at 13,000–16,000 x g. 
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14. Carefully discard the supernatant. Drain the tube on a clean piece of absorbent paper, taking 
care that the pellet remains in the tube. Allow to air dry for up to 10 min. The pellet might be 
loose and easily dislodged. 
15. Add 50 μl DNA Hydration Solution and vortex 5 s at medium speed to mix. 
16. Incubate at 65°C for 1 h to dissolve the DNA. 
17. Incubate at room temperature overnight with gentle shaking. Ensure tube cap is tightly closed 
to avoid leakage. Samples can then be centrifuged briefly and transferred to a storage tube. 
 
6.2 Phosphorus Assay 
Test Summary 
Increased serum inorganic phosphorus concentrations (hyperphosphatemia) are usually the result 
of Vitamin D overdose, hypoparathyroidism, or renal failure. Decreased serum concentrations 
(hypophosphotemia) usually result from rickets, hyperparathyroidism, or Fanconi Syndrome (a 
defect in absorption of phosphorus and other metabolites from the glomerular filtrate). 
 
The majority of methods for determining inorganic phosphorus are based on the reduction of a 
phosphorus-molybdate complex with a reducing agent resulting in the subsequent formation of 
molybdenum blue. In 1972, Daly and Ertingshausen introduced a method for inorganic 
phosphorus which measured the unreduced phosphorus-molybdate complex. This procedure is a 
modification of the Daly and Ertingshausen technique. 
 
Reagents 
Phosphorus Blank Reagent (R1): An acidic solution (pH < 1 at 25°C) containing a surfactant. 
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Phosphorus Molybdate Reagent (R2): An acidic solution (pH < 1 at 25°C) containing 2.8 
mmol/L ammonium molybdate. 
Phosphorus Calibrator: 1 x 15 mL of a solution containing 6.2 mg/dL (2 mmol/L) phosphorus.  
 
Specimen 
Fresh, clear, unhemolysed serum. Serum should be separated promptly from the red blood cells 
because erythrocytes contain phosphate concentrations several times greater than those found in 
sera. 
 
Reference Intervals  
2.7-4.5 mg/dL (0.87-1.45 mmol/L) 
These values are suggested guidelines. It is recommended that each laboratory establish the 




Test Summary  
The majority of calcium in the body is present in bones. The remainder of the calcium is present 
in serum and has various functions. For example, calcium ions decrease neuromuscular 




Hypercalcemia can result from hyperparathyroidism, hypervitaminosis D, multiple myeloma, 
and some neoplastic diseases of bone. Hypocalcemia can result from hypoparathyroidism, 
steatorrhea, nephrosis, nephritis, and pancreatitis.  
 
Calcium has traditionally been difficult to measure accurately and precisely, and a large variety 
of methods have been developed. Among these are flame photometry, oxalate precipitation with 
titration, atomic absorption spectrophotometry, EDTA chelation, and more recently calcium dye 
complexes which are measured spectrophotometrically. Examples of calcium dyes are 
ocresolphthalein complexone and Arsenazo III, the latter being the dye used for calcium 
measurement in this method. 
 
Reagents 
Calcium Reagent: A solution containing ~ 0.15 mmol/L arsenazo III, a buffer, and a surfactant. 
Calcium Calibrator for Manual Assays: 1 x 15 mL of a solution containing 10.0 mg/dL (2.50 
mmol/L) calcium and a preservative (not included with Cat. No. 140-24). 
 
Specimen  
Fresh clear serum. 
 
Reference Intervals  
Serum: 
Premature Infants 6.0-10.0 mg/dL 1.5-2.5 mmol/L 
Full-term Infants 7.3-12.0 mg/dL 1.8-3.0 mmol/L 
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1 to 2 years 10.0-12.0 mg/dL 2.5-3.0 mmol/L 
Adults 8.0-10.5 mg/dL 2.0-2.6 mmol/L 
These values are suggested guidelines. It is recommended that each laboratory establish the 
normal range for the area in which it is located. 
 
6.3 Mouse  PTH 1-84 ELISA Kit 
Introduction  
Mouse intact parathyroid hormone (PTH 1-84) is an amino acid polypeptide produced by the 
parathyroid gland with its biological activity residing in the N-terminal region of the peptide. 
PTH plays an important role in maintaining the concentration of ionized calcium within the 
limits needed to achieve normal metabolic functions. When serum calcium levels are decreased 
the parathyroid gland increases secretion of the hormone which results in increased mobilization 
of calcium from skeletal reserves into the circulation. When levels of serum calcium are 
increased the secretion of PTH is reduced. The similarities between mouse and human 
physiology relative to calcium metabolism make the mouse an excellent live-animal model for 
studying human skeletal disease and in the pre-clinical evaluation of pharmacologic agents that 
may alter bone remodeling. Quantitation of biologically active mouse PTH 1-84 with this kit can 
provide a precise and sensitive assessment of changes in bone and mineral metabolism..  
 
Test Principle  
The Mouse PTH 1-84 ELISA Kit is a two-site enzyme-linked immunosorbent assay (ELISA) for 
the measurement of PTH in mouse plasma or cell culture media. Two different goat polyclonal 
antibodies have been affinity purified against mouse PTH to detect the biologically active intact 
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form of mouse PTH. The antibody which recognizes epitopes within the midregion/C-terminal 
portion (39-84) of the peptide is biotinylated for capture. The other antibody, which recognizes 
epitopes within the N-terminal region (1-34), is conjugated with the enzyme horseradish 
peroxidase (HRP) for detection. A sample containing mouse intact PTH is incubated 
simultaneously with the biotinylated capture antibody and the HRP conjugated antibody in a 
streptavidin coated microtiter well. Intact PTH (1-84) contained in the sample is 
immunologically bound by the capture antibody and the detection antibody to form a “sandwich” 
complex:  
 
Well/Avidin-Biotin Anti-Rat PTH — Rat Intact PTH — HRP Anti-Rat PTH  
 
At the end of this incubation period, the well is washed to remove any unbound antibody and 
other components. The enzyme bound to the well is then incubated with a substrate solution in a 
timed reaction and then measured in a spectrophotometric microtiter plate reader. The enzymatic 
activity of the antibody complex bound to the well is directly proportional to the amount of PTH 
1-84 in the sample. A standard curve is generated by plotting the absorbance versus the 
respective PTH 1-84 concentration for each standard on linear or logarithmic scales. The 
concentration of mouse intact PTH in the samples is determined directly from this curve.  
 
Reagents: Preparation and Storage  
Store the kit at 2-8ºC upon receipt. Store the standards and controls at -20ºC or below after 
reconstitution. For the expiration date of the kit refer to the label on the kit box. All components 




Prior to use allow all reagents to come to room temperature and mix by gentle swirling and 
inversion. Reagents from different kit lot numbers should not be combined or interchanged.  
1. STREPTAVIDIN COATED MICROTITER PLATE (40-0010)  
One plate with 12 eight well strips and frame (96 wells total). This reagent should be stored in 
the foil pouch with desiccant at 2 - 8C and is stable until the expiration date on the kit.  
 
2. MOUSE PTH 1-84 BIOTINYLATED ANTIBODY (40-2315)  
One vial containing 2.7 mL of biotin labeled anti-mouse PTH in TRIS buffered saline with 
protein stabilizers and a non-azide, nonmercury preservative. This reagent should be stored at 2 - 
8C and is stable until the expiration date on the kit.  
 
3. MOUSE PTH 1-84 HRP CONJUGATED ANTIBODY (40-2325)  
One vial containing 2.7 mL of horseradish peroxidase conjugated to anti-mouse PTH in a 
stabilized protein solution with a non-azide, non-mercury preservative. This reagent should be 
stored at 2-8C protected from light and is stable until the expiration date on the kit.  
 
4. MOUSE PTH 1-84 STANDARDS (40-2331 to 40-2336)  
Six vials each containing mouse PTH 1-84 lyophilized in a protein matrix with a non-azide, non-
mercury preservative. Refer to vial label for exact concentration. Before use reconstitute the vial 
with the mouse intact PTH 1-84 concentration of 0 pg/mL with 2.0 mL of deionized water. 
Before use reconstitute each of the other five vials of standards with 1.0 mL of deionized water. 
Allow the vials to sit for approximately 20 minutes with occasional gentle swirling and inversion. 
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Assure complete reconstitution before use. Use the standards immediately after reconstitution; 
freeze the unused portion for later use. After reconstitution the standards are stable until the 
expiration date on the kit when stored at -20ºC or below with up to 3 freeze/thaw cycles.  
 
5. MOUSE PTH 1-84 CONTROLS I & II (40-2341 & 40-2342)  
Two vials each containing mouse PTH 1-84 lyophilized in a protein matrix with a non-azide, 
non-mercury preservative. Refer to vial label for control ranges. Before use reconstitute each 
control with 1.0 mL of deionized water. Allow the vials to sit for approximately 20 minutes with 
occasional gentle swirling and inversion. Assure complete reconstitution before use. Use the 
controls immediately after reconstitution; freeze the unused portion for later use. After 
reconstitution the controls are stable until the expiration date on the kit when stored at -20ºC or 
below with up to 3 freeze/thaw cycles.  
 
6. ELISA WASH CONCENTRATE (40-0041)  
One vial containing 20 mL of a 20 fold concentrate. Before use dilute the content to 400 mL with 
deionized water and mix well. Upon dilution this yields a working wash solution containing a 
surfactant in phosphate buffered saline with a non-azide, nonmercury preservative. The diluted 
wash solution should be stored at room temperature and is stable until the expiration date on the 
kit.  
 
7. ELISA HRP SUBSTRATE (40-0026)  
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One bottle containing 11 mL of tetramethylbenzidine (TMB) with hydrogen peroxide. This 
reagent should be stored at 2 - 8C protected from light and is stable until the expiration date on 
the kit..  
 
8. ELISA STOP SOLUTION (40-0030)  
One bottle containing 11 mL of 1 M sulfuric acid. This reagent may be stored at room 
temperature or at 2 - 8C and is stable until the expiration date on the kit.  
 
9. PLATE SEALER (10-2016)  
Two included in kit; use to prevent evaporation and cross contamination of wells.  
 
Materials Required But Not Provided  
1. 1.0 mL and 2.0 mL volumetric pipettes for reconstituting standards and controls.  
2. Precision pipets capable of delivering 25 μL,100 μL and 150 μL.  
3. Aluminum foil.  
4. Automated microtiter plate washer OR  
5. Repeating dispenser for delivering 350 μL and suitable aspiration device.  
6. Container for storage of wash solution.  
7. Spectrophotometric microtiter plate reader capable of reading absorbance at 450 nm and at 
595 - 650 nm.  
8. Deionized water.  
9. Horizontal rotator capable of maintaining 180 - 220 RPM.  




Specimen Collection  
The intact PTH molecule is unstable, resulting in decreased immunoreactivity over time. Sample 
collection and storage procedures should be carried out in an expeditious manner. Due to the 
variable lability of the molecule, measurement of the mouse PTH 1-84 concentration should be 
made using EDTA plasma or cell culture media. Forty microliters of plasma or culture media are 
required to assay the sample in duplicate. Centrifuge the sample and separate the plasma or 
media from the cells. Samples should be assayed immediately or stored frozen at -20ºC or below. 
Avoid repeated freezing and thawing of specimens. The use of various anesthetics can cause 
significant elevations in blood PTH concentrations. It is therefore imperative to use consistent 
sample collection procedures within studies.  
 
Assay Procedure  
1. Place a sufficient number of Streptavidin Coated Strips in a holder to run PTH standards, 
controls and unknown samples.  
2. Pipet 20 L of standard, control, or sample into the designated or mapped well. Freeze the 
remaining standards and controls as soon as possible after use.  
3. Pipet 50 L of the Working Antibody Solution consisting of equal volumes of Mouse PTH 1-
84 Biotinylated Antibody and Mouse PTH 1-84 HRP Conjugated Antibody into each well.  
4. Cover the plate with one plate sealer, then cover with aluminum foil to avoid exposure to light. 




6. Remove the aluminum foil and plate sealer. Using an automated microtiter plate washer 
aspirate the contents of each well. Wash each well five times by dispensing 350 L of working 
wash solution into each well and then completely aspirating the contents.  
7. Pipet 100 L of ELISA HRP Substrate into each of the wells.  
8. Re-cover the plate with the Plate Sealer and aluminum foil. Incubate at room temperature for 
30 minutes on a horizontal rotator set at 180 - 220 RPM.  
9. Remove the aluminum foil and plate sealer. Read the absorbance at 620 nm (see Note) within 
5 minutes in a microtiter plate reader against the 0 pg/mL Standard wells as a blank.  
10. Immediately pipet 100 L of ELISA Stop Solution into each of the wells. Mix on a 
horizontal rotator for 1 minute.  
11. Read the absorbance at 450 nm within 10 minutes in the microtiter plate reader against a 
reagent blank of 100 L of Substrate and 100 L of Stop Solution.  
 
If dual wavelength correction is available set the Measurement wavelength to 450 nm and 
Reference wavelength to absorbance used in step #9.  
 
Calculation of Results  
The two absorbance readings taken before and after the addition of the ELISA Stop Solution 
allow for the construction of two standard curves using the mouse PTH 1-84 standards contained 
in the kit. Refer to the individual vial label for exact concentration. The primary curve used for 
calculation of results is the second reading taken after the addition of the ELISA Stop Solution 
and read at 450 nm. This data utilizes the absorbance values obtained with the first five 
standards. The first reading taken before the addition of the ELISA Stop Solution and read at 595 
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nm – 650 nm is intended to extend the analytical range to the value of the sixth (highest) 
standard provided in the kit. It should be used only for sample results that fall between the value 
of the fifth and sixth standard. Results obtained with the first reading should not replace the on-
scale reading at 450 nm. Each curve should be generated as follows: 
Primary Procedure — Read at 450 nm  
1. Calculate the average absorbance for each pair of duplicate assay wells.  
2. Subtract the average absorbance of the 0 pg/mL Standard from the average absorbance of all 
other readings to obtain corrected absorbance.  
3. The standard curve is generated by plotting the corrected absorbance of the first five standard 
levels on the ordinate against the standard concentration on the abscissa using linearlinear or log-
log paper. Appropriate computer assisted data reduction programs may also be used for the 
calculation of the mouse PTH 1-84 results. The PTH 1-84 concentration of the controls and 
samples are read directly from the standard curve using their respective corrected absorbance. If 
log-log graph paper or computer assisted data reduction programs utilizing logarithmic 
transformation are used, samples having corrected absorbance between the 0 pg/mL Standard 
and the next highest standard should be calculated by the formula:  
Value of unknown = [Corrected Absorbance (unknown)/Corrected Absorbance(2
nd
 Std.)] x 
Value of the 2nd Std.  
 
Secondary Procedure — Read at 595 nm – 650 nm  
1. Calculate the average absorbance for each pair of duplicate assay wells.  
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2. The standard curve is generated by plotting the absorbance of the three highest standards on 
the ordinate against the standard concentration on the abscissa using linear-linear or log-log 
graph paper.  
3. The PTH 1-84 concentration of samples reading only between the fifth and sixth standard are 
read directly from this standard curve.  
 
6.4 1,25-Dihydroxy Vitamin D EIA kit 
Summary and Explanation 
Vitamin D is a commonly used collective term for a family of closely related molecules derived 
from naturally occurring 7-dehydrocholesterol (pro-vitamin D3). Pro-vitamin D3 undergoes 
photolytic conversion in the skin to ‘parent’ vitamin D3 (cholecalciferol) upon exposure to 
sunlight. This compound is biologically inactive, but enters the circulation and is hydroxylated in 
the liver to active 25-hydroxyvitamin D (25D). A small proportion of this becomes further 
hydroxylated in the kidney to the highly potent calciotropic hormone 1,25D. 1,25D is largely 
bound to Vitamin D Binding Protein and albumin in the circulation.  
 
1,25D is one of the major regulators of calcium (and phosphate) metabolism, stimulating 
intestinal calcium absorption and increasing bone resorption. It also inhibits parathyroid hormone 
(PTH) production both by direct action on the parathyroid glands and indirectly by raising serum 
calcium levels. 1,25D production is itself stimulated by parathyroid hormone (PTH), thus 




Hypovitaminosis D is commonly associated with dietary insufficiency, most frequently with 
vegetarianism, and is also associated with low exposure to sunlight (e.g. the elderly and 
institutionalised) and skin pigmentation. 1,25D production appears to be impaired in early renal 
failure though this may not be a renal effect. In late-stage renal failure, 1α-hydroxylation may be 
impaired, with low 1,25D levels as a result.  
 
Method Description  
The IDS 1,25-Dihydroxy Vitamin D EIA kit is a complete assay system for the purification of 
1,25D in patient samples by immunoextraction followed by quantitation by EIA. Patient samples 
are delipidated and 1,25D extracted from potential cross-reactants by incubation for 90 minutes 
with a highly specific solid phase monoclonal anti-1,25D. The immunoextraction gel is then 
washed and purified 1,25D eluted directly into glass assay tubes. Reconstituted eluates and 
calibrators are incubated overnight with a highly specific sheep anti-1,25D. Then a portion of 
this is incubated for 90 minutes with shaking in microplate wells which are coated with a specific 
anti-sheep antibody. 1,25D linked to biotin is then added and the plate shaken for a further 60 
minutes before aspiration and washing. Enzyme (horseradish peroxidase) labelled avidin is 
added and binds selectively to complexed biotin and, following a further wash step, colour is 
developed using a chromogenic substrate (TMB). The absorbance of the stopped reaction 
mixtures are read in a microtitre plate reader, colour intensity developed being inversely 
proportional to the concentration of 1,25D.  
 
Preparation of Reagents  
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Calibrators CAL: Calibrators CAL are supplied in lyophilised form. Reconstitute immediately 
before use. Add 1 mL distilled or deionised water to each bottle. Replace stopper and leave to 
reconstitute for 5-10 minutes, inverting several times to ensure complete reconstitution. DO NOT 
RECONSTITUTE ON A ROLLING MIXER - this will result in potency loss.  
Controls CTRL: Controls CTRL are supplied in lyophilised form. Reconstitute immediately 
before use. Add 1.2 mL distilled or deionised water to each bottle. Replace stopper and leave 15 
- 20 minutes to reconstitute, inverting several times to ensure complete reconstitution.  
If Calibrators CAL or Controls CTRL are to be used more than once, they must be frozen (-20°C) 
within 15 minutes of reconstitution. When re-using frozen Calibrators CAL or Controls CTRL , 
thaw at room temperature, mix well and use within 15 minutes.  
Primary Antibody Solution Ab SOLN: Primary Antibody Concentrate Ab 6x is supplied as a 
concentrate. Add the entire contents of the bottle of Primary Antibody Buffer Ab BUF , replace 
the stopper and invert several times to ensure complete mixing.  
1,25D Biotin solution 1,25D BIOTIN SOLN: 1,25D Biotin Concentrate 1,25D BIOTIN 6x is 
supplied lyophilised. Add the entire contents of the bottle of the 1,25D Biotin Buffer 1,25D 
BIOTIN BUF. Replace the stopper and stand for 10-15 minutes at room temperature. Invert 
several times to ensure complete reconstitution. If 1,25D Biotin solution 1,25D BIOTIN SOLN 
is to used more than once, it must be frozen (-20°C) within 2 hours of reconstitution. When using 
frozen 1,25D Biotin solution 1,25D BIOTIN SOLN thaw at room temperature, mix well and use 
within 2 hours.  
Wash Solution: Prepare by adding the contents of each bottle of Wash Concentrate WASHBUF 
20x to 950 mL of distilled or de-ionised water. Store at room temperature.  
All other reagents are supplied ready for use.  
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Allow all reagents to come to room temperature before use.  
Reagents should be mixed by repeated inversion prior to use in the assay  
 
Specimen Collection and Storage  
The assay should be performed using serum or plasma (EDTA or heparin) specimens. Specimens 
should be separated as soon as possible after collection. For long term storage, store at -20°C. 
Avoid repeated freeze/thaw of samples.  
Note:  
The specimens’ storage and stability information stated above are general recommendations for 
use in a variety of settings of laboratories. Each laboratory should follow the guidelines or 
requirements of local, state, and/or federal regulations or accrediting organizations to establish its 
own specimens handling and storage stability. For guidance on appropriate practices, please refer 
to the CLSI GP44-A4, Procedures for the Handling and Processing of Blood Specimens for 
Common Laboratory Tests; Approved Guideline - Fourth Edition  
 
Procedure  
Materials Provided  
1. CAL 0 – 6 – Calibrators (REF AC-6201A - AC-6201G): Lyophilised BSA buffer containing 
1,25-dihydroxy-vitamin D and <0.4% sodium azide (0.01% reconstituted). The exact value of 
each calibrator is printed on the QC Report. 1 mL per bottle, 7 bottles per kit.  
2. Ab 6x - Primary Antibody Concentrate (REF AC-6202): Sheep anti-1,25-dihydroxyvitamin D 
in BSA-phosphate buffer with 0.09% sodium azide, 2 mL per bottle.  
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3. Ab BUF - Primary Antibody Buffer (REF AC-6202B): Proprietary reagent containing 
phosphate buffer with 0.09% sodium azide. 10 mL per bottle.  
4. Sac-Wel™ SHEEP - Anti-Sheep coated plate (REF AC-SH02W): Microplate with anti-sheep 
IgG linked to the inner surface of the polystyrene wells, 12 x 8 well strips in a foil pouch with 
desiccant.  
5. 1,25D BIOTIN 6x - 1,25D Biotin Concentrate (REF AC-6203): Lyophilised buffer containing 
1,25-dihydroxy-vitamin D labelled with biotin, and proprietary stabilisers, 2mL per bottle.  
6. 1,25D BIOTIN BUF - 1,25D Biotin Buffer (REF AC-6203B): Phosphate buffered saline with 
0.09% sodium azide, 12 mL per bottle.  
7. ENZYMCONJ - Enzyme Conjugate (REF AC-6204): Phosphate buffered saline containing 
avidin linked to horseradish peroxidase, protein, enzyme stabilisers and preservative, 24mL per 
bottle.  
8. CTRL 1 - CTRL 2 - Controls (REF AC-6205A - AC-6205B): Lyophilised human serum 
containing 1,25-dihydr-oxyvitamin D and <1% sodium azide (0.09% reconstituted), 1.2 mL per 
bottle, 2 bottles per kit.  
9. SORB - Immunocapsules (REF AC-6206): Capsules containing monoclonal antibody to 1,25-
dihydroxyvitamin D linked to solid phase particles in suspension with vitamin D binding protein 
inhibitor, 80 immunocapsules per kit.  
10. REAG 1 - Delipidation Reagent (REF AC-6207): A solution of dextran sulphate and 
magnesium chloride, 2.5 mL per bottle.  
11. REAG 2 - Elution Reagent (REF AC-6208): Ethanol, 44 mL per bottle.  




13. TMB - TMB Substrate (REF AC-TMB): A proprietary aqueous formulation of 
tetramethylbenzidine (TMB) and hydrogen peroxide, 24 mL per bottle.  
14. HCL - Stop Solution (REF AC-STOP): 0.5M Hydrochloric acid, 14 mL per bottle. 
15. WASHBUF 20x - Wash Concentrate (REF AC-WASHL): Phosphate buffered saline 
containing Tween, 50 mL per bottle.  
16. Adhesive Plate Sealer 8 per kit.  
17. Documentation: Package Insert and QC report.  
 
Materials Required but not Provided  
1. Disposable 12 x 75 mm borosilicate glass tubes.  
2. Disposable 12 x 75 mm polystyrene tubes (optional).  
3. Precision pipetting devices to deliver 50 μL, 100 μL, 150 μL, 200 μL, 500 μL and 1 mL.  
4. Repeating pipetting devices to deliver 150μL and 500 μL, e.g. Eppendorf Multipipette 4780 or 
similar.  
5. Precision multi-channel pipettes to deliver 100 μL and 200 μL.  
6. Vortex mixer.  
7. End-over-end or roller mixer.  
8. Heating block or water bath at 40ºC.  
9. Nitrogen supply and manifold.  
10. Centrifuge capable of achieving 2000g.  
11. Orbital shaker.  
12. Automatic microplate washer (optional).  
13. Photometric microplate reader and data analysis equipment.  
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14. Distilled or deionised water.  
 
Sample Preparation  
1. Prepare labelled glass or plastic tubes, one for each Control CTRL and unknown sample. DO 
NOT DELIPIDATE CALIBRATORS CAL.  
2. Add 500 μL of each Control CTRL or sample to appropriately labelled tubes.  
3. Add 50 μL of Delipidation Reagent REAG 1 to each tube. Vortex all tubes.  
4. Centrifuge all tubes at 2000 g for 15 minutes.  
Note: Take care not to disturb the pellet when handling delipidated samples. If the pellet 
becomes suspended or if the sample is not clear, then repeat the centrifugation.  
 
Alternative Sample Preparation:  
Suitable for samples where the volume available is less than 500 μL.  
1. Prepare labelled conical-bottom plastic tubes or microcentrifuge tubes, one for each sample .  
2. Add sample (e.g. 250 μL) to appropriately labelled tubes.  
3. Add 0.1 x sample volume of Delipidation Reagent REAG 1 (e.g. 25 μL) to each tube. Vortex 
all tubes.  
4. Centrifuge all tubes at 2000 g for 15 minutes, or at 10000 gfor 10 minutes (microcentrifuge).  
 
Immunoextraction Procedure  
1. Prepare labelled Immunocapsules SORB, two for each Control CTRL and sample DO NOT 
IMMUNOEXTRACT CALIBRATORS CAL . Note: If a Immunocapsule SORB shows signs of 
leakage or incorrect volume - do not use.  
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2. Vortex Immunocapsules SORB and allow solid phase to settle. Stand Immunocapsules SORB 
upright in foam rack for 3-5 minutes.  
3. Remove top screw caps from Immunocapsules SORB. Add 100 μL of delipidated sample or 
control to Immunocapsules SORB in duplicate. Replace caps securely.  
4. Place Immunocapsules SORB in foam rack and rotate end over-end at 5-20 revolutions per 
minute for 90 minutes at room temperature (18-25°C). Foam racks can be easily attached to a 
blood tube rotator by means of cut out slots. Alternatively, foam rack may be wedged inside a 
suitable plastic beaker and rotated on a bottle roller.  
5. Stand Immunocapsules SORB upright in foam rack for 3-5 minutes to allow gel to settle. Tap 
to dislodge any gel adhering to the screw caps. Allow gel to settle for a further 1-2 minutes. 
Remove screw cap and break off (do not twist off) bottom stopper from Immunocapsules SORB 
and place each Immunocapsule SORB in a plastic (or glass) tube. Centrifuge at low speed (500-
1000g) for approximately 1 minute to remove sample.  
6. Add 500 μL of deionised water to each Immunocapsule SORB. Add carefully to avoid solid 
phase splashing out of the Immunocapsule SORB Centrifuge at low speed (500-1000g) for 
approximately 1 minute to wash immunoextraction gel.  
7. Repeat the above wash step a further two times.  
8. Prepare labelled borosilicate glass tubes, one for each Immunocapsule SORB , and transfer 
Immunocapsules SORB to the glass tubes.  
9. Add 150 μL of Elution Reagent REAG 2 to all Immunocapsules SORB . Allow reagent to 
soak into solid phase for 1 to 2 minutes. Centrifuge at low speed (500-1000g) for approximately 
1 minute to collect eluate.  
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10. Repeat above step a further two times. The total elution volume collected is therefore 450 μL 
for each sample.  
11. Discard Immunocapsules SORB and place tubes in a heating block or water bath set to 40°C. 
Evaporate the eluates under a gentle flow of nitrogen. Evaporation should take 20 - 30 minutes. 
Ensure there is no remaining liquid in the tubes.  
12. Add 100 μL of Assay Buffer BUF to each tube and vortex to dissolve residues.  
The immunopurified samples are now ready for assay.  
 
Assay Procedure  
Reconstitute Calibrators CAL immediately before assay as described in Preparation of Reagents, 
or thaw previously reconstituted materials. Allow all reagents to come to room temperature 
before use. Mix all reagents gently before use in the assay.Prepare labelled borosilicate glass 
tubes, two for each Calibrator CAL.  
1. Add 100 μL of each Calibrator CAL to the appropriately labelled tubes. Pipette directly to the 
bottom of the tube.  
2. Assemble sample extract tubes from step 12 above.  
3. Add 100 μL of Primary Antibody Solution Ab SOLN to all tubes.  
4. Vortex all tubes gently without foaming. Incubate at 2-8ºC overnight (16-20 hrs).  
5. Add 150 μL of solution from step 4 to the Coated plate MICROPLAT. Leave the first two 
wells empty for substrate blanks. Cover the plate with an  




6. Add 100 μL of 1,25D Biotin solution 1,25D BIOTIN SOLNto all wells except for the 
substrate blanks. Cover the plate with an adhesive plate sealer and incubate the plate on an 
orbital shaker (500-750rpm) at 18-25°C for 60 minutes.  
7. Wash all wells three times with Wash Solution:  
a. Automatic plate wash: Set plate washer to dispense at least 300 μL of Wash Solution per well. 
Fill and aspirate for 3 cycles.  
b. Manual Wash: decant the contents of the wells by inverting sharply. Dispense 250 μL of Wash 
Solution to all wells. Decant and repeat twice.  
Tap the inverted plate firmly on absorbent tissue to remove excess Wash Solution before 
proceeding to the next step.  
8. Add 200 μL of Enzyme Conjugate ENZYMCONJ to all wells except for the substrate blanks 
using a multichannel pipette. Cover the plate with an adhesive plate sealer and incubate the plate 
at 18-25°C for 30 minutes.  
9. Repeat Wash Step 7  
10. Add 200 μL of TMB Substrate TMB to all wells including the substrate blanks using a 
multichannel pipette. Cover the plate with an adhesive plate sealer and incubate the plate at 18-
25°C for 30 minutes.  
Note: TMB Substrate is easily contaminated. Only remove the required amount for the assay 
from the bottle. Dispose of unused TMB Substrate. Do not return to bottle.  
11. Add 100 μL of Stop Solution HCL to all wells using a multichannel pipette.  
12. Measure the absorbance of each well at 450nm (reference 650nm) using a microplate reader 




Calculation of Results  
Calculate the percent binding (B/Bo%) of each Calibrator, Control and unknown sample as 
follows:  
B/Bo% = [(mean abs. - mean abs. substrate blank)] x 100/(mean abs. for ‘0’ cal. - mean abs. 
substrate blank)  
Prepare a calibration curve on semi-log graph paper by plotting B/Bo% on the ordinate against 
concentration of 1,25-dihydroxyvitamin D on the abscissa. Calculate B/Bo% for each unknown 
sample and read values off the curve in pmol/L. Alternative data reduction techniques may be 
employed, such as automated data reduction programs, but users should confirm that the selected 
curve fit is appropriate and gives acceptable results. Smoothed spline or 4PL curve fits are 
recommended. IDS calculates results using MultiCalc (PerkinElmer) data reduction software 
with a 4PL curve fit plotting net absorbance versus log concentration.  
 
The reportable range of the assay is 6 – 500 pmol/L. Any value that reads below the lowest 




6.5 FGF23 ELISA Kit 
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